SQI Diagnostics F10 Registration of securities

QuickLinks -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on July 6, 2011

Registration No. 333-

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form F-10
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933

SQI DIAGNOSTICS INC.
(Exact name of Registrant as specified in its charter)


Canada	2835	N/A
(Province or Other Jurisdiction of Incorporation or Organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification Number, if any)

36 Meteor Drive
Toronto, Ontario
Canada M9W 1A4
(416) 674-9500
(Address and telephone number of Registrant's principal executive offices)

Puglisi & Associates
850 Library Avenue, Suite 204
Neward, DE 19711
(302) 738-6680
(Name, address (including zip code) and telephone number (including area code) of agent for service in the United States)

Copies to:

Daniel M. Miller
Dorsey & Whitney LLP
Suite 1605, 777 Dunsmuir Street
P.O. Box 10444, Pacific Centre
Vancouver, B.C.
Canada V7Y 1K4
(604) 630-5199

Andrew Morris
Chief Financial Officer
SQI Diagnostics Inc.
36 Meteor Drive
Toronto, Ontario
Canada M9W 1A4
(416) 674-9500

Vanessa Grant
McCarthy Tetrault LLP
Box 48, Suite 5300
Toronto Dominion Bank Tower
Toronto, Ontario
Canada M5K 1E6
(416) 601-7525

Patrick O'Brien
Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, MA 02199-3600
(617) 951-7000

Gordon Raman
Borden Ladner Gervais LLP
Scotia Plaza
40 King Street West, 44^th Floor
Toronto, Ontario
Canada M5H 3Y4
(416) 367-6000

Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this Registration Statement.

Province of Ontario, Canada
(Principal jurisdiction regulating this offering)

It is proposed that this filing shall become effective (check appropriate box below):


A.	o	upon filing with the Commission, pursuant to Rule 467(a) (if in connection with an offering being made contemporaneously in the United States and Canada).
B.	ý	at some future date (check appropriate box below)
	1.	o	pursuant to Rule 467(b) on ( ) at ( ) (designate a time not sooner than seven calendar days after filing).
	2.	o	pursuant to Rule 467(b) on ( ) at ( ) (designate a time seven calendar days or sooner after filing) because the securities regulatory authority in the review jurisdiction has issued a receipt or notification of clearance on ( ).
	3.	o	pursuant to Rule 467(b) as soon as practicable after notification of the Commission by the Registrant or the Canadian securities regulatory authority of the review jurisdiction that a receipt or notification of clearance has been issued with respect hereto.
	4.	ý	after the filing of the next amendment to this Form (if preliminary material is being filed).

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to the home jurisdiction's shelf prospectus offering procedures, check the following box. o

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered	Proposed Maximum Aggregate Offering Price(1)(2)	Amount of Registration Fee




Common Shares, no par value	$34,500,000	$4,006

(1): Includes common shares that the underwriters have the option to purchase to cover over-allotments, if any.
(2): Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registration Statement shall become effective as provided in Rule 467 under the Securities Act of 1933 or on such date as the Commission, acting pursuant to Section 8(a) of the Act, may determine.

PART I

INFORMATION REQUIRED TO BE DELIVERED TO OFFEREES OR PURCHASERS

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Subject to Completion, dated July 5, 2011

Preliminary Prospectus

US$30,000,000

• common shares

SQI DIAGNOSTICS INC.

Common Shares

We are offering • of our common shares. This is the initial public offering of our common shares in the United States and includes a new issue of our common shares in Canada.

Our common shares are listed and posted for trading on the TSX Venture Exchange under the symbol "SQD-V". Our common shares have been approved for listing on the NYSE Amex LLC under the symbol "SQD". On July 4, 2011, the closing sale price of our common shares on the TSXV was C$ • , or US$ • based on the U.S.-Canadian dollar noon exchange rate on July 4, 2011, as quoted by the Bank of Canada.

Investing in our common shares involves risks. See "Risk Factors" beginning on page • of this prospectus and see the risk factors incorporated by reference into this prospectus.

We are permitted, under a multi-jurisdictional disclosure system adopted by the United States, to prepare this prospectus in accordance with Canadian disclosure requirements, which are different from those of the United States. We prepare our financial statements, which are included in, and incorporated by reference into, this prospectus, in accordance with Canadian generally accepted accounting principles, and they are subject to Canadian auditing and auditor independence standards. Our financial statements may not be comparable to the financial statements of United States companies.

Acquiring, holding and disposing of our common shares may subject you to tax consequences both in the United States and Canada. This prospectus may not describe these tax consequences fully. You should read the tax discussion in this prospectus.

Your ability to enforce civil liabilities under United States federal securities laws may be adversely affected because we are organized under the laws of Canada, the majority of our officers and directors and the experts named in this prospectus are residents of Canada, and all or a substantial portion of our assets and the assets of those officers, directors and experts are located outside of the United States.

Neither the Securities and Exchange Commission nor any state securities regulator has approved or disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

	Price to Public	Underwriters' Fees	Net Proceeds to SQI, before expenses




Per common share	US$	US$	US$

Total	US$	US$	US$

The purchase price for investors in Canada will be payable in Canadian dollars and the purchase price for investors in the United States will be payable in U.S. dollars unless the underwriters otherwise agree. All of the proceeds of the offering will be paid by the underwriters in U.S. dollars based on the U.S. dollar offering price. The Canadian dollar offering price is the equivalent of the U.S. dollar offering price, based upon the U.S.-Canadian dollar noon exchange rate on , 2011, as quoted by the Bank of Canada.

We will pay all expenses of the offering.

The underwriters may also purchase up to an additional • common shares from us at the public offering price, less the underwriters' commission, within 30 days after the closing of this offering to cover over-allotments, if any, and for market stabilization purposes. If the underwriters exercise the option in full, the total underwriters' commission paid by us will be US$ • and the net proceeds to us, before expenses, will be US$ • .

The common shares will be ready for delivery in New York, New York on or about , 2011.


Leerink Swann		Rodman & Renshaw, LLC
Kingsdale Capital Markets Inc.

The date of this prospectus is , 2011

TABLE OF CONTENTS

		Page

GENERAL MATTERS		1
FORWARD-LOOKING STATEMENTS		2
CURRENCY PRESENTATION AND EXCHANGE RATE INFORMATION		3
PROSPECTUS SUMMARY		5
	Corporate Information	11
	Details of the Offering	12
	Selected Financial Information	13
RISK FACTORS		15
CAPITALIZATION		30
USE OF PROCEEDS		30
BUSINESS OF THE COMPANY		31
LEGAL PROCEEDINGS AND REGULATORY ACTIONS		53
ACQUISITION OF SCIENION AG		53
SELECTED CONSOLIDATED FINANCIAL INFORMATION		54
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		55
DIRECTORS AND OFFICERS		86
DESCRIPTION OF CAPITAL STRUCTURE		91
DIVIDEND POLICY		91
MARKET FOR SECURITIES		92
	Prior Sales	92
PRINCIPAL SHAREHOLDERS		94
PLAN OF DISTRIBUTION		95
DOCUMENTS INCORPORATED BY REFERENCE		99
WHERE YOU CAN FIND MORE INFORMATION		100
AUDITORS, TRANSFER AGENTS AND REGISTRARS		100
CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS		100
CERTAIN MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS		103
DOCUMENTS FILED AS PART OF THE U.S. REGISTRATION STATEMENT		108
ENFORCEABILITY OF CIVIL LIABILITIES		108
EXPERTS		109
LEGAL MATTERS		109
MATERIAL CONTRACTS		109
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS		F-1

GENERAL MATTERS

Unless otherwise noted or the context otherwise indicates, in this preliminary short form base PREP prospectus (the "prospectus"), the terms "SQI", "we", "us", "our" or "the Company" refer to SQI Diagnostics Inc. and our wholly-owned subsidiary, SQI Diagnostics Systems Inc., through which we conduct our business. Our trademarks include "SQI Diagnostics™", "SQiDWorks™", "IgXPLEX™", "QuantiSpot™" and others. Our assays for rheumatoid arthritis are referred to in this prospectus as "IgXPLEX RA". Our IgXPLEX RA quantitative assay is marketed in Canada under the name QuantiSpot Rheumatoid Arthritis. This prospectus contains company names, product names, trade names, trademarks and service marks of other organizations, all of which are the property of their respective owners.

Documents incorporated by reference into this prospectus may include market share information and industry data and forecasts obtained from independent industry publications and surveys. References in such documents to research reports, surveys or articles should not be construed as depicting the complete findings of the entire referenced report, survey or article. The information in any such report, survey or article is not incorporated by reference into this prospectus. Although we believe these sources are reliable, we have not independently verified any of the data nor ascertained the underlying economic assumptions relied upon in such reports, surveys or articles. Some data is also based on our estimates, which are derived from our review of our internal surveys, as well as independent sources. We cannot and do not provide you with any assurance as to the accuracy or completeness of such information. Market forecasts, in particular, are likely to be inaccurate, especially in respect of emerging markets, such as those for our products, or over long periods of time.

The information in this prospectus regarding the business of Scienion AG has been furnished by Scienion.

You should rely only on the information contained in or incorporated by reference into this prospectus. Neither we nor the underwriters, have authorized any other person to provide you with different information.

You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus, unless otherwise noted in this prospectus or as required by law. It should be assumed that the information appearing in this prospectus and the documents incorporated by reference into this prospectus are accurate only as of their respective dates. Our business, financial condition, results of operations or prospects may have changed since those dates.

Information contained on our website, www.sqidiagnostics.com, is not part of this prospectus and is not incorporated by reference into this prospectus and may not be relied upon by prospective purchasers for the purpose of determining whether to invest in the common shares.

FORWARD-LOOKING STATEMENTS

This prospectus, including the documents incorporated by reference into this prospectus, contains forward-looking statements. These statements relate to future events or future performance and reflect our expectations and assumptions regarding our growth, results of operations, performance and business prospects and opportunities. Such forward-looking statements reflect our current beliefs and are based on information currently available to us. In some cases, forward-looking statements can be identified by terminology such as "our goal", "may", "would", "could", "will", "should", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the negative of these terms or other similar expressions concerning matters that are not historical facts. The forward-looking statements in this prospectus, including any documents incorporated by reference into this prospectus, include, among others, statements regarding our future operating results, economic performance and product development efforts, and statements in respect of:

•: our expected future losses and accumulated deficit levels;
•: our requirement for, and our ability to obtain, future funding on favourable terms or at all;
•: market competition and technological advances of competitive products;
•: our expectations regarding the acceptance of our products by the market;
•: our expectations regarding the progress and the successful and timely completion of the various stages of the regulatory clearance process;
•: our strategy to develop new products and to enhance the capabilities of existing products;
•: our strategy with respect to research and development;
•: our dependence on expanding our customer base;
•: our plans to market, sell and distribute our products;
•: our plans in respect of strategic partnerships for research and development;
•: our ability to obtain a sufficient supply of the components needed for our systems;
•: the effect of operating as a public company in the United States and our plans for compliance;
•: our plans to acquire Scienion;
•: our plans to retain and recruit personnel;
•: our ability to satisfy customer demand for our systems;
•: our plans to correct defects or errors in our systems;
•: the effect of litigation on our business;
•: our strategy with respect to the protection of our intellectual property; and
•: our expectations with respect to existing and future corporate alliances and licensing transactions with third parties, and the receipt and timing of any payments to be made by us or to us in respect of such arrangements.

A number of factors could cause actual events, performance or results, including those in respect of the foregoing items, to differ materially from the events, performance and results discussed in the forward- looking statements. Factors that could cause actual events, performance or results to differ materially from those set forth in the forward-looking statements include, but are not limited to:

•: the extent of our future losses;
•: our ability to obtain the capital required to fund development and operations;
•: development or commercialization of similar products by our competitors;
•: our ability to develop and market our products;
•: our ability to comply with applicable governmental and securities regulations and standards;

•: our ability to develop and commercialize our technologies;
•: delays or failures in our ability to develop and implement new diagnostic products;
•: our reliance on a few key and significant customers;
•: our ability to attract and retain skilled and experienced personnel;
•: the impact of changes in the business strategies and development priorities of our strategic partners;
•: loss of suppliers or increases to the cost of the components of our systems;
•: the impact of legislative changes to the healthcare system and regulatory process;
•: the expense of compliance initiatives as a result of operating as a public company in the United States;
•: our ability to maintain effective internal control over financial reporting;
•: our ability to complete the proposed acquisition of Scienion and successfully integrate its business;
•: damage to our manufacturing facility or its failure to accommodate future sales growth;
•: the impact of unknown defects or errors and product liability claims;
•: the impact of liability from the use of hazardous and biological materials and other claims;
•: our ability to successfully manage fluctuations in revenue;
•: foreign currency fluctuations;
•: our ability to obtain patent protection and protect our intellectual property rights and not infringe on the intellectual property rights of others;
•: the expense and potential harm to our business of intellectual property litigation;
•: stock market volatility;
•: changing market conditions;
•: the fact that further equity financing may substantially dilute the interests of our shareholders; and
•: other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with applicable securities regulators, and those which are discussed under the heading "Risk Factors".

Although the forward-looking statements contained in this prospectus and in the documents incorporated by reference are based on what we consider to be reasonable assumptions based on information currently available to us, there can be no assurance that actual events, performance or results will be consistent with these forward-looking statements, and our assumptions may prove to be incorrect. These forward-looking statements are made as of the date of this prospectus.

Forward-looking statements made in a document incorporated by reference into this prospectus are made as of the date of the original document and have not been updated by us except as expressly provided for in this prospectus. Except as required under applicable securities legislation, we undertake no obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

CURRENCY PRESENTATION AND EXCHANGE RATE INFORMATION

In this prospectus, unless otherwise specified or the context otherwise requires, all dollar amounts are expressed in Canadian dollars. All references to "dollars", "C$" or "$" are to Canadian dollars and all references to "US$" are to United States dollars. For the amounts referenced under "Use of Proceeds" and "Plan of Distribution", the rate of exchange was US$1.00 = C$0.9598 or C$1.00 = US$1.0419, each based on the Bank of Canada's noon exchange rate on July 4, 2011.

The following table sets out (1) the high and low rate of exchange for one Canadian dollar in U.S. dollars during the indicated periods, (2) the average of the rate of exchange during those periods, and (3) the exchange

rate in effect as at the end of each of those periods, each based on the noon exchange rate published by the Bank of Canada. On July 4, 2011, the Bank of Canada's noon exchange rate was US$1.00 = C$0.9598 or C$1.00 = US$ 1.0419.



Six Month Periods ended March 31,
	2011	1.0324	0.9690	1.0010	1.0290
	2010	0.9888	0.9221	0.9541	0.9846
Fiscal Years Ended
	September 30, 2010	1.0039	0.9221	0.9609	0.9711
	September 30, 2009	0.9426	0.7692	0.8472	0.9327

PROSPECTUS SUMMARY

This summary highlights information contained in greater detail elsewhere in this prospectus. This summary may not contain all the information that you should consider before investing in our common shares. You should read the entire prospectus carefully, including "Risk Factors" starting on page 15 and our consolidated financial statements and related notes included elsewhere in this prospectus, before making an investment decision. Unless otherwise indicated, the terms "SQI", "we", "us", "our" and "the Company" refer to SQI Diagnostics Inc. and our wholly-owned subsidiary, SQI Diagnostics Systems Inc., through which we conduct our business.

SQI Diagnostics Inc.

Overview

We are a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. Our goal is to become a leader in the development and commercialization of microarray and multiplexed diagnostics by offering our customers a comprehensive "turnkey" solution that increases the efficiency and ease of diagnostic testing and test development.

Our target customers — clinical, academic and diagnostic development laboratories — require diagnostic processing equipment and consumable tests ("systems") that are capable of processing large numbers of patient samples at low cost and with minimal labor requirements ("high-throughput systems"). High-throughput systems have not been widely employed in autoimmune disease, allergen or companion diagnostics testing and only limited use of high-throughput systems exists in infectious disease testing. To our knowledge, no fully-automated high-throughput systems exist that are capable of addressing the combined multiplex testing needs of these markets. A fully-automated system capable of providing multiple biomarker measurements in a single test array has the potential to increase a laboratory's throughput with significantly less labor, consumables and other costs.

Our proprietary microarray tests and fully-automated instruments are designed to simplify diagnostic testing workflow, increase throughput and reduce costs, all while providing excellent data quality. In many instances, our technology enables analysis that was traditionally unavailable.

Our Principal Business Lines

•: The development, manufacturing and marketing of fully-automated diagnostics instruments

SQiDworks is the only FDA-cleared, fully-automated, microarray system and multiplexing solution in our target markets, which can perform qualitative or quantitative testing for multiple biomarkers simultaneously. We are also developing a fully-automated, bench-top diagnostic platform as well as a small, semi-automated system.

•: The development and marketing of tests for the autoimmune, allergen, infectious disease and companion diagnostics testing markets

We have received regulatory clearance to market our qualitative rheumatoid arthritis and celiac assays in the United States, our qualitative and quantitative rheumatoid arthritis and celiac assays in Canada, and our quantitative rheumatoid arthritis and celiac assays in the European Union. One of our key operational goals is to continue to develop and seek regulatory approval for additional tests, as we believe that expanding our "test menu" will drive adoption of our platform and products by customers. We also offer development services and manufacturing of diagnostic kits to our customers.

•: Our Printing Solutions

We are commercializing enabling technologies for our clients' microarray printing and assay development, microarray printing equipment, and manufacturing services.

Acquisition of Scienion AG

Scienion develops and markets a range of commercial microarray printing equipment and provides custom print and commercial print services.

We believe that the combination of our platform, our assays and the development of our test menu and, if the acquisition is completed, Scienion's industry leading print technologies, will enable the combined company to become a leader in sales of end-to-end microarray-based diagnostic systems, microarray printing and assay development services.

Our Target Markets

Diagnostics are critical to high-quality healthcare and guide a majority of clinical decisions. Over the last forty years, the number of biomarkers measured by laboratories has increased dramatically, and we believe there is a trend whereby healthcare providers are seeking to run diagnostic tests for an increasing number of biomarkers to aid in the diagnosis of disease. These tests are becoming increasingly complex and costly.

The 2012 global immunoassay diagnostic test market is estimated to be US$10.3 billion, of which we are strategically focusing on a directly addressable market of approximately US$4.5 billion, which includes immunological tests for autoimmune disease, infectious disease, and allergenecity. These three markets are estimated to be US$1.5 billion, US$2.4 billion and US$0.6 billion, respectively.

We have targeted these testing markets because we believe:

•: healthcare providers require the measurement of multiple biomarkers to aid in the diagnosis and therapeutic monitoring of these diseases;
•: these testing markets are typically underserved by fully-automated, high-throughput, multiplexed systems;
•: tests in these markets are generally run at sufficiently high volumes in larger test facilities which would benefit from both multiplexing and automation; and
•: these tests typically qualify for private and public reimbursement in Canada, the United States and the European Union.

We will also address selected areas of the companion diagnostics market, the "research use only" or "RUO" and lab-developed test markets and the market for microarray print and assay development tools.

Autoimmune Disease Tests

We have initially targeted the autoimmune testing segment for several reasons, which include:

•: there are ten autoimmune disease states that command most of the blood testing revenues for the entire autoimmune testing segment;
•: the most common tests for autoimmune diseases currently evaluate approximately 70 biomarkers, representing an average of approximately seven biomarkers per disease;
•: these tests are generally run at high volumes at larger test facilities and in batches and are not typically run on a "one off" basis;
•: each of the autoimmune diagnostic tests we are developing has predicate technologies with FDA clearance on older, single biomarker, manual titer plate technology that we intend to replace; and
•: regulatory clearance for the majority of autoimmune assays is through the FDA 510(k) process, which is well established.

Infectious Disease and Allergen Tests

We also plan to enter the immunoassay segment of the infectious disease diagnostics market, which is estimated to be approximately US$2.4 billion for 2012, followed by the immunoassay segment of the allergen diagnostics market, which is approximately US$0.6 billion for 2012.

Companion Diagnostics

Autoimmune diseases, such as rheumatoid arthritis, Crohn's disease and inflammatory bowel disease ("IBD"), are increasingly being treated with antibody-based or other biologic drugs. We believe that the effectiveness of the treatment of autoimmune patients with these drugs may be enhanced by the monitoring of the concentration of these drugs in a patient's blood by a "companion diagnostic" test. Our multiplexing technology allows us to combine the tests for both the diagnosis and therapeutic monitoring of a patient's disease.

RUO and Lab-Developed Tests

In addition to thein-vitro diagnostics ("IVD") market, we are targeting the market for RUO products and custom microarrays for lab-developed tests. Approximately one-third of the US$3.7 billion U.S. market for RUO and lab-developed tests is directly addressable by our proprietary technologies. We believe the combined U.S. and European markets for RUO and lab-developed tests that are directly addressable by our proprietary technologies to be approximately US$2 billion per year.

Microarray Print and Assay Development Tools

The market for protein and molecular microarray print equipment and services has been estimated to be approximately US$600 million per year.

Limitations of Current Technology

There are an increasing number of complex and costly diagnostic tests used to aid in the diagnosis and monitoring of many diseases. Our target customers — clinical, academic and diagnostic development laboratories — require diagnostic processing equipment and consumable tests that are capable of processing large numbers of patient samples at low cost and with minimal labor requirements. To our knowledge, no high-throughput systems exist that are capable of addressing the combined multiplex testing needs of these markets. A fully-automated system capable of providing multiple biomarker measurements in a single test array has the potential to increase a laboratory's throughput with significantly less labor, consumables, and other costs. We believe these cost savings would be realized because, among other things:

•: a fully-automated system reduces "hands-on" technician time;
•: the volume of liquid reagent is less and the number of other consumables, such as pipette tips, required to process one microarray is fewer when compared to traditional methods of running multiple tests in multiple titer plates;
•: a laboratory does not incur the expense of sending some tests (e.g. a large multiplex panel) to other labs;
•: the cost of managing multiple samples being tested by multiple technicians and combining the results to a single report would be largely eliminated by multiplexing capability; and
•: multiplexing and reducing the number of hands-on steps through automation would potentially reduce error rates.

Microtiter Plates

processed with a high contribution of direct labor. This increases the time to produce a test result and the potential for error and restricts the throughput of a laboratory.

Multiplex Diagnostic Tests

The processes used to complete a single test within a diagnostic panel of several biomarkers are complex and technically difficult. Such complexity has limited the throughput and efficiency of multiplex diagnostic testing, and technical challenges have restricted the widespread adoption of automated systems.

Bead-Based Array Systems

Automated Systems

While laboratories use automated systems for many types of blood tests, to our knowledge, there are no fully-automated high-throughput microarray systems for our target markets.

Antigen, Protein and Antibody Microarrays and Their Technical Challenges

Antigen, protein and antibody microarrays printed on a two-dimensional substrate solve several limitations of bead-based systems such as interactions between beads, but are challenging to develop as we believe there are several technological obstacles, including:

•: precision and accuracy of printing;
•: cross interference of similar molecules in the system;
•: calibration and standardization of multiple separate molecular signals; and
•: complex software systems required to analyze and measure the multiple signals.

Our Solution

Our proprietary microarray tests and automated systems are designed to simplify antigen, protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. In many instances, our technology enables analysis that was traditionally unavailable.

Our high-throughput SQiDworks diagnostic platform is a fully-automated microarray processing and analytical instrument, which provides significant cost savings and other benefits over existing technologies. Additionally, the incremental cost savings of tests run on our fully-automated platform versus existing technologies increase as the complexity of the test increases.

Our IgXPLEX microarrays have the ability to accurately measure multiple biomarkers in a single test. Additionally, our microarray technology uses less patient blood and has fewer steps than traditional methods, which increases the predictive value of the test. The increased predictive value of the test may allow the healthcare provider to choose a treatment plan earlier in the course of the disease.

Our IgXPLEX CHEX technology provides multiple in-microarray checks to ensure that the test has been completed without system, control, calibration or microarray-related errors. These tests reduce undetected errors that are common to microtiter and microarray tests.

Our proprietary multiplex assay development processes and microarray manufacturing capabilities, combined with our automated systems, are designed to significantly reduce the complexity and cost to our customers to commercialize microarray tests using their own biomarkers.

Products

SQI Platforms

		Clearance/Approval Status

	Development Status	Clearance/Approval Status
Product	Development Status	Canada	United States	Europe
SQiDworks	Complete	Licensed	Cleared as a system with IgXPLEX RA	CE Marked
SQiDman	Development RUO	Not Required — RUO	Not Required — RUO	Not Required — RUO
SQiDlite RUO	In development	Not Required — RUO	Not Required — RUO	Not Required — RUO
SQiDlite IVD	In development	To be filed	To be filed	To be filed

We have developed our fully-automated SQiDworks platform to enable our customers to generate numerous patient test results with significantly less labor, consumables and other costs, while maintaining excellent data quality. We have received marketing clearance from the FDA and Canadian regulatory approval for, and have CE marked, our SQiDworks instrument system. SQiDworks is the only fully-automated microarray processing system to achieve these regulatory clearances.

SQiDman is our small semi-automated platform that we are commercialising for RUO purposes, and SQiDlite is our fully-automated, bench-top diagnostic platform.

SQI Assays

Our currently cleared or approved assays are as follows:

		Clearance/Approval Status

	Development Status	Clearance/Approval Status
Product	Development Status	Canada	United States	Europe
IgXPLEX RA (Qualitative)	Complete	Licensed	Cleared	N/A
IgXPLEX RA* (Quantitative)	Complete	Licensed	To be filed	CE Marked
IgXPLEX Celiac (Qualitative)	Complete	Licensed	Cleared	N/A
IgXPLEX Celiac (Quantitative)	Complete	Licensed	To be filed	CE Marked

*: Marketed in Canada under the name QuantiSpot Rheumatoid Arthritis.

Our four cleared or approved assays test for two of the more common autoimmune diseases. Rheumatoid arthritis is a chronic inflammatory disease. The prevalence of rheumatoid arthritis is approximately 2% world wide. It is estimated that total size of the patient market in the United States for rheumatoid arthritis diagnostic testing for 2010 was approximately six million patients. Celiac is an inherited autoimmune disorder that affects the digestive process of the small intestine. It is estimated that the total size of the patient market in the United States for celiac diagnostic testing for 2010 was approximately 3.5 million patients.

We also have IgXPLEX Lupus, IgXPLEX Vasculitis and IgXPLEX TNF products in the development stage and IgXPLEX IBD/Crohn's and IgXPLEX Antiphospholipid Syndrome products at the proof of concept stage. In addition, we are developing rheumatoid arthritis and celiac assays with greater sensitivity that measure additional biomarkers.

Scienion Products

Scienion offers a range of microarray printing equipment and associated services. Scienion's sciFLEXARRAYER range of microarray printing equipment is targeted to address research customers seeking bench-top equipment up to large customers seeking commercial-scale automated microarray printing equipment

as described in the table below. Scienion also markets contract microarray manufacturing and microarray development services.

Application	Product	Description

Printing	sciFLEXARRAYER S1 / DW	Entry-level model of Scienion's sciFLEXARRAYER product line
	sciFLEXARRAYER S3	Automated non-contact dispensing system of ultra-low volumes designed for academic and research and development labs
	sciFLEXARRAYER S5 and S11	Automated non-contact dispensing systems of ultra-low volumes designed to manufacture high quality arrays
	sciFLEXARRAYER Sx	Scalable robotic dispensing platforms that enable users to choose size of working area
	sciFLEXARRAYER S100	High-throughput array and biosensor production instrument
Microarray Platform	sciPLEXPLATE	A specifically developed plate to array RNA, DNA, proteins, antigens and antibodies
Liquid Handling	sciSWIFT	Storable and disposable liquid dispensing pens

Key Competitive Strengths

We believe that our key competitive strengths include the following:

•: Only FDA Cleared, Fully-Automated Microarray Processing System. We have received marketing clearance from the FDA, Canadian regulatory approval for, and have CE marked, our SQiDworks instrument system as well as diagnostic tests for rheumatoid arthritis and celiac. SQiDworks is the only system for automatically processing, analyzing and providing test results in protein-based and antibody-based microarrays to achieve these regulatory clearances.
•: Fully-Integrated, High-Throughput Solution Dramatically Reduces Workflow and Cost. Our proprietary microarray tests and fully-automated systems are designed to significantly simplify antigen, protein and antibody workflow, increase throughput and reduce costs, all while providing excellent data quality. For example, competing systems require hundreds of steps to produce the same number of test results as can be produced by our SQiDworks fully-integrated diagnostics system in five steps.
•: Expertise in Microarray Assay Development. We have clinically validated development experience and have created processes, systems and development algorithms to simplify the commercialization of our products. We believe our expertise will reduce the time required to complete the commercial development of our pipeline products.
•: Focus on Penetrating Existing Markets that Are Technically Challenging and Have Established Reimbursement. We focus on disease testing markets that have existing reimbursement and payment programs in place, which allows us to quickly bring our products into established markets. Additionally, antigen, protein and antibody multiplex tests are more technically challenging to develop, which may restrict others from easily entering these markets.

•: Partnerships with Leading Institutions. We have entered into agreements with leading institutions and healthcare providers to collaborate with us in developing and validating our assays including providing us with access to approximately 10,800 clinically validated patient blood samples.
•: Significant Intellectual Property Portfolio. Our intellectual property covers key areas of our commercial business as well as our pipeline, including microarray surfaces, multiplexing, microarray analytics, and microarray processing.

Strategy

Our goal is to become an industry leader in the development and commercialization of microarray and multiplexing diagnostic systems. We intend to accomplish this goal through:

•: Product development efforts. We are continuing to focus our research and development on high-volume, high-margin, multiplexed tests for diseases for which there are existing tests that have reimbursement programs in place and predicate technologies that have received FDA clearance.
•: Strategic market penetration. We have identified and are marketing our turnkey SQiDworks platform and approved assays to a specific group of laboratories which process high volumes of tests and typically adopt new technologies to gain market share. Please see "— Sales and Marketing" for a description of our target laboratories.
•: Leveraging our core technology and expertise to access new markets and new customers. Our technology and microarray development processes enable us to provide customized third party microarray formatted test development and manufacturing services.
•: Seeking partnerships and strategic acquisitions. With our proposed acquisition of Scienion, we intend to become the industry leader in printing solutions, which will enable us to quickly expand our third party development and microarray manufacturing services. We intend to continue to seek partnerships that will enable us to expand into new markets, broaden and deepen our lines of business and develop and strengthen our relationships with our customers.
•: Leading through innovation. We intend to continue our research and development in each of our lines of business in order to become the industry leader in multiplexing microarrays.

Corporate Information

Our principal and registered office is located at 36 Meteor Drive, Toronto, ON M9W 1A4, and our telephone number is (416) 674-9500. We have a single subsidiary, SQI Diagnostics Systems Inc., which is wholly-owned.

Emblem Capital Inc., the predecessor to SQI Diagnostics Inc. was incorporated on September 11, 2003 pursuant to theCanada Business Corporation Act (the "CBCA") and filed articles of amendment to change its name to "SQI Diagnostics Inc."

On April 20, 2007, an amalgamation between Umedik Inc. and 670194 Canada Inc., a wholly-owned subsidiary of Emblem Capital Inc., was completed and the amalgamated company changed its name to "SQI Diagnostics Systems Inc." on September 7, 2007.

The predecessor to Umedik Inc. was formed on April 19, 1999 pursuant to theBusiness Corporations Act (Ontario) under the corporate name of Pockit Corporation. Pockit Corporation filed articles of amendment on June 9, 1999 to change its name to Poc•Kit Corporation. Poc•Kit Corporation was continued under the CBCA on December 1, 1999 under the name of e-umedik Inc. and e-umedik Inc. filed articles of amendment on October 20, 2000 to change its name to Umedik Inc. 6701914 Canada Inc. was incorporated on January 12, 2007 pursuant to the CBCA.

Details of the Offering


Common Shares Offered:		• common shares.
Offering Price:		US$ • (C$ • ) per common share.
Size of Offering:		US$ • (C$ • )
Common Shares Outstanding Assuming Completion of the Offering:		As of July 4, 2011, we had 33,946,258 common shares outstanding (38,387,444 on a fully diluted basis). There will be • common shares outstanding immediately following the closing of the offering ( • on a fully diluted basis). These calculations assume no exercise of the over-allotment option. See "Capitalization".
Offering Type:		Offering in the U.S. under the MJDS and in the province of Ontario.
Use of Proceeds:		The estimated net proceeds of the offering of common shares to us, assuming no exercise of the over-allotment option, after deducting the underwriters' commission and our estimated expenses will be $ • . We intend to use approximately $15 million of the net proceeds in satisfaction of the cash portion of the purchase price payable for the Scienion acquisition, a portion for sales and marketing initiatives, a portion for research and development activities, a portion for the expansion of our manufacturing operations and the balance for working capital and other general corporate purposes. See "Use of Proceeds".
Over-Allotment Option:		We have granted the underwriters the over-allotment option exercisable for a period of 30 days from the closing of the offering to purchase up to an additional • common shares equal to 15% of the offered shares at the offering price to cover over-allotments, if any, and for market stabilization purposes. See "Underwriting".
Dividend Policy:		To date, we have not paid any dividends and do not expect to do so in the foreseeable future. We currently intend to retain all future earnings for the operation and expansion of our business. See "Dividend Policy".
Listing:		Our outstanding common shares are listed and posted for trading on the TSXV under the symbol "SQD". Our common shares have been approved for listing on NYSE Amex under the trading symbol "SQD".
Risk Factors:		There are certain risk factors inherent in an investment in our common shares and in our activities. You should carefully review the information set out under "Risk Factors" and all other information in and incorporated by reference into this prospectus before making an investment in our common shares.
Lock-up Agreements:		Our directors and certain of our officers have agreed to enter into lock-up agreements with the underwriters. These lock-up agreements restrict the ability of our directors and these officers to sell or transfer their common shares for a period of 90 days after the date of the final prospectus.

Selected Financial Information

The following table sets forth selected financial information for the dates and periods indicated. Our selected financial information as of September 30, 2010 and 2009 has been derived from our audited consolidated financial statements for those annual periods, which are included elsewhere in this prospectus and incorporated by reference into this prospectus, and our selected financial information as of March 31, 2011 and 2010 has been derived from our unaudited interim consolidated financial statements for the six month periods ended March 31, 2011 and 2010, which are included elsewhere in this prospectus and incorporated by reference into this prospectus. Our consolidated financial statements have been prepared in Canadian dollars and in accordance with Canadian generally accepted accounting principles. For a reconciliation of the significant differences in our consolidated annual financial statements between Canadian GAAP and U.S. GAAP, see "Supplemental Note Regarding the Reconciliation of the Consolidated Financial Statements for the Years Ended September 30, 2010 and 2009 with U.S. GAAP", which is included elsewhere in this prospectus and incorporated by reference into this prospectus. For a reconciliation of the significant differences in our interim consolidated financial statements between Canadian GAAP and U.S. GAAP, see the "Supplemental Note Regarding the Reconciliation of the Interim Consolidated Financial Statements for the Three and Six Month Periods Ended March 31, 2011 and 2010 with U.S. GAAP", which is included elsewhere in this prospectus and incorporated by reference into this prospectus. Operating results for the six month period ended March 31, 2011 are not necessarily indicative of the results that may be expected for the fiscal year ended September 30, 2011 or any other future period. The summary financial information below should be read in conjunction with our financial statements and the notes thereto and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this prospectus and incorporated by reference into this prospectus.

		Year Ended September 30,						6 Months Ended March 31

Consolidated Statement of Operations Data C$ in 000's except per share data		2009			2010			2010			2011
Revenue:
	Product sales	$	5		$	5		$	—		$	13
	Consulting fees		27			30			15			9

Total Revenue			32			35			15			22

Expenses
	Salaries and wages		469			556			265			332
	General and administrative		447			471			202			324
	Professional and consulting		436			659			297			200
	Sales and marketing		409			474			193			215
	Stock based compensation		380			402			115			228
	Research and Development		3,362			5,059			2,327			2,612
	Amortization — property and equipment		417			415			209			225
Amortization — patent and trademark			98			100			56			57

Total expenses			6,018			8,136			3,664			4,193

Operating loss before interest			(5,986	)		(8,101	)		(3,649	)		(4,171	)
Interest Income			121			32			12			42
Interest Expense			(45	)		(4	)		(3	)		—

Net loss		$	(5,910	)	$	(8,073	)	$	(3,640	)	$	(4,129	)

Basic and diluted loss per share		$	(0.23	)	$	(0.27	)	$	(0.13	)	$	(0.12	)
Weighted average number of shares			25,158			30,349			28,924			33,806

Consolidated Balance Sheet Data	September 30, 2009		September 30, 2010		March 31, 2011

Cash and cash equivalents	$	3,180	$	9,408	$	4,669
Working capital		3,280		8,930		5,121
Total assets		6,205		13,134		9,190
Total shareholders' equity		5,836		12,162		8,456

RISK FACTORS

An investment in our common shares involves a number of risks. In addition to the other information contained in this prospectus and in the documents incorporated by reference into this prospectus, including our consolidated financial statements and related notes, you should give careful consideration to the following risk factors. Any of the matters highlighted in these risk factors could have a material adverse effect on our business, results of operations and financial condition, causing an investor to lose all, or part of, its, his or her investment.

The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are not aware of or focused upon, or that we currently deem to be immaterial, may also impair our business operations and cause the trading price of our common shares to decline.

If our proposed acquisition of Scienion is completed, our combined businesses will face similar risks to those described below.

Risks Related to Our Business and Strategy

We have incurred losses since inception, and we expect to continue to incur losses for the foreseeable future.

We have a limited operating history and have incurred significant losses in each fiscal year since our inception, including net losses of $3.8 million, $5.9 million, $8.1 million and $4.1 million during fiscal 2008, 2009, 2010 and the six months ended March 31, 2011, respectively. As of March 31, 2011, we had an accumulated deficit of $37.6 million. These losses have resulted principally from costs incurred in our research and development programs and from our selling, general and administrative expenses. We expect to continue to incur operating and net losses and negative cash flow from operations, which may increase, for the foreseeable future due in part to anticipated increases in expenses for research and product development and expansion of our sales and marketing capabilities. Additionally, following this offering, we expect that our selling, general and administrative expenses will increase due to the additional operational and reporting costs associated with being a SEC reporting company. We anticipate that our business will generate operating losses until we successfully implement our commercial development strategy and generate significant additional revenues to support our level of operating expenses. Because of the numerous risks and uncertainties associated with our commercialization efforts and future product development, we are unable to predict when we will become profitable, and we may never become profitable. Even if we do achieve profitability, we may not be able to sustain or increase our profitability.

Our future capital needs are uncertain and we may need to raise additional funds in the future, which may not be available on a timely basis or on commercially reasonably terms.

We believe that the net proceeds from this offering remaining after the completion of our proposed acquisition of Scienion described in this prospectus, together with our existing cash and cash equivalents, will be sufficient to meet our anticipated cash requirements for at least the next 10 months. However, we may need to raise substantial additional capital to:

•: expand the commercialization of our products;
•: manufacture our platforms in advance of placing them with our customers;
•: fund our operations; and
•: further our research and development.

Our future funding requirements will depend upon many factors, including:

•: development of new and existing products;
•: market acceptance of our products;
•: the cost of our research and development activities;
•: the cost of potential licensing of technologies patented by others;
•: the cost of filing and prosecuting patent applications;

•: the cost of defending, in litigation or otherwise, any claims that we infringe third party patents or violate other intellectual property rights;
•: the cost and timing of regulatory clearances or approvals;
•: the cost and timing of establishing additional sales, marketing and distribution capabilities;
•: the cost and timing of establishing additional technical support capabilities;
•: the effect of competing technological and market developments; and
•: the extent to which we acquire or invest in businesses, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions, other than our proposed acquisition of Scienion.

If we raise additional funds by issuing equity securities, our shareholders may experience dilution. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt or additional equity financing may contain terms that are not favorable to us or our shareholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us.

If we do not have, or if we are unable to timely obtain additional funds on acceptable terms, or at all, we may have to delay development or commercialization of our products or license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to liquidate some or all of our assets, reduce the scope of or eliminate some or all of our development programs, reduce marketing, customer support or other resources devoted to our products, or cease operations. Any of these factors could harm our business, financial condition and results of operations.

Market competition and technological advances of similar diagnostics products could reduce the attractiveness of our products or render them obsolete.

The markets for our products are characterized by rapidly changing technology, evolving industry standards, changes in customer needs, emerging competition, new product introductions and strong price competition. We compete with both established and development stage companies, universities, research institutions, governmental agencies and healthcare providers that design, manufacture and market similar diagnostic products. Many of our current competitors have significantly greater name recognition, greater financial and human resources, broader product lines and product packages, larger sales forces, larger existing installed bases, larger intellectual property portfolios and greater experience and capabilities in researching, developing and testing products, in obtaining FDA and other regulatory approvals or clearances, and in manufacturing, marketing and distribution, than we have. For example, companies such as Bio-Rad Laboratories Inc., Phadia AB, Axis-Shield plc, and INOVA Diagnostics, Inc. have products that compete in certain segments of the market in which we sell our products, including immunoassays. In addition, a number of other companies and academic groups are in the process of developing novel products and technologies for diagnostics markets.

With respect to our proposed acquisition of Scienion, the largest array print manufacturers that are also offering custom array services and whom we believe represent Scienion's most significant competitors include, in the United States, Arrayit Corporation, Bio-Synthesis Inc., Full Moon Biosystems, Inc., Microarrays Inc., Aushon BioSystems, Inc., and Applied Microarrays, Inc. and, in Europe, GeSiM mbH, and Arrayjet Limited.

Our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. In light of these advantages, even if our technology is more effective than the product or service offerings of our competitors, current or potential customers might accept competitive products and services in lieu of purchasing our technology. We anticipate that we will face increased competition in the future as existing companies and competitors develop new or improved products and as new companies enter the market with new technologies. We may not be able to compete effectively against these organizations. Increased competition is likely to result in pricing pressures, which could harm our sales, profitability or market share. Our failure to compete effectively could materially and adversely affect our business, financial condition and results of operations.

If our products fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected.

We currently have one customer and our success depends, in part, upon our ability to develop and market products that are recognized and accepted as reliable, accurate, timely and cost effective by physicians, lab technicians and administrators. Most of our potential customers already use expensive diagnostic products and systems in their laboratories and may be reluctant to replace those systems. Market acceptance of our products and technologies will depend upon many factors, including our ability to provide a broad test menu of assays to potential customers, and our ability to convince potential customers that our systems are an attractive cost- and time-saving alternative to existing technologies. Compared to most competing technologies, our microarray assay technology is relatively new, and most potential customers have limited knowledge of, or experience with, our products. Prior to adopting our microarray assay technology, some potential customers may need to devote time and effort to testing and validating our systems. Any failure of our systems to meet these customer benchmarks could result in customers choosing to retain their existing systems or to purchase systems other than ours.

We are subject to complex regulatory compliance requirements and the failure to obtain, or the withdrawal of, regulatory clearance or approval for our products could adversely affect our ability to market our products and/or require us to incur significant costs to comply with such requirements.

We operate in a highly regulated industry and we are subject to the authority of certain regulatory agencies, including Health Canada, the FDA, European Conformity (CE) and applicable health authorities in other countries, with regard to the development, testing, manufacturing, marketing and sale of our diagnostic products. The process of obtaining such clearances or approvals can be costly and time-consuming, and if we are unable to timely obtain or maintain regulatory clearances or approvals, it would have a material adverse effect on our business. Clearance by regulatory authorities can be suspended or revoked, or we could be fined, based on a failure to continue to comply with applicable standards. Any failure to obtain (or significant delay in obtaining) or maintain applicable regulatory clearances or approvals (or, to a lesser extent, approval of applicable health authorities in other countries) for our new or existing products could materially affect our ability to market its products successfully and could therefore have a material adverse effect on our business. Additionally, the authority of the regulatory agencies or the application of certain regulations may be expanded or otherwise changed in such a manner that would place additional regulatory burdens on us or our customers. Such a change in our industry could have a material adverse effect on our business.

We must manufacture products in compliance with regulatory requirements, in sufficient quantities and on a timely basis, while maintaining product quality and acceptable manufacturing costs. If we or our suppliers are unable to manufacture or contract for such capabilities on acceptable terms, our plans for commercialization could be materially adversely affected.

Our manufacturing facilities are subject to periodic regulatory inspections by the regulatory agencies and these facilities are subject to quality standards requirements of the applicable regulatory authorities. We, or our contractors, may not satisfy such regulatory or standards requirements, and any failure to do so may have a material adverse effect on our business, financial condition and results of operations.

We may not be able to develop new products or enhance the capabilities of our existing diagnostics products to keep pace with rapidly changing technology and customer requirements.

The field of diagnostics is characterized by rapidly changing and developing technologies that include new products that could render our diagnostic processing equipment and consumable tests obsolete at any time and thereby adversely affect our financial condition and future prospects. Our success depends upon our ability to develop new products with improved performance and cost effectiveness in existing and new markets. New technologies, techniques or products could emerge that might offer better combinations of price and performance than our current or future product lines. It is critical to our success for us to anticipate changes in technology and customer requirements and to successfully introduce new, enhanced and competitive technology to meet our prospective customers' needs on a timely basis.

Developing and marketing new products and services will require us to incur substantial development costs and we may not have adequate resources available to be able to successfully introduce new versions of, or

enhancements to, our products. We cannot guarantee that we will be able to maintain technological advantages over emerging technologies in the future. While we plan to continue to make improvements to our current and future cleared or approved and marketed diagnostic processing equipment and consumable tests, we may not be able to successfully implement these improvements. If we fail to keep pace with emerging technologies, demand for our products will not grow, and our business, revenue, financial condition and operating results could suffer materially. Even if we successfully implement some or all of these planned improvements, we cannot guarantee that potential customers will find our enhanced products to be an attractive alternative to existing technologies, including our current products.

Research and development of diagnostic products requires significant testing and investment and may not result in commercially viable products within the timeline anticipated, if at all.

New diagnostic products, and improvements to existing diagnostic products, require significant research, development, testing and investment prior to any final commercialization. Our business depends upon the continued development and improvement of our existing products, our development of new products to serve existing markets and our development of new products to create new markets and applications that were previously not practical with existing systems. We believe that the adoption of our platform by potential customers depends, in part, upon our ability to provide a test menu of assays to potential customers. To date, we have obtained regulatory approval for only a few diagnostic assays.

We intend to devote significant personnel and financial resources to research and development activities designed to advance the capabilities of our diagnostic technology and, in the case of ourin vitro diagnostics business, to obtain regulatory approval of additional assays. In the past, our product development projects have been delayed. We may have similar delays in the future, and we may not obtain any benefits from our research and development activities. Any delay or failure by us to develop new products or enhance existing products would have a material adverse effect on our business and results of operations. If we are unable to successfully develop these products, accomplish such improvements, receive applicable regulatory clearances or approvals, produce the products in commercial quantities at reasonable costs, or successfully market the products, it would have a material adverse effect on our business and results of operations. Our long-term success must be considered in light of the expenses, difficulties and delays frequently encountered in connection with the development of new technology and the competitive and highly regulated environment in which we operate.

We may need additional capacity to meet our manufacturing needs at the end of 2012.

Based on our microarray manufacturing forecasts, we expect that there is adequate capacity in our current location to expand our manufacturing capacity to meet our expected needs until the end of 2012. Until a facility upgrade is completed, we intend to undertake equipment upgrades to ensure sufficient manufacturing capacity to meet our expected requirements for commercial sales and our internal validation studies until the end of 2012. Pending the contemplated upgrades to, or expansion of, our facility, we are leasing our facility under short-term arrangements. We do not anticipate any requirement to relocate any of our operations. However, we may need to relocate our facility upon one month's notice from our landlord.

Our inability to obtain our required manufacturing space in a timely manner and on terms acceptable to us will result in delays which could have a material adverse effect on our financial condition and results of operations.

Even if we are able to enter into a lease for a new facility, we must also implement and maintain an international standard "ISO" quality management system for such new facility. Any delay in implementing an ISO quality management system will have a material adverse effect on our financial condition and results of operations.

Our future success depends upon our ability to expand our customer base and introduce new products and services.

Our success will depend upon our ability to gain acceptance, and then increase our market share, among our customers, attract additional customers outside of our initial target markets, and bring to market new products and services. Attracting new customers and introducing new products and services requires substantial time and expense. For example, it may be difficult to identify, engage and market to customers who are

unfamiliar with the benefits of our products and services. Any failure to establish and expand our existing customer base or launch new products or services would adversely affect our ability to increase our revenues.

We have limited experience in marketing, selling and distributing our products, and we need to expand our internal and external sales and marketing force and distribution capabilities to successfully commercialize and sell our products.

As we are in the early stages of commercializing and marketing our products, we have limited experience in marketing, selling and distributing our products. We may not be able to market, sell and distribute our products effectively enough to support our planned growth. We intend to market, sell and distribute our products directly through our own sales force in North America, Europe and elsewhere. Our future sales will depend in large part upon our ability to develop and substantially expand our direct sales force and to increase the scope of our marketing efforts.

Our products are technically complex and used for specialized applications. Our ability to market our products effectively will depend, in part, upon our ability to convince laboratories that our products will deliver accurate patient results in less time and with significantly reduced labor, consumables and other costs. As a result, we believe it is necessary to develop a direct sales force that includes people with specific scientific backgrounds and expertise and a marketing group with technical sophistication. Competition for such employees is intense. We may not be able to attract and retain personnel, or be able to build an efficient and effective sales and marketing force, which could negatively impact sales of our products, and reduce any future revenues and profitability.

If our sales, marketing and distribution efforts are not successful, our technologies and products may not gain market acceptance, which would materially impact our business operations.

We rely on strategic partnerships for research and development and commercialization of our products.

We have entered into and may continue to enter into strategic partnerships with a number of medical institutions. For example, we have entered into strategic agreements with the Cleveland Clinic, Beth Israel Deaconess Medical Center, Hospital Clinic De Barcelona, University Hospital Maastricht, and The University of North Carolina at Chapel Hill. If any of our strategic partners were to change their business strategies or development priorities, they may no longer be willing or able to participate in such strategic partnerships which could have a material adverse effect on the timing of our future development efforts. In addition, we may not control the strategic partnerships in which we participate. We may also have certain obligations with regard to our strategic partnerships, in addition to the obligation to pay money, such as an obligation to publish the results of research.

If any of our strategic partners terminate their relationship with us or fail to perform their obligations in a timely manner, or if we fail to perform our obligations in a timely manner, the development or commercialization of our technology in potential products may be affected, delayed or terminated.

We depend upon key suppliers for some of the components and materials used in our platform technologies and our microarrays, and the loss of any of these suppliers could harm our business.

We rely on key suppliers for certain components and materials used in our platform technologies, including our SQiDworks diagnostic platform and our microarrays. We do not have agreements with these key suppliers to supply us with components in the future. The loss of any of these key suppliers would require significant time and effort to locate and qualify an alternative source of supply. There are a limited number of suppliers who can manufacture the highly specialized equipment that forms a part of our SQiDworks system.

Our first set of assays being commercialized requires a highly specific mono-layer coating on the glass surface which is used to bond each of the microarray "spots". We have worked closely with these manufacturers to extend the capabilities of their standard products to support the unique needs of our platform technologies and microarray devices. Any change in any component that forms a part of our SQiDworks system will require additional testing to ensure that it performs in a substantially similar manner to the existing component.

Our reliance on these suppliers also subjects us to other risks that could harm our business, including the following:

•: we may be subject to increased component costs;
•: we may not be able to ensure that any component that we change performs in a substantially similar manner to the existing component;
•: we may not be able to obtain adequate supply in a timely manner or on commercially reasonable terms;
•: our suppliers may make errors in manufacturing components that could negatively affect the efficacy of our systems or cause delays in shipment of our systems; and
•: our suppliers may encounter financial hardships unrelated to our demand for components, which could inhibit their ability to fulfill our orders and meet our requirements.

We may not be able to quickly establish additional or replacement suppliers, particularly for our single source components. Any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our strategic partners and future customers.

Future legislative or regulatory changes to the healthcare system, including reimbursement, may adversely affect our business.

The healthcare regulatory environments in the jurisdictions in which we operate and plan to operate may change in a way that restricts our ability to market our diagnostic testing products due to medical coverage or reimbursement limits. Sales of our diagnostic systems will depend, in part, upon the extent to which the costs to patients of such tests are paid by health maintenance, managed care, and similar healthcare management organizations, or reimbursed by government health payor administration authorities, private health coverage insurers and other third party payors. These healthcare management organizations and third party payors are increasingly challenging the prices charged for medical products and services. The containment of healthcare costs has become a priority of governments. Accordingly, our potential products may not be considered cost effective, and reimbursement to the ultimate patient may not be available or sufficient to allow us to sell our products on a competitive basis. Legislation and regulations affecting reimbursement for our products may change at any time and in ways that are difficult to predict and these changes may be adverse to us. For example, a reduction in U.S. Medicare, Medicaid or other third party payor reimbursements for diagnostic services could have a negative effect on our operating results. In June 2011, the FDA issued draft guidance that sets forth the FDA's proposed interpretation of laws regarding the marketing of IVD products labelled as RUO products that could be used forin vitro diagnostic purposes. Among other things, the draft guidance suggests that it is generally inappropriate for a manufacturer to sell RUO products to clinical laboratories that the manufacturer knows, or has reason to know, use the products for clinical diagnostic uses. Given that the guidance is in draft form and has only recently been issued by the FDA, it is not clear how the FDA will interpret this guidance. As a result, we cannot be certain what impact, if any, this guidance will have on our business.

We will incur significant increased costs as a result of operating as a public company in the United States, and our management will be required to devote substantial time to new compliance initiatives.

As a new public company in the United States, we will incur significant legal, accounting and other expenses that we did not incur previously. In addition, the United States Sarbanes-Oxley Act, as well as new rules subsequently implemented by the SEC, have imposed various new requirements on public companies, including requiring changes in corporate governance practices. We expect to become subject to additional rules as a result of the adoption of the United States Dodd-Frank Wall Street Reform and Consumer Protection Act. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage.

If we fail to maintain effective internal control over financial reporting in the future, the accuracy and timing of our financial reporting may be impaired, which could adversely affect our business and our share price.

The Sarbanes-Oxley Act requires, among other things, that we perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our testing, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses. Our compliance with Section 404 will require that we incur substantial accounting expense and expend significant management time on compliance-related issues. If we are not able to comply with the requirements of Section 404 in a timely manner, or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our shares could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources to address.

Failure to complete our planned Scienion acquisition or to successfully integrate Scienion's business with ours could negatively affect our business, financial condition and results of operations.

The completion of our acquisition of Scienion is subject to the satisfaction of certain closing conditions, including the closing of the offering for gross proceeds of at least $30,000,000. If we do not complete our proposed acquisition of Scienion, we will not realize any of the expected benefits of the acquisition.

Our pending Scienion acquisition may consume a significant amount of our management resources. The success of the acquisition will depend, in part, upon our ability to realize the anticipated benefits from integrating Scienion's business with our existing businesses. The integration process may be complex, costly and time-consuming. To realize these anticipated benefits, we must successfully combine the business of Scienion in an efficient and effective manner. If we are not able to achieve these objectives within the anticipated time frame, or at all, the anticipated benefits of the acquisition may not be realized fully, or at all, or may take longer to realize than expected. We will also incur significant costs in connection with the completion of the Scienion acquisition. Most of these costs will be non-recurring transaction expenses.

We rely on certain key personnel and our ability to successfully grow our business would be adversely affected by their departure from our company.

Our performance depends substantially upon the performance of our senior management and key scientific and technical personnel, including our Chief Executive Officer, Claude Ricks, our Chief Financial Officer, Andrew Morris, and our Chief Scientific Officer, Dr. Peter Lea. Retaining these key personnel and recruiting additional qualified personnel in the future will be critical to our success. We believe there is only a limited number of individuals with the requisite skills to serve in many of our key positions. Competition for qualified personnel in the diagnostics industry is intense and recruiting and retaining qualified personnel with experience in our industry is very difficult. We compete for key personnel with other medical equipment and software manufacturers and technology companies, as well as universities and research institutions.

If we are unable to attract and retain skilled and experienced personnel, or if we lose the services of any member of our senior management or our scientific or technical staff, we could experience significant delays in, or we could be unable to, complete the development and commercialization of our products or achieve our other business objectives, and such a development could require our management to divert its attention to transition matters and identification of suitable replacements, if any. Such a development could have a material adverse effect on our business, financial condition and results of operations.

We do not maintain, and do not intend to obtain, key employee life insurance on any of our personnel.

A portion of our compensation to our key employees is in the form of stock option grants. A prolonged decline in our share price could make it difficult for us to retain our employees and recruit additional qualified personnel.

Additionally, following our proposed acquisition of Scienion, we expect that the current Chief Executive Officer of Scienion, Dr. Holger Eickhoff, will enter into an employment agreement with us to develop and

commercialize Scienion's and our products. If we lose the services of Dr. Eickhoff, we may experience significant delays in connection with the integration of Scienion's business with our existing business or we may fail to realize some of the expected benefits of the acquisition which would have a material adverse effect on our business, financial condition and results of operations.

If we cannot provide quality technical support, we could lose customers and our operating results could suffer.

The placement of our products and the introduction of our technology into our customers' existing operations and on-going customer support can be complex. Accordingly, we need highly trained technical support personnel. To effectively support new customers, we will need to substantially expand our technical support staff. If we are unable to attract, train or retain the number of highly qualified technical services personnel that our business will require, our business, financial condition and results of operations will suffer.

We may experience development or manufacturing problems or delays that could limit the growth of our revenue or increase our losses.

We have been developing our core technologies in our facilities in Toronto, Canada, which we believe has adequate space to expand the manufacturing capacity to our expected needs for the foreseeable future. However, we may encounter unforeseen situations at this facility that would result in delays or shortfalls in our development and production. In addition, our development and production processes and assembly methods may have to change to accommodate any significant future expansion of our manufacturing capacity. If we are unable to keep up with development of or demand for our products, our revenue could be impaired, market acceptance for our products could be adversely affected and our customers might instead purchase our competitors' products. Our inability to successfully manufacture our products would have a material adverse effect on our business, financial condition and results of operations.

Our products could have unknown defects or errors, which may give rise to claims against us and adversely affect market adoption of our systems.

Our products utilize complex technology applied on a small scale, and our systems may develop or contain undetected defects or errors. As our production levels increase, material performance problems, defects or errors could arise. We may determine to correct any defects or errors in response to customer concerns, in order to preserve customer relationships, and to help foster continued adoption and use of our systems. The costs incurred in correcting any defects or errors may be substantial and could adversely affect our operating margins.

In manufacturing our products, we depend upon third parties for the supply of various components. Many of these components require a significant degree of technical expertise to produce. If our suppliers fail to produce components to specification, or if the suppliers, or we, use defective materials or workmanship in the manufacturing process, the reliability and performance of our products will be compromised.

If our products contain defects, we may experience:

•: a failure to achieve market acceptance or expansion of our product sales;
•: loss of customer orders and delay in order fulfillment;
•: damage to our brand reputation;
•: increased cost of our warranty program due to product repair or replacement;
•: product recalls or replacements;
•: inability to attract new customers;
•: diversion of resources from our manufacturing and research and development departments into our service department; and
•: legal claims against us, including product liability claims, which could be costly and time consuming to defend and result in substantial damages.

The occurrence of any one or more of the foregoing could negatively affect our business, financial condition and results of operations.

We operate in an industry where there is the potential for substantial product liability claims that would cause us to incur significant costs, create adverse publicity and/or prevent us from commercializing our products.

We may be subject to claims of personal injury and could become liable to clinical laboratories, hospitals, physicians and patients for harm resulting from use of our products. We could suffer financial loss due to defects in our products, and such financial loss and potential litigation expenses could have a material adverse effect on our business, financial condition and results of operations. If our product liability insurance is not adequate to cover all claims or if we are unable to maintain such insurance at reasonable cost, it would have a material adverse effect on our business, financial condition and results of operations.

We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.

Our research and development and manufacturing processes involve the controlled use of hazardous materials, including flammables, toxics, corrosives and biologics. We maintain a level 2 biohazard laboratory (a laboratory that has established specific procedures for handling bacteria and viruses that may pose a risk of mild disease in humans) and our operations produce hazardous biological and chemical waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials. We do not currently maintain separate environmental liability coverage and any such contamination or discharge could result in significant cost to us in penalties, damages and suspension of our operations.

We may be unable to successfully manage fluctuations in revenue, which could impede our ability to successfully develop, market and sell our products.

Our quarterly and annual revenues may fluctuate due to several factors, including customer order patterns, the rate of acceptance of our products, regulatory uncertainties or delays, costs and timing associated with business development activities, including potential licensing of technologies, and international market conditions. The impact of one, or a combination of several, of these factors could have a significant adverse effect on our business, financial condition and results of operations.

Our future financial results may be adversely affected by foreign exchange fluctuations.

We expect that a significant portion of our future revenues will be denominated in U.S. and European currencies, and, therefore, we will be subject to fluctuations in exchange rates. There is a risk that significant fluctuations in exchange rates would negatively affect our operating margins and would therefore have an adverse effect on our future results of operations.

Risks Related to Intellectual Property

Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain.

Our commercial success depends in part upon our ability to protect our intellectual property and proprietary technologies. We rely on patent protection, where appropriate and available, as well as a combination of copyright, trade secret and trademark laws, and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Our pending Canadian, U.S. and foreign patent applications may not issue as patents or may not issue in a form that will be sufficient to protect our proprietary technology and gain or keep our competitive advantage. Any patents we have obtained or do obtain may be subject to re-examination, reissue, opposition or other administrative proceeding, or may be challenged in litigation, and such challenges could result in a determination that the patent is invalid or unenforceable. In addition, competitors may be able to design alternative methods or devices that avoid infringement of our patents. To the extent our intellectual property,

including licensed intellectual property, offers inadequate protection, or is found to be invalid or unenforceable, we are exposed to a greater risk of direct competition. If our intellectual property does not provide adequate protection against our competitors' products, our competitive position could be adversely affected, as could our business, financial condition and results of operations. Both the patent application process and the process of managing patent disputes can be time consuming and expensive. Furthermore, the laws of some foreign countries may not protect our intellectual property rights to the same extent as do the laws of Canada and the United States.

The patent positions of companies in the diagnostics industry can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies' patents has emerged to date in Canada and the United States. The laws of some non-Canadian countries do not protect intellectual property rights to the same extent as the laws of Canada, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Changes in either the patent laws or in interpretations of patent laws in the United States, Canada or other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents. For example:

•: we might not have been the first to make the inventions covered by each of our pending patent applications;
•: we might not have been the first to file patent applications for these inventions;
•: others may independently develop similar or alternative products and technologies or duplicate any of our products and technologies;
•: it is possible that none of our pending patent applications will result in issued patents, and even if they issue as patents, they may not provide a basis for commercially viable products, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties;
•: we may not develop additional proprietary products and technologies that are patentable;
•: the patents of others may have an adverse effect on our business; and
•: we may fail to apply for patents on important products and technologies in a timely fashion or at all.

In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside Canada and the United States may be less willing to protect trade secrets.

We may be involved in lawsuits to protect or enforce our patents and proprietary rights, to determine the scope, coverage and validity of others' proprietary rights, or to defend against third party claims of intellectual property infringement that could require us to spend significant time and money and could prevent us from selling our products or services or impact our share price.

The diagnostics industry relies heavily upon patented technology. We follow a patent program to protect our technology and take precautions to avoid infringement against the technology of others. Litigation may be necessary for us to enforce our patent and proprietary rights and/or to determine the scope, coverage and validity of others' proprietary rights. Litigation on these matters has been prevalent in our industry and we

expect that this will continue. To determine the priority of inventions, we may have to initiate and participate in interference proceedings declared by the Canadian Intellectual Property Office, the U.S. Patent and Trademark Office, and patent offices in other countries that could result in substantial legal fees and could substantially affect the scope of our patent protection. Also, our intellectual property may be subject to significant administrative and litigation proceedings such as invalidity, unenforceability, re-examination and opposition proceedings against our patents. The outcome of any litigation or other proceeding is inherently uncertain and might not be favorable to us, and we might not be able to obtain licenses to technology that we require on commercially acceptable terms or at all. We could therefore incur substantial costs related to royalty payments for licenses obtained from third parties. Further, we could encounter delays in product introductions, or interruptions in product sales, as we develop alternative methods or products.

In addition, if we resort to legal proceedings to enforce our intellectual property rights or to determine the validity, scope and coverage of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail.

Our commercial success may depend in part upon our non-infringement of the patents or proprietary rights of third parties. Numerous significant intellectual property issues have been litigated, and will likely continue to be litigated, between existing and new participants in the diagnostics market and competitors may assert that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into that market. Third parties may assert that we are employing their proprietary technology without authorization.

In addition, our competitors and others may have patents or may in the future obtain patents and claim that use of our products infringes these patents. As we move into new markets and applications for our products, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us.

Patent infringement suits can be expensive, lengthy and disruptive to business operations. We could incur substantial costs and divert the attention of our management and technical personnel in prosecuting or defending against any claims, and may harm our reputation. There can be no assurance that we will prevail in any suit initiated against us by third parties. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products, and could result in the award of substantial damages against us, including treble damages and attorneys' fees and costs in the event that we are found to be a willful infringer of third party patents.

In the event of a successful claim of infringement against us, we may be required to obtain one or more licenses from third parties, which we may not be able to obtain at a reasonable cost, if at all. In addition, we could encounter delays in product introductions while we attempt to develop alternative methods or products to avoid infringing third party patents or proprietary rights. Defense of any lawsuit or failure to obtain any required licenses on favorable terms could prevent us from commercializing our products, and the risk of a prohibition on the sale of any of our products could adversely affect our ability to grow and gain market acceptance for our products.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares.

In addition, our agreements with suppliers, customers, and other entities with whom we do business, may require us to defend or indemnify these parties to the extent they become involved in infringement claims against us, including the claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify any of these third parties in connection with

any infringement claims, we could incur significant costs and expenses that could adversely affect our business, financial condition or operating results.

We may in the future depend upon licensed technology to conduct our business. We might not control these technologies and any loss of our rights to them could in the future prevent us from selling our products.

We may in the future rely on licenses in order to be able to use various proprietary technologies that become material to our business. We might not own the patents that underlie these licenses. This may subject us to certain risks that might not be present if we develop the technology and intellectual property independently. In particular, our proposed acquisition of Scienion may require us to rely on licenses that Scienion depends on to be able to use its proprietary technologies that are material to its business.

In many potential third party licenses, we might not control the prosecution, maintenance, or filing of the patents to which we may in the future hold licenses, or the enforcement of these patents against third parties. We cannot be certain that drafting and/or prosecution of the licensed patents by the licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. As a result, we may depend upon the licensor to diligently pursue and prosecute these intellectual property rights. The failure of the licensor to diligently pursue such protection could adversely affect our business and financial condition.

Our rights to use the technology we might license may be subject to the validity of the owner's intellectual property rights. Enforcement of such licensed patents or defense of any claims asserting the invalidity of these patents is often subject to the control or cooperation of our licensors. Legal action could be initiated against the owners of the intellectual property that we may license. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent these other companies or institutions from continuing to license intellectual property that we may need to operate our business.

Our rights to use the technology we may in the future license are subject to the negotiation of, continuation of and compliance with the terms of those licenses. Specifically, license agreements typically subject us to milestone obligations and royalty payments. Some of these obligations may be substantial and may obligate us to obtain certain regulatory clearances or approvals by a specified date or exercise diligence in bringing potential products to market. The failure to meet these obligations typically results in the termination of the license and the loss of rights to the technology. Any such termination could prevent us from marketing some or all of our products and could adversely affect our business, financial condition and results of operations.

Because of the complexity of our products and the patents we may license, determining the scope of such licenses and related royalty obligations can be difficult and can lead to disputes between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant to the license. If a licensor believed we were not paying the royalties due under the license or were otherwise not in compliance with the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful, we might be barred from producing and selling some or all of our products.

Finally, many potential third party licenses of technology expire when the patents underlying the technology expire or at some period of time after expiration. As a result, our ability to exploit and fully commercialize the licensed technology over time may be limited. This may adversely affect our business, financial condition and results of operations.

We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our employees' former employers.

Many of our employees were previously employed at universities or other life sciences companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper or prevent our ability to commercialize potential products, which could severely harm our business. Even if we are

successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.

Risks Related to Our Common Shares and This Offering

We expect that our share price will fluctuate significantly, and you may not be able to resell your common shares at or above the offering price.

Prior to this offering, our common shares have been listed for trading on the TSXV in Canada. Following this offering, we expect that our common shares will be listed on NYSE Amex. We cannot predict the extent to which investor interest in our company will lead to the development of an active trading market on the TSXV or NYSE Amex, or how liquid those markets might become. If an active trading market does not develop, you may have difficulty selling any of our common shares that you buy. We and the underwriters will determine the public offering price of our common shares through negotiation. This price will not necessarily reflect the price at which investors in the market will be willing to buy and sell our common shares following this offering. In addition, the market price of our common shares on the TSXV in Canada, like the share prices of many publicly traded life sciences companies, has been highly volatile, and the trading price of our common shares following this offering may remain volatile in response to various factors, some of which are beyond our control. These factors could include, for example:

•: actual or anticipated quarterly variation in our results of operations or the results of our competitors;
•: announcements by us or our competitors of technological innovations, new commercial products, significant contracts, commercial relationships or capital commitments;
•: developments or disputes concerning our intellectual property or other proprietary rights;
•: commencement of, or our involvement in, litigation;
•: market conditions in the diagnostics sector;
•: regulatory developments in the U.S., Canada and other countries;
•: failure to complete significant sales;
•: issuance of new or changed securities analysts' reports or recommendations for our common shares;
•: any future sales of our common shares or other securities;
•: any major change to the composition of our board of directors or management; and
•: general economic conditions and slow or negative growth of our markets.

The stock market in general, and market prices for the securities of technology-based companies like ours in particular, have from time to time experienced volatility that often has been unrelated to the operating performance of the underlying companies. A certain degree of stock price volatility can be attributed to being a newly public company. These broad market and industry fluctuations may adversely affect the market price of our common shares, regardless of our operating performance. In several recent situations where the market price of an issuer's shares has been volatile, holders of those shares have instituted securities class action litigation against the company that issued the shares. If any of our shareholders were to bring a lawsuit against us, the defense and disposition of the lawsuit could be costly, and could divert the time and attention of our management and harm our operating results.

If securities or industry analysts do not publish research or publish unfavorable research about our business, our share price and trading volume could decline.

The trading market for our common shares will rely in part on the research and reports that equity research analysts may publish about us and our business. We do not currently have and may never obtain research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common shares after the completion of this offering, and such lack of research coverage may adversely affect the market price of our common shares. If we obtain equity research analyst coverage, we will not have any control

over the analysts or the content and opinions included in their reports. The price of our common shares could decline if one or more equity research analysts downgrade our common shares or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our common shares could decrease, which in turn could cause our share price or trading volume to decline.

Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment.

The offering price of our common shares is substantially higher than the net tangible book value per common share immediately prior to this offering. Therefore, if you purchase our common shares in this offering, you will incur an immediate dilution of $ • in pro forma as adjusted net tangible book value per share as of March 31, 2011. In addition, new investors who purchase common shares in this offering will contribute approximately • % of the total amount of equity capital raised by us through the date of this offering, but will only own approximately • % of the outstanding share capital and approximately • % of the voting rights. In addition, we have issued options and warrants to acquire common shares at prices below the offering price. To the extent outstanding options and warrants are ultimately exercised, there will be further dilution to investors who purchase common shares in this offering. In addition, if the underwriters exercise their over-allotment option or if we issue additional equity securities, investors purchasing common shares in this offering will experience additional dilution. For a further description of the dilution that you will experience immediately after this offering, see "Dilution."

Future sales of common shares by existing shareholders could cause our share price to decline.

If our existing shareholders sell, or indicate an intention to sell, substantial amounts of our common shares in the public market, the trading price of our common shares could decline. Based on the number of our common shares outstanding as of July 4, 2011, upon completion of this offering, we will have outstanding a total of • common shares, assuming no exercise of the underwriters' over-allotment option. Certain of our directors and officers will enter into lock-up agreements with the underwriters that restrict their ability to sell or transfer their common shares. The lock-up agreements pertaining to this offering will expire 90 days after the date of the final prospectus, although they may be extended for up to an additional 18 days under certain circumstances. Our underwriters, however, may, in their sole discretion, permit our officers and directors to sell common shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on common shares outstanding as of • , 2011, up to an additional • common shares will be eligible for sale in the public market. If these additional common shares are sold, or it is perceived that they will be sold in the public market, the trading price of our common shares could decline.

Our directors and executive officers will continue to have substantial control over us after this offering and could limit your ability to influence the outcome of key transactions, including changes of control.

Following the completion of this offering, our executive officers, directors and their affiliates will beneficially own or control approximately • % of our outstanding common shares assuming no exercise of the underwriters' over-allotment option. Accordingly, these executive officers, directors and their affiliates, acting as a group, would have substantial influence over the outcome of corporate actions requiring shareholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transactions or agreements. These shareholders may also delay or prevent a change of control of our company, even if such a change of control would benefit our other shareholders. The significant concentration of share ownership may adversely affect the trading price of our common shares due to investors' perception that conflicts of interest may exist or arise.

We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

We will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common shares. We intend to use the net proceeds from this offering to complete the acquisition of Scienion, sales and marketing initiatives, research and development activities, the expansion of our facilities and manufacturing operations as well as for working capital and other general corporate purposes. We may use a portion of our net proceeds to

acquire and invest in complementary products, technologies or businesses; however, we currently have no agreements or commitments to complete any such transaction (other than the acquisition of Scienion). We have not allocated these net proceeds for any specific purposes. We might not be able to yield a significant return, if any, on any investment of these net proceeds. You will not have the opportunity to influence our management's decisions on how to use the net proceeds from this offering, and our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our products and cause the price of our common shares to decline.

We have never paid dividends on our common shares, and we do not anticipate paying any cash dividends in the foreseeable future.

To date, we have not paid any dividends and do not expect to do so in the foreseeable future. We currently intend to retain all future earnings for the operation and expansion of our business. Dividends on our common shares are declared at the discretion of our board of directors and will depend on our results of operations, capital requirements, financial condition, prospects, contractual arrangements and other factors that our board determines is relevant.

If we become a "passive foreign investment company", adverse U.S. federal income tax consequences will likely result for U.S. holders

Based on our current business plans and financial projections, we believe that we should not be classified as a passive foreign investment company ("PFIC") during our current tax year ending September 30, 2011. However, no assurance can be provided that we will not become a PFIC for any taxable year during which a "U.S. holder" (as defined in "Certain Material United States Federal Income Tax Considerations" below) holds common shares. If we are classified as a PFIC for any year during a U.S. holder's holding period, then such U.S. holder generally will be required to treat any gain realized upon a disposition of our common shares, or any so-called "excess distribution" received on our common shares, as ordinary income, and to pay an interest charge on a portion of such gain or distributions, unless the shareholder makes a timely and effective "qualified electing fund" election ("QEF Election") or a "mark-to-market" election with respect to the common shares. We do not currently intend to provide U.S. holders with the information required to make a QEF Election effective in the event we are a PFIC. A U.S. holder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the U.S. holder's common shares over the U.S. holder's basis therein. This paragraph is qualified in its entirety by the discussion below under the heading "Certain Material United States Federal Income Tax Considerations." Each U.S. holder should consult its own tax advisor regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares.

CAPITALIZATION

The table below sets out our capitalization as of March 31, 2011 on an actual basis, and on a pro forma basis to give effect to the sale of • of our common shares in this offering at the initial public offering price of US$ • per share after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

	As of March 31, 2011

Capitalization	Actual			Pro Forma
Common Shares — 33,912,921 shares issued and outstanding unlimited authorized (actual), • shares issued and outstanding unlimited authorized (pro forma)	$	35,329			•
Warrants — 2,632,852 warrants convertible into 2,632,852 shares		1,614			•
Employee share purchase loan		(10)	*		•
Contributed Surplus		9,137			•
Accumulated Deficit		(37,614	)		•

Total shareholder's equity	$	8,456			•

*: Repaid on June 1, 2011.

The table above excludes 1,867,000 shares of common shares issuable upon exercise of stock options outstanding as of March 31, 2011, at a weighted average exercise price of $1.86 per share, and 291,367 common shares reserved for future issuance under our 2007 stock-based compensation plans. If approved by our shareholders at our annual general meeting to be held on July 7, 2011, the number of common shares reserved for issuance under our stock option plan will be equal to 10% of our issued and outstanding common shares, which as of the date hereof would be equal to 3,394,625 common shares.

USE OF PROCEEDS

We estimate that the net proceeds from the offering will be US$ • , after deducting estimated underwriting commissions of US$ • and estimated offering expenses of US$ • . If the underwriters' overallotment option is exercised in full, we estimate that we will receive aggregate net proceeds of US$ • .

We expect to use the net proceeds that we will receive from this offering as follows:

•: $15,000,000 million in satisfaction of the cash portion of the purchase price payable for our acquisition of Scienion (see "Acquisition of Scienion AG");
•: a portion for sales and marketing initiatives to support the ongoing commercialization of our systems, including expanding our sales force;
•: a portion for research and development activities to build out our test menu and expand our line of diagnostic platforms;
•: a portion for the expansion of our manufacturing operations; and
•: the balance for working capital and other general corporate purposes.

As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. The actual use of the net proceeds of the offering will depend on operating and capital needs and the progress of all research and development programs. We may also use a portion of our net proceeds to acquire and invest in complementary products, technologies or businesses. However, other than the Scienion acquisition, we currently have no agreements or commitments to complete any such transaction and are not involved in negotiations to do so. Accordingly, we will have broad discretion in the application of the net proceeds and potential investors will be relying on the judgment of our management regarding the application of the proceeds from this offering. Pending these uses, we intend to invest the net proceeds of the offering in investment grade, short-term, interest bearing securities.

BUSINESS OF THE COMPANY

Overview

Our proprietary microarray tests and fully-automated instruments are designed to simplify antigen, protein and antibody testing workflow, increase throughput and reduce costs, all while providing excellent data quality. In many instances, our technology enables analysis that was traditionally unavailable.

Our principal lines of business include:

•: the development, manufacturing, and marketing of fully-automated diagnostic instruments (our "platform");
•: the development and marketing of tests for the autoimmune, allergen, infectious disease and companion diagnostics testing markets (our "assays"); and
•: the commercialization of microarray printing technology (our "printing solutions").

Our Platform

Our FDA-cleared SQiDworks platform is comprised of three key elements: a proprietary one-time-use consumable microarray device, a validated and integrated instrument system that fully-automates the processing of patient samples in the microarray device, and a proprietary software processing system that processes and analyses the array and reports the presence or absence of a biomarker ("qualitative testing") and/or the amount of biomarker present ("quantitative testing"). Our SQiDworks platform can perform qualitative or quantitative testing for multiple biomarkers simultaneously. Our SQiDworks platform is currently the only FDA-cleared, fully-automated, microarray system and multiplexing solution in our target markets and we believe there are significant barriers to entry in these markets. We believe that our SQiDworks platform addresses many of the key challenges faced by our customers today by delivering accurate patient results in less time and with significantly reduced labor, consumables and other costs.

We are developing SQiDlite, our fully-automated, bench-top diagnostic platform for bothin vitro diagnostic ("IVD") and research use only ("RUO") applications. We are also currently commercializing SQiDman, our small semi-automated platform for processing microarrays, to be used by research customers or development partners for RUO applications in the microarray development process.

Our Assays and the Development of Our Test Menu

We have received regulatory clearance to market our qualitative rheumatoid arthritis and celiac assays in the United States, our qualitative and quantitative rheumatoid arthritis and celiac assays in Canada, and our quantitative rheumatoid arthritis and celiac assays in the European Union for use on our SQiDworks platform. We have a robust pipeline of autoimmune tests and one companion diagnostic test in development, and plan to develop a broad test menu for autoimmune disease, companion diagnostics, infectious disease and allergen testing markets in the future. Our current in-development tests include multiplexed panels to aid in the diagnosis of vasculitis, lupus, antiphospholipid syndrome ("APS"), Crohn's disease and inflammatory bowel disease

("IBD") and in the management of treatment of autoimmune affected patients with a class of drugs referred to as "anti-TNF drugs" such as Remicade®, Enbrel® and Humira®.We are currently developing more sensitive rheumatoid arthritis and celiac assays that measure additional biomarkers.

We have targeted these testing markets because we believe:

•: healthcare providers require the measurement of multiple biomarkers to aid in the diagnosis and therapeutic monitoring of these diseases;
•: these testing markets are underserved by fully-automated, high-throughput, multiplexed systems;
•: tests in these markets are generally run at sufficiently high volumes in larger test facilities that would benefit from both multiplexing and automation; and
•: these tests typically qualify for private and public reimbursement in Canada, the United States, and the European Union.

One of our key operational goals is to continue to develop and seek regulatory approval for additional tests, as we believe that expanding our "test menu" will drive adoption of our platform and products by customers.

The development of our test menu is augmented by our partnerships with leading research institutions, including Beth Israel Deaconess Medical Center, the Cleveland Clinic, and the University of North Carolina. Our partnerships provide us with many advantages, including the rights to approximately 10,800 patient samples, which aid us in the development and validation of our assays.

We also offer development services and manufacturing of diagnostic kits and microarrays to our customers. We will convert content of laboratories and third parties into microarray products, manufacture microarray test kits for sale to these customers and, in the case of third parties, enable them to re-sell our high throughput systems on which these proprietary assays can be run. Our laboratory customers may use these custom microarray components to perform diagnostic test services using our platforms and may subsequently sell the results to their customers.

Our Printing Solutions and Our Proposed Acquisition of Scienion

On July 4, 2011, we announced that we entered into a definitive agreement to acquire all of the issued and outstanding shares of Scienion, which we believe is a market leader in microarray printing development, production arrayer systems and contract print and development services for the life sciences industry. We believe our proposed acquisition of Scienion will further our entry into the market for providing enabling technologies and processes for multiplexed protein, antibody, antigen and molecular (genetic) microarrays. We believe Scienion is a leader in the commercialization of non-contact array printing equipment, as well as the "in-array" development and manufacturing services to a broad set of customers in all microarray printing markets. See "— Proposed Acquisition of Scienion" and "Acquisition of Scienion AG".

The Market for Our Products

The diagnostic products and services market is increasing in importance, complexity, breadth and size. Diagnostics are critical to high-quality healthcare and guide a majority of clinical decisions.

Over the last forty years, the number of biomarkers that can be measured by commercial laboratories has grown dramatically, with less than 4,000 different types of biomarker measured in the 1970s, more than doubling to approximately 10,000 with automation in the 1980s, and increasing to approximately 25,000 in the early 2000s.

Since 1976, the number of biomarkers measured by assays cleared through the FDA's 510(k) process to aid in the diagnosis of the six autoimmune diseases that comprise our target market has increased from four to 48. This represents an increase in the average number of biomarkers per disease state in our autoimmune disease target market from 0.7 to 8. We believe that this increase in biomarkers is indicative of a healthcare trend whereby healthcare providers are seeking to run diagnostic tests for increasing numbers of biomarkers to assist in the diagnosis of disease.

Researchers and laboratories are accelerating the rate at which new biomarkers are being commercialized for the known set of diseases being diagnosed today. It is estimated that an additional 30,000 biomarkers (molecular and protein) in various stages of development have been identified and not yet commercialized. We believe that the increased use of existing assays and the introduction of new assays will drive growth of the diagnostics testing market, a market that is estimated to have a growth rate of approximately five to nine percent annually from 2009 to 2014.

Our strategy is to focus initially on the immunoassay segment of the diagnostic test market since there are no multiplexed, microarray, IVD solutions in the immunoassay space. The 2012 global immunoassay diagnostic test market is estimated to be US$10.3 billion, of which approximately US$4.5 billion is within our strategic market focus, which includes tests for autoimmune disease, infectious disease, and allergen tests. These three markets are estimated to be US$1.5 billion, US$2.4 billion and US$0.6 billion, respectively.

Autoimmune Disease Tests

Our primary testing market in the immunoassay segment is for products that aid in the diagnosis of autoimmune disease, which is estimated to be approximately US$1.5 billion per year. We have targeted the autoimmune testing segment for the following reasons:

•: there are ten autoimmune disease states, which include the autoimmune diseases in our target market, that command most of the blood testing revenues for the entire autoimmune testing segment;
•: the most common tests for autoimmune diseases currently evaluate approximately 70 biomarkers, representing an average of approximately seven biomarkers per disease;
•: these tests are generally run at high volumes at larger test facilities and in batches and are not typically run on a "one off" basis;
•: generally, autoimmune disease tests have an established reimbursement model from private and public healthcare payers;
•: each of the autoimmune diagnostic tests we are developing has predicate technologies with FDA clearance on older, single biomarker, manual titer plate technology that we intend to replace;
•: regulatory clearance for the majority of autoimmune assays is through the FDA 510(k) process, which is well established; and
•: autoimmune disease tests are regulated as Class II devices by the FDA. Class II diagnostic clearance is generally obtained following a shorter review period than for a Class III device. See — Government Regulation.

Infectious Disease and Allergen Tests


SQI's Addressable Market — Global Immunoassay Diagnostic Test Market		SQI's Strategic Market Focus — Global Autoimmune, Infectious Disease and Allergen Diagnostic Testing Market
US$10.3 Billion*		US$4.5 Billion*

*Annual estimate for 2012
Source: Freedonia 2011

Print Services

According to a press release issued by F. Hoffmann-La Roche Ltd., in 2007, the estimated market for protein and molecular microarray print equipment and services was approximately US$600 million per year.

RUO and Lab-Developed Tests

Approximately 34% of the US$3.7 billion U.S. annual market for RUO and lab-developed tests is directly addressable by our proprietary technologies. Additionally, we believe that the US$2.2 billion European market for RUO and lab-developed tests has approximately the same segmentation as the U.S. market. As such, we anticipate that the combined U.S. and European markets for RUO and lab-developed tests that are directly addressable by our proprietary technologies to be approximately US$2 billion.


U.S. Annual Market for RUO and Lab-Developed Test		Global Annual Market for RUO and Lab-Developed Tests

*Source: Kalorama 2010

Companion Diagnostics

We believe that the commercialization of "companion diagnostics" tests is a meaningful market opportunity for us. Autoimmune diseases are increasingly being treated with antibody-based or other biologic drugs. Often, there are different variants of the antibody or biologic drugs. For example, anti-TNF-based drugs are used to treat rheumatoid arthritis, Crohn's disease and IBD. The market for anti-TNF drugs was estimated to be approximately US$16 billion per year in 2008. Anti-TNF drugs are currently marketed under brand names such as Remicade®, Enbrel® and Humira® which represented more than 99% of the anti-TNF drug market in 2008. The effectiveness of the treatment of autoimmune patients with these drugs may be enhanced by the monitoring of the concentration of these drugs in a patient's blood by a "companion diagnostic" test. Our multiplexing technology allows us to combine the tests for both the diagnosis and therapeutic monitoring of a patient's disease. We expect this test combination to result in significantly less labor, consumables and other costs and provide us with a large market opportunity.

Diagnostics

Assays are used world-wide to assist healthcare providers in preventing, diagnosing and treating diseases. In order to be able to determine whether someone has a particular disease, a typical assay will test for "biomarkers", a term used to refer to a specific antigen, protein or antibody. The amount or "concentration" of the biomarker in a person's blood usually indicates one or more of the following: the predisposition or risk of getting the disease; presence or absence of the disease; and severity of the disease. For example, assays have been used for more than 50 years to detect the presence of rheumatoid factors, which are diagnostic markers for rheumatoid arthritis. The use of assays to detect rheumatoid factors first received 510(k) clearance by the FDA approximately 35 years ago. Rheumatoid factors can be detected in the blood of a patient before the first symptoms appear, can indicate the progression of the disease, and provide information that may guide a healthcare provider's determination of a patient's treatment plan.

Diagnostics "platforms" refer to the specific technology or instrument system on which a consumable device is "run" to generate test results. There are a number of different platforms on which assays can be run. For example, ELISA (enzyme-linked immunosorbent assay, a test involving an enzyme and an antibody) plates and readers, ELISA bead technology and polymerase chain reaction-based systems are all platforms for running assays.

A microarray is a device that is used to perform multiple tests simultaneously. A microarray is comprised of two principal elements.

•: A surface upon which capture molecules are printed in the form of spots. The surface is typically glass or plastic and is chemically coated to more easily "accept" and bind the molecules being printed without damaging the molecules.
•: A physical superstructure to separate individual wells. Each well contains numerous spots. Each of the spots within an individual well is analogous to a traditional microtiter plate test well.

The biological and chemical reactions that occur in each test well generate multiple test results. Each of these test results is a billable event for our customers.

Limitations of Current Technologies

Clinical, academic, and diagnostic development laboratories are faced with increasing numbers of tests or experiments required to support a diagnostic conclusion or development decision. In the diagnostic setting, there are a growing number of biomarkers that are used for each patient to aid in the diagnosis and monitoring of many diseases. This has led to a growing workload of increasingly complex and costly diagnostic tests for laboratories. Additionally, laboratories face pressure to reduce overall healthcare system costs.

Our target customers — clinical, academic and diagnostic development laboratories — require diagnostic processing equipment and consumable tests that are capable of processing large numbers of patient samples at low cost and with minimal labor requirements. High-throughput systems have not been widely employed in autoimmune disease or allergen testing and limited use of high-throughput systems exists in infectious disease

testing. To our knowledge, no high-throughput systems exist that are capable of addressing the combined multiplex testing needs of these markets. A fully-automated system capable of providing multiple biomarker measurements in a single test array has the potential to increase a laboratory's throughput with significantly less labor, consumables, and other costs. We believe these cost savings would be realized because, among other things:

•: a fully-automated system reduces "hands-on" technician time;
•: the volume of liquid reagent is less and the number of other consumables, such as pipette tips, required to process one microarray is fewer when compared to traditional methods of running multiple tests in multiple titer plates;
•: the amount of serum required per patient to produce results on a 12 biomarker test is approximately 240 times greater using titer plates than using microarray plates;
•: a laboratory does not incur the expense of sending some tests of a larger multiplex panel to other labs;
•: the cost of management of multiple samples being tested by multiple technicians and combining the results to a single report would be largely eliminated by multiplexing capability; and
•: reducing the number of hands-on steps through automation would potentially reduce error rates.

Microtiter Plates

Laboratories almost exclusively use microtiter plates to perform immunoassay tests. The use of microtiter plates restricts an immunoassay test to the analysis of a single biomarker. Microtiter plates are predominantly processed with a high contribution of direct labor. This increases the time to produce a test result and the potential for error. Since equipment available to reduce labor is limited, the use of microtiter plates restricts the throughput of a laboratory. We estimate that 60% of our target customers' costs to produce a diagnostic result are due to direct labor.

Skilled laboratory labor capable of performing diagnostic testing in our target markets is limited and is expected to contribute to laboratories' growing cost structure at an increasing rate. The United States Department of Health and Human Services reported in 2009 that by 2012, 138,000 lab professionals, including medical technicians and laboratory assistants, will be needed, but fewer than 50,000 will be trained.

Multiplex Diagnostic Tests

A solution to the cost and labor constraints of immunoassay testing for single biomarkers is to perform diagnostic tests for multiple biomarkers simultaneously in a single assay (a "multiplex diagnostic test"). The processes used to complete a single test within a diagnostic panel of several biomarkers are complex and technically difficult. Such complexity has limited the throughput and efficiency of multiplex diagnostic testing, and technical challenges have restricted the widespread adoption of automated systems. Most laboratories do not use automated processing equipment to augment their workforce in our key target markets where the measurement of multiple antigens, proteins or antibodies is required.

Bead-Based Array Systems

Bead-based array systems were initially developed for DNA-based testing and were subsequently adapted for protein-based and antibody-based testing. Bead-based methods, however, have faced limitations that reduce their utility, particularly for multiplex diagnostics and experimentation. In particular, the workflow for bead arrays is complex, time consuming and costly. For example, standard protocols for a nine-biomarker bead array require multiple complex operations including approximately 190 steps and approximately five hours of "hands-on" time to complete.

Automated Systems

While laboratories use automated systems for many types of blood tests, to our knowledge, there are no fully-automated high-throughput microarray systems. A number of diagnostics companies have developed

automated single-plex fully-automated, bench-top systems for autoimmune testing and we are only aware of one bead-based automated multiplex system.

Antigen, Protein and Antibody Microarrays and Their Technical Challenges

An alternative to bead-based array systems is a microarray printed on a two-dimensional substrate. These antigen, protein and antibody microarrays solve several limitations of bead-based systems such as interactions between beads, but are challenging to develop as we believe there are several technological obstacles, including:

•: precision and accuracy of printing;
•: cross interference of similar molecules in the system;
•: calibration and standardization of multiple separate molecular signals in a single microarray well; and
•: complex software systems required to measure and analyze the multiple signals measured within the microarray.

Precision and Accuracy of Printing

Microarray printing has been traditionally done with contact printers that, like a quill pen, physically "spot" the biomarker capture molecules onto the microarray surface. These contact methods of printing are imprecise and lead to microarrays with high degrees of variability and significant background noise. This reduces the commercial applications of contact spotted microarrays. Contact spotting does not typically lead to IVD capable microarrays in antigen, protein and antibody applications. Some earlier versions of non-contact printers are also used today, but these technologies have similar drawbacks to contact spot printers.

Cross Interference

The ability to discriminate among different "isotypes" (types) of individual target antibodies and different antigens and proteins is important to the measurement of biomarkers and it has proven challenging to develop multiplex tests that discriminate between these different entities in a single microarray.

Calibration and Standardization

The processing of multiplex arrays is complex and is prone to high degrees of variation between test arrays. This error potentially leads to reduced test performance and has restricted the use of multiplex arrays almost exclusively to the research market where there is a tolerance for less accurate measurements.

Diagnostic approaches for measuring multiple antigen, protein or antibody biomarkers for large numbers of patients are generally unavailable or are not cleared or approved as IVD tests. Multiplexing, as it is available today, does not adequately address antigen, protein and antibody focused measurement. Most multiplexing technologies have been developed and commercialized for the processing of high-density genetic or molecular arrays. These technologies generally work from a different set of technological principles than those needed to measure multiple antigens, proteins or antibodies. Further, these technologies are used in a research setting and are generally inadequate for use in commercial diagnostic testing.

Software Systems

The sophistication of the automated systems and processing software required to analyze microarrays has restricted the commercial viability of microarrays in diagnostic laboratories.

Our Solution

Our proprietary microarray tests and automated instruments are designed to simplify antigen, protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. In many instances, our technology enables analysis that was traditionally unavailable.

Traditional biomarker testing methods using microtiter plates require approximately four minutes on average of technician "hands-on" time per biomarker per patient ("test effort"). For example, a four biomarker

test for celiac on samples from 74 patients would, on average, require eight microtiter plates, assuming each patient's blood sample is tested in duplicate using standard good laboratory practices. This would have traditionally required approximately 20 hours of direct "hands-on" labor using predicate technology.

Our Fully-Automated SQiDworks Diagnostic Platform

Our high-throughput SQiDworks diagnostic platform is a fully-automated microarray processing and analytical system capable of 888 results per hour. By way of example, for a celiac assay that measures four biomarkers, our SQiDworks platform requires approximately 30 seconds of technician "hands-on" time per patient per panel compared to approximately 16 minutes of technician "hands-on" time using microtiter plate technology, and uses one microarray kit instead of 8 single biomarker microtiter kits to generate diagnostic results for the four biomarkers. The difference between the approximately 20 hours of direct hands-on labor using microtiter plate technology and the approximately 30 minutes of direct hands-on labor using our system results in significant cost savings, as does using one microarray kit rather than eight microtiter kits.

Additionally, the cost savings demonstrated above increase as the number of biomarkers per diagnostic test increase. For example, for a lupus test that measures twelve biomarkers, our SQiDworks platform requires the same amount of technician "hands-on" time as the celiac assay, and also requires only one microarray kit. However, microtiter plate technology would require approximately 48 minutes of technician "hands-on" time per patient per panel and the use of 24 single biomarker microtiter kits. This equates to a reduction of approximately 59 hours of direct hands-on labor using our system as well as greater savings with respect to consumables.

Our IgXPLEX Microarrays

Our IgXPLEX microarrays have the ability to discriminate between individual isotypes of antibodies and antigens and proteins within a single well of a microarray, resulting in the measurement of multiple biomarkers in a single test.

Our microarray technology requires the use of significantly less patient blood than traditional methods. Our system requires a ten microliter drop of blood to be processed from a single sample tube, compared to the multiple milliliters of blood used by traditional methods. Our system dispenses the single drop of blood once per patient in a microarray well. Traditional methods require multiple blood samples to be manipulated into multiple test vessels over many steps. The reduction in processing steps and the ability to generate simultaneous multiplexed measurements from a single drop of blood increase the predictive value of the test. The increased predictive value of the test would allow the healthcare provider to choose a treatment plan earlier in the course of the disease.

Our IgXPLEX CHEX Technology

Our IgXPLEX CHEX technology provides multiple in-microarray checks to ensure that the test has been completed without system, control, calibration or microarray-related errors. These tests reduce errors that are common to microtiter and microarray tests.

Our proprietary multiplex assay development processes and microarray manufacturing capabilities, combined with our automated instruments, are designed to significantly reduce the complexity and cost to our customers to commercialize microarray tests using their own biomarkers. Customers with a need to perform large numbers of experiments may benefit from the use of our microarrays in their screening and development programs when traditional methods may be too onerous due to the large number of single tests that would be required.

Proposed Acquisition of Scienion

On July 4, 2011, we announced the proposed acquisition of all of the issued and outstanding shares of Scienion, a German company that we believe is a market leader for microarray development, production arrayer systems and contract print and development services for the life sciences industry. We believe that the proposed acquisition represents a compelling opportunity to capitalize on the global trend towards miniaturisation and

parallelisation of tests for diagnostics and pharmaceutical applications, instruments, application development, service and software.

Scienion develops and markets a range of microarray printing equipment and provides custom print and commercial print services. Scienion's equipment prints microarray spots with high precision and positional accuracy on a variety of surfaces. Scienion's equipment is able to print with volumes of biomarkers as small as ten picolitres. This enables the printing of very small diameter microarray spots, which allows more spots to be printed in a given area and more data to be produced from a single microarray. Scienion has developed advanced "in-process" methods to measure the mass and position of spots as they are being printed. This design feature results in a more reliable and reproducible print process and more accurate microarrays.

We believe that the combination of our platform, our assays and the development of our test menu and, if the acquisition is completed, Scienion's industry leading print technologies, will enable the combined company to become a leader in sales of end-to-end diagnostic systems, microarray printing and assay development services.

We believe that the proposed acquisition will:

•: enable us to combine our assay commercialization capabilities, our range of cleared and in-development processing and analytical systems for running microarray tests and the expertise of the two companies for highly technical microarray printing capabilities;
•: strengthen our technology leadership position in microarray printing, surface chemistry, and automation of microarray processes;
•: accelerate the commercialization of our pipeline of RUO and IVD systems through the use of Scienion's arrayer equipment and complete "print solutions";
•: provide us with access to Scienion's base of more than 400 customers, many of whom are potential customers for our service offerings and RUO and IVD products;
•: provide sales support for Scienion's equipment, products and services in North America;
•: give us access to Scienion's sales and engineering field service to leverage our suite of diagnostic products and services in Europe and Asia;
•: diversify our revenues and add financial strength.

Our Key Competitive Strengths

We believe that our key competitive strengths include the following:

•: Only FDA Cleared, Fully-Automated Microarray Processing System. We have received marketing clearance from the FDA, a Canadian regulatory medical device licence, and have CE marked, our SQiDworks instrument system. SQiDworks is the only system for automatically processing, analyzing and providing test results in protein-based and antibody-based microarrays to achieve these regulatory clearances.
•: Fully-Integrated, High-Throughput Solution Dramatically Reduces Workflow and Cost. Our proprietary microarray tests and fully-automated instruments are designed to significantly simplify antigen, protein and antibody workflow, increase throughput and reduce costs, all while providing excellent data quality. For example, competing systems require hundreds of steps to produce the same number of test results as can be produced by our SQiDworks fully-integrated diagnostics system in five steps.
•: Expertise in Microarray Assay Development. We have clinically validated development experience and have created processes, systems and development algorithms to simplify the commercialization of our products. We believe our expertise will reduce the time required to complete the commercial development of our pipeline products. We also believe that our experience can be applied to custom products to allow us to commercialize our own and other's content in significantly less time than our competition.

•: Focus on Penetrating Existing Markets that Are Technically Challenging and Have Established Reimbursement. We focus on disease testing markets that have existing reimbursement and payment programs in place, which allows us to quickly bring our products into established markets. Additionally, antigen, protein and antibody multiplex tests are more technically challenging to develop, which may restrict others from easily entering these markets.
•: Partnerships with Leading Institutions. We have entered into agreements with leading institutions and healthcare providers to collaborate with us in developing and validating our assays including providing us with access to approximately 10,800 clinically validated patient blood samples.
•: Significant Intellectual Property Portfolio. Our intellectual property covers key areas of our commercial business as well as our pipeline, including microarray surfaces, multiplexing, microarray analytics, and microarray processing. We have issued patents and pending patent applications that cover aspects of our microarray technology for analyzing, identifying and quantifying analytes. We are actively seeking protection for our methods of achieving high-throughput quantitative analysis for our proprietary methods for making microarray substrates and for the systems that carry out these methods for manufacturing microarray substrates. In the course of improving our products, from time to time we develop processes and systems that provide us with a competitive advantage and we will keep such developments confidential.

Products

SQI Platforms

		Regulatory Status

	Development Status	Regulatory Status
Product	Development Status	Canada	United States	Europe
SQiDworks	Complete	Licensed	Cleared as a system with IgXPLEX RA	CE Marked
SQiDman	Development RUO	Not Required — RUO	Not Required — RUO	Not Required — RUO
SQiDlite RUO	In development	Not Required — RUO	Not Required — RUO	Not Required — RUO
SQiDlite IVD	In development	To be filed	To be filed	To be filed

SQiDworks

We have developed our fully-automated SQiDworks platform (shown below) to enable laboratory customers to generate multiple patient test results with less than one unit of traditional "test effort". "Test effort" refers to the number of steps required to perform a test using microtiter plate technology.

We have received marketing clearance from the FDA, a medical device license from Health Canada, and have CE marked, our SQiDworks instrument system. SQiDworks is the only fully-automated microarray processing system to achieve these regulatory clearances.

Our SQiDworks platform integrates a microfluidics station, an automated microarray scanner, our drying device and our proprietary processing and analytic software.

The microfluidics station automatically performs sample handling and processing of the patient serum sample and prepares our IgXPLEX microarray for scanning and analysis.

Our dryer technology dries the microarray surface, which uniformly enhances the signal to noise ratios of our microarrays. The microarray scanner reads the various IgXPLEX microarray signals.

Our proprietary software uses complex algorithms to locate the array of spots containing reagents and to process the spots to measure each of the biomarkers of interest. This measurement can be either qualitative or quantitative.

SQI Assays

Our four cleared or approved assays, two for rheumatoid arthritis and two for celiac, test for two of the more common autoimmune diseases. Rheumatoid arthritis is a chronic inflammatory disease, the cause of which is unknown. The incidence of rheumatoid arthritis in North America is 1.4 cases per 100,000 in men and 3.6 cases per 100,000 in women. The prevalence of rheumatoid arthritis is approximately 2% world wide. It is estimated that total size of the patient market in the United States for rheumatoid arthritis diagnostic testing for 2010 was approximately six million patients. Celiac is an inherited autoimmune disorder that affects the digestive process of the small intestine. It is estimated that the total size of the patient market in the United States for celiac diagnostic testing for 2010 was approximately 3.5 million patients.

Our currently cleared or approved assays are as follows:

		Clearance/Approval Status

	Development Status	Clearance/Approval Status
Product	Development Status	Canada	United States	Europe
IgXPLEX RA (Qualitative)	Complete	Licensed	Cleared	N/A
IgXPLEX RA* (Quantitative)	Complete	Licensed	To be filed	CE Marked
IgXPLEX Celiac (Qualitative)	Complete	Licensed	Cleared	N/A
IgXPLEX Celiac (Quantitative)	Complete	Licensed	To be filed	CE Marked

*: Marketed in Canada under the name "QuantiSpot Rheumatoid Arthritis".

We also have IgXPLEX Lupus, IgXPLEX Vasculitis and IgXPLEX TNF products in the development stage and IgXPLEX IBD/Crohn's and IgXPLEX Antiphospholipid Syndrome ("APS") products at the proof of concept stage. We also have rheumatoid arthritis and celiac assays with greater sensitivity that measure additional biomarkers in development.

The table below sets out estimates by Frost and Sullivan of the total number of patients in the United States who required diagnostic testing for diseases for which we are developing diagnostic tests.

Autoimmune Segment		Lupus			Vasculitis			Anti-TNF			IBD/Crohn's

Estimated Total Patient Market 2010 (US)			5,000,000			400,000			3,100,000			550,000

Scienion Products

as described in the table below. Scienion also markets contract microarray manufacturing and microarray development services.

Application	Product	Description

Printing	sciFLEXARRAYER S1 / DW	Entry-level model of Scienion's sciFLEXARRAYER product line
	sciFLEXARRAYER S3	Automated non-contact dispensing system of ultra-low volumes designed for academic and research and development labs
	sciFLEXARRAYER S5 and S11	Automated non-contact dispensing systems of ultra-low volumes designed to manufacture high quality arrays
	sciFLEXARRAYER Sx	Scalable robotic dispensing platforms that enable users to choose size of working area
	sciFLEXARRAYER S100	High-throughput array and biosensor production instrument
Microarray Platform	sciPLEXPLATE	A specifically developed plate to array RNA, DNA, proteins, antigens and antibodies
Liquid Handling	sciSWIFT	Storable and disposable liquid dispensing pens

History of the Company

Our business was founded in 1999 on the concept that more sensitive, timely and less costly disease diagnostics based on antigen, protein and antibody detection would benefit healthcare providers. We believed that diagnostic testing based on ELISA technology, the diagnostic technology used at the time, had not changed significantly since its development in the 1950s and lacked accuracy and sensitivity, while the testing procedures were lengthy, difficult to execute and labor intensive. We also believed that DNA microarray technology, which was instrumental throughout the 1990s in mapping the human genome, could provide the basis for new antigen, protein and antibody detection technology that could advance beyond the limitations imposed by ELISA technology. However, antigen, protein and antibody microarrays present a very different set of challenges from the DNA microarrays used for the human genome project.

Until 1999, there was little published research on the use of microarrays for antigen, protein and antibody detection for human IVD applications. Our founders believed the problem stemmed from the following scientific problems:

•: Microarray surface coatings and printing technology were not sufficiently advanced to enable antigen, protein and antibody microarrays to be reliably printed with diagnostic grade signal;
•: Users could not reliably or consistently measure multiple biomarkers (specifically, antigens, proteins and antibodies) in the same test because these biomarkers have very different surface charge and binding characteristics; and
•: High levels of variability were likely related to the lack of standardization and control of titer plate-based ELISA tests leading to inaccurate or less predictable outcomes.

We believe that we have addressed these problems with our platform that allows us to detect and measure multiple antibodies and their different sub-types in the same two-dimensional planar microarray. Our use of specialty surface treatments and surface-coating processes allows us to create microarrays with consistent spot

characteristics and limited background noise (in other words, with high signal to noise ratios). Our two dimensional planar array design securely fixes all reagents used in an assay to the glass surface independently of one another, which eliminates unwanted biochemical interactions. Our IgXPLEX technology can detect different antibody isotypes (IgA, IgG, IgM) simultaneously from a single microarray spot using multiple detection wavelengths of light. Our calibration technology adjusts each microarray for every test, which reduces the variability that may result from environmental factors or from the use of external calibrators. We have enhanced the precision of our microarrays through the use of our system, which uses a statistically valid number of replicate spots for each biomarker being tested in combination with complex software algorithms. We believe that our technology delivers consistent, repeatable, precise test results and can measure the concentration of multiple biomarkers in a single test. Our automated technology can analyze multiple patient samples simultaneously using less time, effort, and consumables than existing titer plate technology.

Research and Development

We have assembled an experienced research and development team at our Toronto facility with the scientific, microarray printing, immunoassay, engineering, software, and process development expertise that we believe is necessary to grow our business.

Platform Development

SQiDman is our small semi-automated platform that we are commercialising for RUO purposes, and SQiDlite is our fully-automated, bench-top diagnostic platform.

SQiDlite. Our engineering development team is currently focused on the near term delivery of SQiDlite, our fully-automated, bench-top diagnostic platform. This platform, shown below in concept form, will be a fully-automated microarray processing and analytic platform. We expect that SQiDlite will be able to process multiple sizes of microarray devices from single eight-well strips up to a single 96-well microarray plate.

SQiDlite is designed to serve the following markets;

•: IVD Customers who wish to run IgXPLEX assays in flexible batch sizes up to and including 96 patients per test kit. We believe that many hospitals and other laboratories would benefit from SQiDlite's more flexible batch size capability. SQiDlite is designed to run tests in volumes per run of eight to 96 patients in multiples of eight. We believe that a platform that allows for scalable testing volumes for our assays would

increase the number of our potential hospital customers in North America from the largest 1,000 to the largest 5,000 by diagnostic testing volume.

•: Customers who seek a customizable automated microarray analyzer for RUO purposes. We believe that many RUO customers would benefit from an automated microarray analyzer that can be used in a configurable manner to optimize the development of assays. However, once assays are developed, many RUO customers seek to "lock" the settings to prevent modifications by the platform's operator. Our SQiDlite platform has been designed to accommodate these RUO customers and provide this functionality.

SQiDman. We are currently commercializing SQiDman on a pilot basis. SQiDman, our small semi-automated platform for processing microarrays, is intended to be used by research customers or development partners for RUO purposes in the microarray development process. We currently use SQiDman systems for in-house development and quality control processes. We expect the full commercial launch of SQiDman for RUO purposes in late 2011, following the enhancement of its user interface software.

Microarray Assay Development

The largest component of our current research and development efforts is microarray development. We plan to continue to focus on the commercialization of microarray content that can be run by our customers on our diagnostic platforms. Our research and development efforts are focused on the following areas:

Autoimmune Disease. We have a broad menu of autoimmune disease tests in our microarray development pipeline to augment our current product offerings. For example, in addition to our products for which we have marketing clearance or approval, we have IgXPLEX Vasculitis, IgXPLEX Lupus, and IgXPLEX TNF products in the development stage and IgXPLEX IBD/Crohn's and IgXPLEX APS at the proof of concept stage. Additionally, we have rheumatoid arthritis and celiac assays with greater sensitivity that measure additional biomarkers in development. Refer to "— SQI Assays" for a description of the markets for the autoimmune disease tests in our microarray development pipeline.

Infectious Disease. We plan to develop tests in the area of infectious disease. Infectious disease panels leverage our strengths in multiplexing, antibodies and high-throughput diagnostic systems. We have scientists and assay development specialists with experience in infectious disease assay development.

Allergen Testing. Allergen tests are very similar to, and depend upon many of the same technological advances as, autoimmune disease tests. Because allergen panels have large numbers of biomarkers, we believe this is an excellent area of opportunity to apply our multiplexing and microarray technology.

Custom Assay Development and Print Services. We plan to add assay design and print services to our product offerings. This expansion is intended to enable our laboratory and diagnostic customers to expand their use of our platforms by converting their content to microarrays. We believe that applying our in-house processes and systems to develop microarray formatted tests incorporating customers' content will allow them to reduce their assay costs with less development risk and effort by purchasing their microarrays and development services directly from us. For example, our customers will be able to add requested target biomarkers to an existing panel of biomarkers or they may request an entire panel of protein-based or antibody-based biomarkers to be developed into a RUO microarray that they may use as a lab-developed test.

(1): Approved or cleared in the U.S. and Canada.
(2): Approved or cleared in Canada and Europe.
(3): Development status for clearance in the U.S.

Our Strategy

Our goal is to become an industry leader in the development and commercialization of microarray and multiplexing IVD medical systems. We intend to accomplish this goal through:

•: Product development efforts. We intend to continue to focus our research and development on high-volume, high-margin, multiplexed tests for diseases for which there are existing tests that have reimbursement programs in place.
•: Strategic market penetration. We have identified and are marketing our turnkey SQiDworks platform and approved assays to a specific group of laboratories that process high volumes of tests and typically adopt new technologies to gain market share. Please see "— Sales and Marketing" for a description of our target laboratories.
•: Leveraging our core technology and expertise to access new markets and new customers. Our technology and microarray development processes enable us to provide customized third party microarray formatted test development and manufacturing services.
•: Seeking partnerships and strategic acquisitions. With our proposed acquisition of Scienion, we intend to become the industry leader in printing solutions, which will enable us to quickly expand our third party development and microarray manufacturing services. We intend to continue to seek partnerships that will enable us to expand into new markets, broaden and deepen our lines of business and develop and strengthen our relationships with our customers.
•: Leading through innovation. We intend to continue our research and development in each of our lines of business in order to become the industry leader in multiplexing microarrays.

Strategic Alliances

We have a number of collaboration agreements with leading global research and treatment institutes. These collaborations improve our ability to develop products by providing us with access to patient serum required for assay development, verification of products in development and final product clinical validation.

The following table provides an overview of our partnering collaborations and the relevant pipeline product as at June 15, 2011:

Partner Institute	Pipeline Product	Purpose

Cleveland Clinic	Rheumatoid arthritis, IBD	Serum Samples Clinical Validation Collaboration
Beth Israel Deaconess Medical Center	Celiac, anti-TNF	Serum Samples Collaboration / Publication
Hospital Clinic De Barcelona, Spain	Vasculitis	Serum Samples Collaboration / Publication
University Hospital Maastricht, The Netherlands	Vasculitis	Serum Samples Collaboration
The University of North Carolina at Chapel Hill	Vasculitis	Collaboration Serum Samples Clinical Validation

We collaborate with these partners to assist our development of new candidate biomarkers for future tests and intend to continue to seek additional alliances and partnerships. We have been active in strategically publishing our progress and successes both alone and in collaboration with certain of our partners.

Sales and Marketing

We currently have a three-person marketing team. Our marketing efforts are focused on generating sales of our currently cleared or approved system, which includes SQiDworks, IgXPLEX RA and IgXPLEX Celiac, to targeted, high-volume laboratories in North America and Europe.

We have identified the 400 largest laboratories, by testing volume, of the approximately 14,000 laboratories that provide blood testing services in North America and a select group of approximately 30 European laboratories. We believe this group contains laboratories that would readily adopt new technologies, look to obtain an economic advantage over their competitors, and attempt to increase their market share of diagnostic testing services. We believe that this initial target group has sufficient testing volume to support the use of SQiDworks, our currently cleared or approved tests, and the tests that we anticipated to be cleared or approved by the end of 2011. We use various marketing strategies to provide incentives to the laboratories in our initial target group that are among the first to adopt our technology. As we expand our test menu, we intend to broaden our target market and reduce the incentives provided to the early adopters of our products.

We believe our proposed acquisition of Scienion and Scienion's four person sales team will enable us to accelerate our penetration into European markets.

Customers

We focus on two customer markets:

•: Diagnostic Markets — this market consists of reference and other diagnostic laboratories that provide for-profit diagnostic blood tests.

Customers in this market seek to purchase a full diagnostics solution, including automated platforms and IVD assays. These customers sell the results produced by running our IVD assays on our automated platforms. In addition, customers in this market seek to purchase automated platforms and RUO assays that they intend to

convert into lab-developed tests that incorporate their biomarkers. These customers would run these lab-developed tests on our automated platforms and sell the results to their customers.

•: Life Sciences Markets — this market consists of customers seeking to commercialize their biomarkers as turnkey multiplexed products delivered by our contract development and manufacturing services. The customers in this market are expected to buy our automated platform and consumable microarray test kits, and to pay a royalty to us on their sales.

There are two types of customers in the life sciences markets:

•: Contract Manufacturing and Development Customers — these customers seek expertise for pilot and scale up microarray printing, and have needs in the molecular or protein/antibody areas; and
•: OEM customers — these customers seek full contract development and manufacturing services to commercialize biomarkers owned by them and seek high-throughput automated microarray analyzers to sell through their channels.

Manufacturing

Our manufacturing facility is located in Toronto, Canada. We manufacture all of our microarray kits for commercial sale and internal research and development in our facility.

We operate a "current good manufacturing practices", or "cGMP", facility that has been certified ISO 13485:2003 compliant, which enables us to meet both regulatory requirements and customer expectations. This is an international standard developed by the International Organization for Standardization that specifies the requirements for a quality management system for organizations providing medical devices and related services. Our microarray production facility is operated to ISO Class 7 clean room specifications, commonly referred to as a Class 10,000 operating level, which defines the maximum level of particles permitted per cubic foot.

Based on our microarray manufacturing forecasts, we expect that there is adequate space in the current location to expand our manufacturing capacity to meet our expected needs until the end of 2012. Until a facility upgrade is completed, we intend to undertake equipment upgrades to ensure sufficient manufacturing capacity to meet our expected requirements for commercial sales and our internal validation studies until the end of 2012.

To manufacture consumable tests, we acquire raw materials and custom molecules for our assays from well-established vendors who are either ISO certified or who have an established quality system. Each incoming reagent ingredient undergoes quality testing as required and scrutiny before being released to the manufacturing unit, and the reagent ingredients are then incorporated into finished goods as a IgXPLEX kit. Each kit contains the printed diagnostic array and several self-contained wet reagents that are loaded into the SQiDworks platform prior to use by the customer. We have been producing products suitable for validation studies since the beginning of 2007.

Certain key components of our SQiDworks platform are manufactured by third parties in FDA or ISO certified facilities and we manufacture one component. We assemble the components and deliver them to our customers, where they undergo a series of quality acceptance tests.

Competition

We compete with both established and development-stage life sciences companies that design, manufacture and market basic ELISA technology, lab automation products or multiplexing technologies. For example, companies such as INOVA Diagnostics, Inc., Phadia AB, Axis-Shield plc and Hycor Biomedical, Inc. have immunoassay products based on basic ELISA technology. Companies such as Roche Diagnostics Corporation, bioMérieux SA, Siemens AG and Abbott Laboratories Inc. provide laboratory automation technology. Companies such as Luminex Corporation and Bio-Rad Laboratories Inc. also provide bead-based multiplexing technology. These companies provide products that compete in certain segments in which we sell our products. In addition, a number of other companies and academic groups are in the process of developing novel technologies for life science markets.

Intellectual Property Strategy and Position

Our core intellectual property consists of patents that cover the following:

•: multiplexed qualification of antigens and antibodies;
•: internal (in-array) calibration; and
•: methods to create diagnostic level spot morphology.

We originated our core technology. Our patent strategy is to seek broad patent protection on new developments in microarray technology, tests and systems and then later file patent applications covering new implementations of the technology and new microarray platforms utilizing the technology. As these technologies are implemented and tested, we file new patent applications covering scientific methodologies enabled by our technology.

We have developed our own portfolio of issued patents, patent applications and design patents directed to our methodologies, commercial products and technologies in development. For our core technology relating to multiplexed qualification of antigens and antibodies and internal (in-array) calibration, we have obtained issued patents and approvals in certain jurisdictions from the patent family having the title "Method to Measure Dynamic Internal Calibration True Dose Response Curves". This patent family is directed to our calibration technology that adjusts each microarray for every test, which reduces the variability that may result from environmental factors or from the use of external calibrators. Other patent applications are currently pending. Patents issuing from this patent family will be in force until July 20, 2025, provided that all maintenance fees are paid.

We have also obtained either an issued patent or an allowance in some jurisdictions directed to our core technology relating to methods to create diagnostic level spot morphology. The patent family for this core technology has the title "Method and Device to Optimize Analyte and Antibody Substrate Binding by Least Energy Adsorption". The patent family is directed to the use of specialty surface treatments and surface coating process means that can create microarrays with consistent spot characteristics and limited background noise (in other words, with high signal to noise ratios). Other patent applications are currently pending. Patents issuing from this patent family will be in force until July 20, 2025, provided that all maintenance fees are paid.

We have filed patent applications that are currently pending in several jurisdictions directed to our qualitative and quantitative rheumatoid arthritis assays. In addition, patent applications are pending in several jurisdictions directed to our products and methodologies including patent families entitled "Method for Double-Dip Substrate Spin Optimization of Coated Micro-Array Supports", "Method and Device to Remove Fluid and Vapor", "Array Fluorescence Equalization Method", "Methods for Multiplex Analyte Detection and Quantification" and "Multiplex Microarrays and Methods for Quantification of Analytes".

Our proposed acquisition of Scienion allows us to acquire the right to commercialize technology relating to the printing of multiplexed molecular (genetic) microarrays. Scienion's core technology is picolitre liquid handling systems in the area of the life sciences. This technology is particularly advantageous for applications involving miniturization and printing of microarrays for diagnostic assays.

Scienion's core technology includes microarray printing equipment. Scienion's equipment prints microarray spots with high precision and positional accuracy on a variety of surfaces. This equipment is able to print with volumes of biomarkers as small as ten picolitres. Printing with such small volumes enables the printing of very small diameter microarray spots, which allows more spots to be printed in a given area and more data to be produced from a single microarray. Scienion has developed advanced "in-process" methods to measure the mass and position of spots as they are being printed.

Scienion has in-licensed patent applications and patents from the Max Planck Institute of Germany. The key in-licensed patents and patent applications relate to means of aspirate dispensing. This patented technology is relevant to microarray printing development, production arrayer systems and contract print and development services for the life sciences. Seven patent families have been in-licensed from the Max Planck Institute.

The patents in-licensed from Max Planck Institute of Germany will be in force until June 2, 2019 for the earliest filed of these patent families ranging to November 4, 2025 for the latest filed of these patent families, provided that all maintenance fees are paid.

Scienion has also filed patent applications directed to equipment for printing microarray spots that it has developed and owns. The technology that Scienion has developed relates to storage and dispensing modes. In particular, Scienion has filed patent applications directed to a microdispenser that can be stored and/or transported with the filled sample container independently of and fluidically separated from the actual dispensing device, without the sample liquid escaping from the sample container during storage or during transport. The filling of the sample container with the sample liquid takes place separately from the dispensing operation, whereas the filling operation in the case of the known microdispensers using a flexible supply line takes place immediately before or during the dispensing operation. In practice, the sample container of the microdispenser is usually filled prior to the dispensing operation, whereas no refilling is provided during the subsequent dispensing operation.

Scienion has focused its patent filings on key jurisdictions where it carries on business, namely the United States, Germany and the UK.

Patents that issue from the patent applications filed by Scienion will be in force until October 20, 2024 for the earliest filed of these patent families ranging to August 18, 2029 for the latest filed of these patent families, provided that all maintenance fees are paid.

Government Regulation

We believe that our major markets are the United States, Canada and the European Union. The following describes the regulatory clearance or approval process for diagnostic systems in each of those jurisdictions.

United States

Research Use Only

"Research use only" components are those components in the laboratory research phase of development that are not represented as effective IVD products. These components must be labeled "For Research Use Only. Not for use in diagnostic procedures." These components are exempt from regulatory oversight in the United States. Manufacturers frequently sell these components to laboratories certified under the Clinical Laboratory Improvement Amendments, or "CLIA", which are the United States federal regulatory standards that apply to clinical laboratory testing performed on human specimens in the United States with certain exceptions, including clinical trials and basic research.

Lab-Developed Tests

CLIA-compliant labs frequently develop and validate an assay from RUO components, sold to them by manufacturers, but the lab must validate these tests and assume all liability for use on patient samples. These tests are regulated as lab-developed tests.

Diagnostic Tests

Diagnostic tests or assays, known as "in vitro diagnostic", or "IVD", products by the FDA, are those reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including a determination of a person's state of health, in order to cure, mitigate, treat or prevent disease or its sequelae. These tests are intended for use in the collection, preparation and examination of specimens taken from the human body.

Diagnostic tests are classified into one of three categories for FDA clearance or market approval. These categories are based on the degree of risk they pose to humans and their importance in preventing impairment in human health.

All IVD tests are subject to the following "general" requirements or controls, as well as, in the case of Class II and Class III diagnostic tests, additional requirements (except where a particular device is expressly exempt from one or more of such requirements). General controls include:

•: Registering the manufacturer with the FDA;
•: Listing the product to be marketed with the FDA;
•: Manufacturing the products in accordance with quality systems regulation (also known as current good manufacturing practices);
•: Labelling the test in accordance with labelling regulations;
•: Submitting a pre-market notification (also known as a "510(k)") before marketing a test; and
•: Reporting of adverse events and product recalls (corrections and removal).

Class I

Class I tests are subject to the least regulatory control as they present minimal potential for harm to the user. Most Class I devices and IVD products are exempt from the pre-market notification and/or good manufacturing practices regulation. Examples of Class I IVD products include pregnancy or cholesterol tests.

Class II

The FDA defines Class II test as those for which "general controls" alone are insufficient to assure safety and effectiveness, and existing methods are available to provide such assurances. In addition to complying with general controls, Class II devices are also subject to special controls.

Class II tests often require pre-market notification under the FDA's 501(k) process, in connection with which the manufacturer submits data to the FDA to demonstrate that its test is substantially equivalent to a legally marketed test (known as a "predicate" test).

Special controls may include special labelling requirements, mandatory performance standards and post-market monitoring. Examples of Class II tests include most blood tests, such as blood tests for rheumatoid arthritis, vasculitis, lupus and other immunological tests.

Class III

Class III is the most stringent regulatory category for tests. Class III tests are those for which the FDA believes insufficient information exists to assure safety and effectiveness solely through general or special controls.

Class III devices are usually those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury.

The FDA typically requires "pre-market approval" for these tests to ensure the safety and effectiveness of Class III tests. This type of approval would require the submission and FDA review of clinical data to assess the safety and effectiveness of the test.

Examples of Class III tests include tests for the diagnosis of many infectious diseases and cancer.

European Economic Area

The European Economic Area, which consists of the 27 member states of the European Union and the European Free Trade Association countries of Iceland, Norway, Switzerland and Liechtenstein, requires what is called "CE" approval (the letters "CE" stand for "conformité Européenne" ("European Conformity") for, among other things, IVD tests). Under the CE regulations, a manufacturer does a preliminary self-assessment to

determine whether the products comply with all relevant legislative requirements. At its most basic, the manufacturer must do a conformity assessment, set up a technical file and sign an EC declaration of conformity. This documentation must be made available to authorities upon request. The relevant European Union directive may also require that the product be examined by a conformity assessment body.

We have completed CE marking for our IgXPLEX RA quantitative assay, IgX PLEX Celiac quantitative assay, and the SQiDworks platform, which allows us to market these assays and SQiDworks platform in the European Union. We must also implement and maintain an ISO quality management system. We received our initial ISO 13485 certification in June 2008 and have maintained this certification to date.

As in the United States, components sold without any representation of performance claims may be labeled for "research use only," and are exempt from regulatory oversight in the European Union.

Canada

The Canadian Health Protection Branch regulatory regime requires approvals and submissions similar in timing and scope to European Union CE approvals. TheMedical Devices Regulations (the "Regulations"), promulgated under theFood and Drugs Act (Canada), set out, among other things, the requirements for the licensing of an "in vitro diagnostic device" or "IVDD".In vitro diagnostic devices include reagents, assays and equipment used for examining specimens taken from the body. IVDDs are designated as Class I, II, III and IV, based on the degree of risk associated with their use. For example, a blood test that detects bacterial meningitis is categorized as a Class III IVDD because of the risk that a false-negative test result may cause death or long-term disability due to delayed diagnosis. Class IV IVDDs include donor screening tests for transmissible viruses such as HIV and hepatitis, which present a high public health risk.

For Class I IVDDs, all that is required is an establishment licence to manufacture the IVDD. For Class II, III and IV IVDDs, the Medical Devices Regulations require the IVDDs to meet ISO standard 13485:2003, which provides both design and manufacturing standards.

An application for a Class II medical device includes, in addition to information regarding the manufacturer and specific document, the following:

•: a description of the medical conditions, purposes and uses for which the device is manufactured, sold or represented;
•: a list of the standards complied with in the manufacture of the device to satisfy the safety and effectiveness requirements;
•: an attestation by a senior official of the manufacturer that the manufacturer has objective evidence to establish that the device meets the safety and effectiveness requirements;
•: an attestation by a senior official of the manufacturer that the device label meets the applicable labelling requirements of the Regulations;
•: in the case of a near patientin vitro diagnostic device, an attestation by a senior official of the manufacturer that investigational testing has been conducted on the device using human subjects representative of the intended users and under conditions similar to the conditions of use; and
•: a copy of the quality management system certificate certifying that the quality management system under which the device is manufactured satisfies National Standard of Canada CAN/CSA-ISO 13485:03, Medical devices — Quality management systems — Requirements for regulatory purposes.

As in the United States and Europe, components sold without any representation of performance claims may be labeled for "research use only," and are exempt from regulatory oversight in Canada.

Approvals/Clearances

Health Canada

We have received licenses for all applications which have been made to Health Canada to date as listed in the following table.

	Product		Date of Issuance

10005	QuantiSpot Rheumatoid Arthritis Assay*	78512	November 2008
10105	IgX PLEX Rheumatoid Arthritis Qualitative Assay	81016	October 2009
10505	IgX PLEX Celiac Qualitative Assay	83945	September 2010
10515	IgX PLEX Celiac Panel*	85930	April 2011
01003	SQiDworks Diagnostics Platform	78513	November 2008

*: Quantitative assays

United States

Our 510(k) submission for IgX PLEX Rheumatoid Arthritis Qualitative Assay and SQiDworks Diagnostics Platform was cleared by the FDA in October 2009 and our 510(k) submission for IgX PLEX Celiac Qualitative Assay and SQiDworks Diagnostics Platform was cleared by the FDA in June 2011.

European Union

Our IgXPLEX Celiac quantitative assay (Catalog #10515), IgXPLEX RA quantitative assay (Catalog #10005) and SQiDworks Diagnostics Platform (Catalog #01004) have been CE marked and registered with the competent authority for our authorized representative.

Specific registrations for each product will be made with the notified body of each country in which commercialization is anticipated once applicable label translations have been completed.

Employees

As of May 31, 2011, we had 54 employees, of which three were in sales and marketing, 31 were in research and development, 14 were in manufacturing and operations and six were in administration. Our employees have specialized knowledge in areas such as multiplexing, immunology, microarray design and manufacture, assay development, systems engineering and medical-systems sales and servicing.

We have never experienced a work stoppage or other labor disturbance. To our knowledge, none of our employees belongs to, or is represented by, a labor union.

LEGAL PROCEEDINGS AND REGULATORY ACTIONS

From time to time we are involved in various claims and legal proceedings of a nature considered normal to our business. While it is not feasible to predict or determine the outcome of these proceedings, management believes any current actions to be without merit, and no provision in respect of these matters has been made in our financial statements.

ACQUISITION OF SCIENION AG

On July 4, 2011 we entered into an agreement with those of Scienion's shareholders having the required percentage ownership of share capital to "drag along" the other shareholders pursuant to the Scienion Shareholders' agreement (the "Vendors") to purchase all of the shares of Scienion AG ("Scienion") for aggregate consideration to be satisfied by a closing cash payment of $15,000,000 (of which, approximately $7,700,000 will be utilized to satisfy certain debt settlements and $1,750,000 will be placed in escrow pursuant to the terms of a holdback escrow agreement) and the issuance of 735,294 SQI common shares.

The completion of our acquisition of Scienion is subject to the satisfaction of certain closing conditions, including the closing of the offering for gross proceeds of at least $30,000,000.

The acquisition agreement may be terminated if the closing does not occur on or before September 30, 2011. Additionally, either party may terminate the acquisition upon payment of a break fee in the amount of $250,000 if a party terminates its obligations as a result of the non-terminating party's breach of its obligations or failure to use commercially reasonable efforts to satisfy any conditions precedent within such non-terminating party's control.

SELECTED CONSOLIDATED FINANCIAL INFORMATION

		Year Ended September 30,						6 Months Ended March 31,

Consolidated Statement of Operations Data C$ in 000's except per share data		2009			2010			2010			2011
Revenue:
	Product sales	$	5		$	5		$	—		$	13
	Consulting fees		27			30			15			9

Total Revenue			32			35			15			22

Expenses
	Salaries and wages		469			556			265			332
	General and administrative		447			471			202			324
	Professional and consulting		436			659			297			200
	Sales and marketing		409			474			193			215
	Stock based compensation		380			402			115			228
	Research and Development		3,362			5,059			2,327			2,612
	Amortization — property and equipment		417			415			209			225
Amortization — patent and trademark			98			100			56			57

Total expenses			6,018			8,136			3,664			4,193

Operating loss before interest			(5,986	)		(8,101	)		(3,649	)		(4,171	)
Interest Income			121			32			12			42
Interest Expense			(45	)		(4	)		(3	)		—

Net loss		$	(5,910	)	$	(8,073	)	$	(3,640	)	$	(4,129	)

Basic and diluted loss per share		$	(0.23	)	$	(0.27	)	$	(0.13	)	$	(0.12	)
Weighted average number of shares			25,158			30,349			28,924			33,806

Consolidated Balance Sheet Data	September 30, 2009		September 30, 2010		March 31, 2011

Cash and cash equivalents	$	3,180	$	9,408	$	4,669
Working capital		3,280		8,930		5,121
Total assets		6,205		13,134		9,190
Total shareholders' equity		5,836		12,162		8,456

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

For the purposes of this Management's Discussion and Analysis of Financial Condition and Results of Operations only, capitalized terms have the meaning given to them in this section.

This discussion and analysis covers the unaudited financial statements for the quarters ended March 31, 2011 and 2010, prepared in accordance with Canadian generally accepted accounting principles (Canadian GAAP). The fiscal year end of SQI Diagnostics Inc. ("SQI" or "Company") is September 30 of each calendar year. This discussion and analysis was prepared by management using information available as at May 26, 2011.

All amounts are expressed in Canadian dollars unless otherwise indicated.

OVERVIEW

SQI Diagnostics Inc. is a medical systems company that has developed, manufactured and markets a proprietary human diagnostic technology using multiplexing, miniaturization and automation. Our technologies enable laboratories to analyze multiple biomarkers simultaneously (multiplexing), deliver accurate and quantitative patient results in less time, significantly reduce labour costs, and increase profits when compared with current diagnostic instrumentation. The Company's proprietary SQiDworks™ instrument and its consumable tests together form a system capable of providing many of the diagnostic tests currently performed in reference laboratories engaged in testing human blood for a wide range of disease markers. The Company's strategy is to develop and commercialize test kits for the autoimmune disease market as further described below, and plans to pursue commercialization of tests in infectious disease and allergen testing in the future.

The Company has been primarily involved in research, development and commercialization activities related to its core technology platform since 2003. The Company has expended significant resources to create and protect its technology platform through the filing of patents and in building an automated instrument and multiplexed assay platform. The Company has invested in fostering partnerships with clinicians who are leaders in our disease areas of focus and with potential novel biomarker collaborators. The Company has also incurred costs associated with gathering market intelligence concerning prospective customers, developing a direct sales platform and in marketing and selling to prospective customers.

The Company has developed its fully automated SQiDworks and semi-automated SQiDman™ microarray-based test platforms that enable laboratory customers to generate multiple patient test results with less than one unit of traditional 'test effort'. The Company has received marketing clearance from the United States Food & Drug Administration ("FDA"), Canadian regulatory approval for, and has CE Marked its fully automated, high throughput SQiDworks platform. SQiDworks is the only such platform to achieve these regulatory clearances.

Subsequent to quarter end the Company received Health Canada approval for IgX PLEX Celiac Quantitative test. This represents the first approval of the Company's second generation fully quantitative test. The Company has also received Canadian regulatory approval for its qualitative celiac test kits and filed for US FDA regulatory clearance to market its qualitative celiac product.

The Company is currently pursuing and is optimistic of winning additional Canadian customers based on Health Canada licensing of its quantitative celiac product during 2011.

Gamma Dynacare Medical Labs (GDML) is in the process of evaluating the Company's quantitative celiac test kits. The Company believes that if the GDML evaluation is positive, GDML will purchase the quantitative celiac test kits, in addition to their commercial use of our RA product.

The Company is focusing on the continued development of a pipeline of other tests that can be processed on the SQiDworks platform. The Company is moving these assays through the development pipeline and expects

to advance additional test kits through the regulatory process during fiscal 2011 as discussed further in this document. The Company is also focused on the release of SQiDlite, our second generation diagnostic platform. This platform will be a fully-automated microarray processing and analytic platform. It is intended to be a bench-top system able to process multiple sizes of microarray devices from single 8-well strips up to a single 96 well microarray plate. This system is based on the same technology and uses many of the same components as our SQiDworks system. It is targeted at small to medium sized diagnostic customers.

We plan to add additional services targeted at laboratory and other customers to leverage our expertise in assay design and microarray printing. This initiative is intended to enable our customers to expand the use of our SQiDworks and SQiDlite platforms by converting their content to microarrays. Subsequent to the period end, we presented the results of a collaborative research study where we included biomarkers of interest to a target customer to our in-development vasculitis panel. Our additional services will enable customers to add target biomarkers to an existing panel of biomarkers that they can then offer to their customers, or they may request an entire panel of protein-based biomarkers to be developed into a Research Use Only (RUO) microarray for which they may decide to seek Lab Developed Test regulatory clearance.

The Company also has future plans to explore in-licensing opportunities to expand its product pipeline as well as to continuously improve its in-market products through the addition of novel biomarkers to the existing diagnostic panels of tests.

Status of Development Program

The Company's development program includes several major components which the Company expects will advance its commercialization strategy. The status of each component is summarized and discussed in further detail below:

		Approval Status

	Development Status	Approval Status
Product	Development Status	Canada	United States	Europe
SQiDworks™ Diagnostics Platform	Complete	Licensed	Cleared as a system with IgX PLEX RA Assay	CE Marked*
SQiDlite Platform	Development
SQiDman Analyzer	Development	Not required — RUO	Not required — RUO	Not required — RUO
IgX PLEX Rheumatoid Arthritis Assay (Qualitative)	Complete	Licensed	Cleared
QuantiSpot™ Rheumatoid Arthritis Assay (Quantitative)	Complete	Licensed		CE Marked*
IgX PLEX Celiac Qualitative Assay	Complete	Licensed	Filed
IgX PLEX Celiac Panel (Quantitative)	Complete	Licensed (on April 27, 2011 subsequent to quarter end)	IUO	CE Marked*
IgX PLEX Vasculitis Panel	Final Development
IgX PLEX Celiac DGP Panel	Final Development
IgX PLEX Rheumatoid Arthritis Panel with expanded markers	Final Development
IgX PLEX Lupus Panel	Development
IgX PLEX TNF Assay	Development
IgX PLEX IBD — Crohn's Disease	Proof of Concept

*: Devices were self-certified or re-self-certified, in May 2011 following a change of our authorized representative.

The Company's SQiDworks and SQiDman platforms are also capable of running Research Use Only (RUO) and Investigational Use Only (IUO) test kits and the Company is exploring sales opportunities related to these applications of its platform with the Company's products as well as through the potential development of target customer's content. Delivering RUO/IUO product based on customer owned content would require collaboration and assay development though this effort would be materially less than that experienced with the Company's pipeline of regulatory-cleared products. This creates additional new revenue opportunities for the Company. The Company continues to focus on its in-market tests and believes that it must continuously improve

and update its products. The Company has identified and has moved into development enhancements to the existing RA and celiac test panels. Subsequent to quarter end the Company received Health Canada approval for IgX PLEX Celiac Quantitative test kit. This represents the first approval of the Company's second generation fully quantitative test. The enhancements to the RA panel are in the advanced stages of development. These improvements, requiring regulatory approvals, will represent second generation, fully quantitative IgX PLEX microarray technology and include expanded biomarker content for IgX PLEX RA and IgX PLEX Celiac.

All in-development tests will utilize this second generation, fully quantitative multiplexing technology; the Company believes these enhancements will provide significant market advantages compared to our competitors.

The Company's development pipeline includes multiplexed test for vasculitis, lupus and IBD-Crohn's. These tests are advancing through the development pipeline with the goal of moving some if not all of these tests into the regulatory filed stage during the remainder of fiscal 2011

During the quarter ended March 31, 2011 the Company began implementing the feedback received from our partner related to the development of our IgX PLEX TNF assay used to measure the quantity of therapeutic agents in the body and the information from this test could be used by clinicians in the management of several autoimmune diseases, including but not limited to rheumatoid arthritis, vasculitis and irritable bowel disease. The Company believes that it will deliver a commercial product to its partner during the 2011 calendar year.

Status of Commercialization Activities and Other Events in the Fiscal Year to Date

During the quarter ended March 31, 2011, the Company invested in its sales and marketing team, its science, commercialization, and regulatory groups, and in infrastructure. The Company's sales efforts are focusing on the North American market and European targets to generate sales to targeted customers of the currently approved system, including the SQiDworks fully automated analytical platform and RA and celiac tests.

Following is an overview of the Company's achievements for the fiscal year to date:

(a)

The company continued to develop its commercial relationship with Gamma Dynacare Medical Labs (GDML) during the quarter ended March 31, 2011 and achieved additional sales of our RA product in this quarter. The Company is working closely with GDML to develop its multiplexed RA business and during the quarter ended March 31, 2011 GDML released its first monthly newsletter that focussed on our RA multiplexed product. This marketing material featured the benefits of multiplexing rheumatoid arthritis biomarkers on an automated platform to all of GDML's customers and is featured on GDML's website. The Company believes that this and similar marketing efforts will drive the continued growth of our RA product at GDML.

(b)

The company has provided quantitative celiac test kits on an investigational use only basis to GDML enabling their internal review of the product's performance. Successful internal review by GDML is expected to lead to the expansion of the current contract to include the sale to them of our quantitative celiac test kits. The approval by Health Canada of our quantitative celiac tests, achieved subsequent to the quarter end, will enable the company to actively pursue such an expansion with GDML, as well as pursue opportunities with other laboratories in Canada.

(c)

Progressed a number of pipeline diagnostic tests through our discovery and development program;

(i): During the first half of fiscal 2011, the Company received and responded to questions from the FDA regarding its celiac panel. The questions and responses are described by the Company as those expected in the normal course of its regulatory processes.
(ii): The Company's vasculitis assay continues to progress through the assay development pipeline and is expected to complete clinical validation in the third quarter of fiscal 2011. Collaborative studies demonstrating the utility of the Company's assays were presented at the 15^th International Vasculitis and ANCA Workshop May 15^th — 18^th, 2011.

(iii): The Company's quantitative lupus test panel is in the assay development stage. Moving the lupus panel through development is a significant achievement. The current development results show that SQI is able to effectively multiplex up to 16 protein biomarkers, including double stranded DNA. This is our largest panel to date and management believes the progress will provide SQI with the only such product in the market. Management believes that the successful completion and clearance of the lupus product will be transformative to the Company's commercial position. The Company expects to initiate clinical validation of this product in the second calendar quarter of 2011, and to complete regulatory filings shortly thereafter.
(iv): The Company's IBD-Crohn's candidate test panel is in the proof of concept stage and is being actively developed with the expectation of being completed and filed for regulatory approvals during 2012.
(v): Development continued on the anti-TNF test candidate, based on the expanded performance requirements requested by our partner, Mount Sinai Services. The Company continues to complete the commercialization of this product and expects to have a commercial product available by the end of 2011.
(vi): Initiated the platform development program for SQiDlite and continued platform development to commercialize our SQiDman platform with a target to complete development on a timeline to coincide with customer requirements for potential research use collaborations. The SQiDman platform is currently not targeted at IVD applications but in the near-term may be used by our collaborators and customers to assist in the development of their content into SQI-developed microarray RUO/IUO or Lab Developed Test products. The development of the SQiDlite platform addresses the needs of smaller and mid-market IVD customers and of the research market. The SQiDlite platform will be developed as an automated device with the flexibility to process and analyze varying sizes of consumables up to the current 96-well consumable used in the SQiDworks;

(d): Partnering Summary

The following table provides an overview of our partnering collaborations and the relevant pipeline product as at the period end:

Partnering Institute*	Principal Investigator	Pipeline Product	Purpose



Cleveland Clinic	Dr. R. Tubbs	IBD-Crohn's	Serum Samples Collaboration

Beth Israel Deaconess Medical Center	Dr. C. Kelly	Celiac	Serum Samples Collaboration/Publication

Beth Israel Deaconess Medical Center	Dr. A. Moss	Anti-TNF	Serum Samples Collaboration/Publication

Hospital Clinic de Barcelona, Spain	Dr. R. Cervera	Vasculitis	Serum Samples Collaboration/Publication

Cleveland Clinic	Dr. S. Wang	All Rheumatoid Arthritis Various	Clinical Validation Collaboration Serum Samples

University Hospital Maastricht, the Netherlands	Dr. J. Damoiseaux	Vasculitis	Serum Samples Collaboration

The University of North Carolina at Chapel Hill	Dr. R. Falk	Vasculitis	Collaboration Serum Samples Clinical Validation

University of Maryland	Dr. A. Fasano	Celiac	Serum Samples

Mount Sinai Services Toronto, Canada	Dr. G. Greenberg and Dr. M. Silverberg	IBD-Crohn's	Serum Samples

*: All Partnering Institutes are located in the USA unless otherwise annotated.

(e): PATENTS. In the quarter ended March 31, 2011 the company received the patent "METHOD AND DEVICE TO OPTIMIZE ANALYTE AND ANTIBODY SUBSTRATE BINDING BY LEAST ENERGY ADSORPTION (LEAP) in Europe. This patent is a key element of the Company's intellectual property strategy related to its multiplexing surfaces and capture analyte binding.

CORPORATE FINANCING TRANSACTIONS

During the three months ended March 31, 2011 a total of 40,834 employee stock options were exercised at an average price of $1.60 for total proceeds of $65,000.

Also during the quarter ended March 31, 2011 106,520 warrants with an expiry of January 22, 2011 were exercised for total proceeds of $133,000.

CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT ESTIMATES

These financial statements are prepared in accordance with Canadian GAAP.

The significant accounting policies that management believes are the most critical in fully understanding and evaluating the reported financial results include the following:

Patents and Trademarks

The costs relating to patent and trademark fees are deferred and amortized over 10 years on a straight-line basis. Patents and trademarks are recorded net of accumulated amortization of $685,000 (September 30, 2010 — $627,000).

Research and Development Costs

Research costs are charged to earnings in the period in which they are incurred. Development costs are expensed as incurred or deferred if they meet the criteria for deferral under Canadian generally accepted accounting principles and are expected to provide future benefits with reasonable certainty. At March 31, 2011, the Company has developed a pipeline of novel tests for its diagnostic system. Deferral criteria have not yet been met, and accordingly, all development costs have been expensed.

Stock-Based Compensation and Other Stock-Based Payments

The Company applies a fair value based method of accounting for all stock-based payments. Accordingly, stock-based payments are measured at the fair value of the consideration received or the fair value of the equity instruments issued or liabilities incurred, whichever is more reliably measurable. Stock-based compensation is charged to operations over the vesting period and the offset is credited to contributed surplus. Consideration received upon the exercise of stock options is credited to share capital and the related contributed surplus is transferred to share capital.

Share Issuance Costs

Costs incurred in connection with the issuance of capital stock are netted against the proceeds received.

Income Taxes

The Company follows the liability method of accounting for income taxes. Under this method, future income tax assets and liabilities are determined based on temporary differences between financial reporting and tax bases of assets and liabilities, as well as for the benefit of losses available to be carried forward to future years for tax purposes. Future income tax assets and liabilities are measured using enacted or substantively enacted tax rates and laws that will be in effect when the differences are expected to reverse. Future income tax assets are recorded in the financial statements if realization is considered more likely than not.

Use of Estimates

The preparation of financial statements in conformity with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Actual results could differ from those estimates. Significant areas requiring the use of management estimates relate to the determination of the useful lives of property and equipment and patents and trademarks for amortization purposes, valuation of ITC's receivable, valuation of stock options and warrants and valuation allowance on future tax assets.

Recent Accounting Pronouncements

Business Combinations

In January 2009, the CICA issued Section 1582, Business Combinations, which replaces former guidance on business combinations. Section 1582 establishes principles and requirements of the acquisition method for business combinations and related disclosures. In addition, the CICA issued Sections 1601, Consolidated Financial Statements, and 1602, Non-Controlling Interests, which replaces the existing guidance. Section 1601 establishes standards for the preparation of consolidated financial statements, while section 1602 provides guidance on accounting for a non-controlling interest in a subsidiary in consolidated financial statements subsequent to a business combination.

These standards apply prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after January 1, 2011 with earlier application permitted. The Company is currently evaluating the new sections to determine the potential impact of any future transactions on its consolidated financial statements.

International Financial Reporting Standards (IFRS)

The CICA plans to converge Canadian generally accepted accounting principles with International Financial Reporting Standards ("IFRS") over a transition period expected to end in 2011, when IFRS will be fully adopted. The Company will be required to adopt IFRS for its 2012 fiscal year end and will be required to provide IFRS comparative information for the previous fiscal year. The Company continues to monitor and assess the impact of the convergence of Canadian GAAP and IFRS on its financial statements. We have identified the main differences between existing Canadian GAAP and IFRS standards and begun quantifying the reporting differences. The Company has a conversion plan in place and believes it has the resources in place to meet the conversion timelines. The following are the main differences and the expected impact on our business processes and information systems:

Key Accounting Areas		Difference with potential impact on the Company



IFRS 1 First time adoption of IFRS		The Company is in the process of selecting the applicable exemptions under IFRS. Additional reconciliations and disclosure upon the initial conversion to IFRS will be included in the initial statements presented under IFRS commencing in the first quarter of fiscal 2012. During 2011 the company will assess and prepare the additional disclosures. The Company is reviewing the disclosure requirements including the disclosure of other corporations adopting earlier in 2011.

IAS 16 Property Plant and Equipment		The Company has commenced a study of the useful life of each component of property plant and equipment and will restate, if applicable, the historic amortization expense.

IAS 36 Impairment of Assets		The Company will evaluate potential impairments using discounted cash flow analysis as required under IFRS

IAS 12 Income Tax		The Company has accumulated non-capital losses, undeducted scientific research and development costs, and investment tax credits that have not been reflected in the financial statements. These items will need to be assessed based on the IFRS criteria to ensure proper classification on the balance sheet.

IFRS 2 Share based payments		IFRS 2 requires that each tranche of options with graded vesting be treated as a separate award. IFRS 2 also requires an estimate of forfeitures to be factored into the determination of compensations costs. The Company expects to utilize the exemptions under IFRS 1 when converting to the new standard. The company has begun to calculate the impact on all unvested tranches of options at the date of transition.

IAS 1 Financial Statement Presentation		Additional disclosure required as well as selection between presentation alternative will be addressed in the initial statements presented under IFRS. The Company is analyzing the impact of the changes on its financial statements through a review of the standards as well as a review of the financial reports of corporations with earlier adoption dates.

SELECTED FINANCIAL INFORMATION

Second Quarter Commentary

The table below summarizes quarterly financial information for the 3 month periods shown.

	March 31, 2011 (000s)			December 31, 2010 (000s)			September 30, 2010 (000s)			June 30, 2010 (000s)



Revenue	$	4		$	18		$	14		$	6

Net Loss	$	1,874		$	2,255		$	2,621		$	1,811

Net Loss Per Share	$	(0.06	)	$	(0.07	)	$	(0.08	)	$	(0.06	)

Weighted Average Shares		33,852			33,759			32,705			30,790

	March 31, 2010 (000s)			December 31, 2009 (000s)			September 30, 2009 (000s)			June 30, 2009 (000s)



Revenue	$	10		$	5		$	7		$	8

Net Loss	$	2,020		$	1,620		$	1,616		$	1,354

Net Loss Per Share	$	(0.07	)	$	(0.06	)	$	(0.06	)	$	(0.05	)

Weighted Average Shares		29,917			27,930			27,271			26,326

Revenue for the quarter ended March 31, 2011 was $4,000 compared to $10,000 for the quarter ended March 31, 2010. Revenue for the six months ended March 31, 2011 was $22,000 compared to $15,000 for the six months ended March 31, 2011. Revenue for the first and second quarter of 2011 included sales of its QuantiSpot RA test kits, there were no product sales during the same period in 2010. Revenue in the three and six months ended March 31, 2010 resulted from consulting services provided to a related party; these services were not performed in the quarter ended March 31, 2011.

For the quarter ended March 31, 2011, the Company recorded a net loss of $1,874,000 ($0.06 net loss per share) compared to a net loss of $2,020,000 ($0.07 net loss per share) for the quarter ended March 31, 2010. Per share values are based on the weighted average shares outstanding in the period. The net loss for the six months ended March 31, 2011 was $4,129,000 ($0.12 net loss per share) compared to a net loss of $3,640,000 ($0.13 net loss per share) for the six months ended March 31, 2010. For the quarter ended March 31, 2011 there was an average of 33,852,000 shares outstanding (six months ended March 31, 2011 — 33,806,000).

The net loss was greater for the six months ended March 31, 2011 compared to the six months ended March 31, 2010. The increase in costs is primarily related the Company's increased activity and expenses in the discovery efforts for and development of assays as detailed below. Additional other expenses incurred included ordinary increases in wage and wage-related expenses owing to an increase in personnel, increased lab expenditures to support the greater number of projects, and other direct costs including serum acquisition and development and validation partner costs. Sales and marketing expense was higher in the six months ended March 31, 2011 owing to additional travel and contract resources in sales and marketing as the company continued to increase its sales effort for approved IgX PLEX assays in Canada and the United States and in anticipation of further product approvals. The decrease in the loss for the three months ending March 31, 2011 was related to the Scientific Research and Experimental Development ("SRED") cash refund accrued in the quarter ended March 31, 2011 as discussed in detail below. Also contributing to the reduced cost was the decreased in recruiting fees in the quarter ended March 31, 2011 compared to the quarter ended March 31, 2010. Sales and Marketing expense were lower in the quarter ended March 31, 2011 owing to sales incentives paid out in the quarter ended March 31, 2010 upon the placement of our first platform with a major Canadian laboratory. These decreases in expenses offset the increases in R&D and other expenses in the quarter.

R&D expenditures for the quarter ended March 31, 2011 were $1,114,000 compared to the $1,273,000 for the quarter ended March 31, 2010. R&D expenditures for the six month period ended March 31, 2011 were $2,612,000 compared to the $2,327,000 for the six month period ended March 31, 2010. The increase in R&D expense for the six month period ended March 31, 2011 compared to the six months ending March 31, 2010

resulted from increased R&D activity with an increased number of assay panels in development and to continued regulatory validation efforts related to the celiac products. In the second quarter of fiscal 2011, in addition to the celiac assay in regulatory validation, the company had 5 panels in development and 1 additional panel in early discovery and development. In the second quarter of fiscal 2010 the Company had 3 panels in discovery and development. The decrease in R&D expenditures for the quarter ended March 31, 2011 compared to the quarter ended March 31, 2010 is due to the accrual of the SRED cash refund. This ITC tax credit has offset the increased expenses incurred in the quarter ended March 31, 2011 compared to the same quarter in 2010. The SRED cash refund for the prior year was recorded in the third quarter of 2010.

Corporate expenses include, primarily, salaries and related expenses (including benefits and payroll taxes) of the Company other than salaries and related expenses paid to personnel engaged in research and development. General and Administrative expenses include facility costs, insurance costs, and foreign exchange expenses. Corporate and general expenses totalled $326,000 for the three months ended March 31, 2011 compared to $258,000 for the three months ended March 31, 2010. Corporate and general expenses totalled $656,000 for the six months ended March 31, 2011 compared to $467,000 for the six months ended March 31, 2010. The increase from the quarter and six months ended March 31, 2010 compared to the same periods in 2011 was primarily a result of higher salary costs, increased personnel and increased occupancy costs. Corporate expenses also included a loss on the disposition of equipment in the six months ended March 31, 2011, there was no similar loss in the six months ended March 31, 2010.

Professional consulting (legal, accounting, Board of Directors compensation, recruiting, administrative contractor, and investor relations) costs in the three months ended March 31, 2011 were $94,000 compared to $176,000 for the three months ended March 31, 2010. Professional consulting costs were $200,000 for the six months ended March 31, 2011 compared $297,000 for the six months ended March 31, 2010. The decrease in professional and consulting costs in the quarter ended March 31, 2011 were primarily related to reduced legal and recruiting fees. The Company incurred significant recruiting fees in the first half of fiscal 2010 as it increased personnel to expand its research and development efforts.

Sales and Marketing expenses were primarily related to sales and marketing consultant fees and to travel related to selling activities in the quarter. Sales and marketing expenses totalled $109,000 for the three months ended March 31, 2011 compared to $129,000 for the three months ended March 31, 2010. Sales and marketing expenses totalled $215,000 for the six months ended March 31, 2011 compared to $193,000 for the six months ended March 31, 2010. The increase in sales and marketing expenses for the six months ended March 31, 2011 compared to the six months ended March 31, 2010 were primarily related to additional consulting costs paid to increase staffing to support product pipeline and commercialization efforts. The decrease in sales and marketing expenses for the three months ended March 31, 2011 compared to the three months ended March 31, 2010 is due to a sale incentive paid in the second quarter of fiscal 2010 upon the placement of our first platform with a major Canadian laboratory.

Operational expenses were partially offset by interest income earned on short-term investments of $18,000 for the three ended March 31, 2011 (six months — $42,000) compared to $9,000 for three months ended March 31, 2010 (six months — $12,000) .. The Company invests its cash in variable term cashable government investment certificates and short-term money market deposits.

Non-cash stock based compensation charges totalled $113,000 for the three ended March 31, 2011 (six months — $228,000 ) compared to $66,000 for the three months ended March 31, 2010 (six months — $115,000 ). The related stock option issuances are described further below in the Outstanding Share Capital section.

Outlook

Subsequent to GDMLs 90 day internal acceptance and validation testing the Company executed a commercial agreement and has generated revenue since the fourth quarter of fiscal 2010. The Company is in the process of having GDML evaluate its quantitative celiac test kits and with the Health Canada approval, obtained subsequent to quarter end, is optimistic that this evaluation will lead to additional revenues from GDML attributed to IgX PLEX Quantitative Celiac kits starting in the first half of calendar 2011.

Our analysis of the market would indicate that there are over 315 laboratories in the United States with sufficient volume of rheumatoid arthritis testing to be target customers for the SQiDworks platform running RA tests. Management believes that the addressable market is sufficiently large and that with the completion of additional quantitative test kits, including celiac, licensed in Canada and targeted for US FDA review in 2011, the company will be well-positioned for wider scale commercial acceptance of our platforms during the 2011 fiscal year, and beyond. Management believes the number of potential customers will, upon regulatory clearance of multiple products (ex RA and celiac) in the US, greatly exceed the number currently targeted with only one approved product in the US. Further, completion of the SQiDlite platform in 2011 for IVD and RUO/IUO applications will greatly enhance the addressable market into the 1,000s of potential customers. Following licensing in Canada of its quantitative celiac product subsequent to quarter end the Company has intensified its Canadian sales efforts and is optimistic that it will convert additional Canadian reference laboratories to customers in the ensuing several quarters. The Company plans to further explore interest expressed by target customers in the US with a stated desire for the custom design, microarray development and printing of biomarkers by the Company as further described below.

In the quarter ended March 31, 2011 and in anticipation of successful validation and CE marking of its next product, IgX PLEX Quantitative Vasculitis, the Company began exploring customer opportunities in a focussed business development effort in Europe. The initial feedback on the benefits and performance of the SQiDworks platform and multiplexed test panels for RA and celiac testing has been very positive. These meetings have also resulted in a positive response to the expanded product and service offerings to assist these customers to convert their content into SQI-based microarrays. During the remainder of 2011 the Company will continue to evaluate its capability to generate revenue in Europe — successful test marketing may lead the Company to officially launch its European sales efforts in the 2011 fiscal year.

Based on its successful FDA clearance, its Health Canada licenses and EU authorization, management increased the intensity of the development and commercialization of several new test candidates in 2010. This increased intensity continued into the first half of 2011 and the Company expects this expanded development activity to result in the submission of an on-going flow of autoimmune test kit applications to the US, Canadian and EU regulatory bodies during the 2011 calendar year. This activity has generated similar R&D expenses in the first half of fiscal 2011 as was experienced in the second half of the 2010 fiscal year related to internal development, internal verification and validation studies and third party validation studies. This activity is expected to continue in the foreseeable future as the company completes the autoimmune pipeline, continues to improve in-market tests and initiates development in new clinical areas.

During the 2011 calendar year the Company believes it to be strategic to expand its marketing and sales program to RUO/IUO customers that conduct research in the relevant disease markets or to those that have an interest in companion testing during drug development and that are targeted in our clinical areas of interest. The Company may target customers conducting research with its SQiDman platform and RUO/IUO products, higher throughput customers with our SQiDworks platform or SQiDlite platform. Management believes that SQiDlite will be an important system for future clinical areas and non-reference lab customers. SQiDlite is expected to be fully automated, allow smaller batch sizes and to have equivalent analytical performance when compared to the fully automated SQiDworks platform.

We also intend to work with third parties who have developed their own proprietary assay biomarkers for multiplexed tests. Our goal is to provide both these companies and their customers with the services to develop SQI-based microarray tests and with SQiDworks or SQiDlite systems to process these tests as well as print and manufacturing services for their SQI-based microarray products.

These third parties may include reference laboratories, diagnostic companies, or research organizations. We intend to target companies which intend to convert their biomarkers to microarrays but which have been unable to develop fully functioning assay systems or who have customers who require high throughput automated

systems to process microarray tests. We believe that our expertise in the areas of microarray printing, microarray test development and systems integration will enable us to generate revenues from customers in a market that is not currently served by a fully integrated service and product offering.

It will also be necessary to invest in expanding the Company's customer service and administrative elements to support our customers and sales, as we are successful in growing our placement of SQiDworks platforms across Canada and the United States, and increase our product menu available to our customers. Management will add these resources as needed to support forecasted customer installations of SQiDworks platforms and sales of consumable kits.

Management will continue to monitor its cash resources in relation to the capital available to it and will manage cash flows as required in the context of the capital markets. Management believes that it may, at some point, seek additional capital to advance and accelerate the number of tests under development and being validated for regulatory submissions, to expand our areas of focus beyond autoimmune disease at the appropriate times, expand our fully marketed analytical platform system portfolio enabling us to address a broader market, to build SQiDworks platforms to address customer demand, as well as to expand our sales team and its efforts in the United States and other jurisdictions as appropriate.

Related Party Transactions

Transactions with related parties occur in the normal course of business and are measured at the exchange amount. Related party transactions are described below, unless they have been disclosed elsewhere in the financial statements.

Included in general and administrative expense for the three month period ended March 31, 2011 is $13,000 (three month period ended March 31, 2010 — $21,000) compared to $25,000 for the six month period ended March 31, 2011 (six month period ended March 31, 2010 $39,000), related to recovery of occupancy costs from a corporation in which an officer of the Company is also an officer. Consulting fee revenue of NIL for the three month ended March 31, 2011 (three month ended March 31, 2010 — $10,000) was earned from this corporation compared to $9,000 for the six month period ended March 31, 2011 (six month period ended March 31, 2010 $15,000). At quarter end, $2,000 (September 30, 2010 — $1,000) due from this corporation is included in amounts receivable.

Sources and Uses of Cash

Operational activities for the quarter ended March 31, 2011 were financed by cash on hand.

At March 31, 2011, current assets were $5,855,000 compared to $9,902,000 at September 30, 2010. Working capital as at March 31, 2011 was $5,121,000 compared to $8,930,000 at September 30, 2010.

Cash used in investing activities for the quarter ended March 31, 2011 was $146,000 compared to $95,000 for the quarter ended March 31, 2010. The increase in investing activities is due to the increase in patent assets as the company continued to protect is proprietary technology. Cash used in investing activities for the six months ended March 31, 2011 were $427,000 compared to $181,000 for the six months ended March 31, 2010. Increased additions to property and equipment in the current six month period reflect the Company's investment in (1) an overhaul of its out-dated network and data storage infrastructure to expand its data storage capacity required to support the research and development program and to enhance its disaster recovery system to protect the vast amounts of data generated through product development and validation, and (2) a SQiDworks platform for internal use for platform development activities.

During the quarter ended March 31, 2011 a total of 40,834 options were exercised at an average price of $1.60 for total proceeds of $65,000.

During the quarter 106,520 warrants with an expiry date of January 22, 2011 were exercised for total proceeds of $133,000.

Management believes that cash on hand at March 31, 2011, and cash generated from revenues will be sufficient to fund the Company's operations for at least 12 months. The continued successful commercial launch and generation of revenue in the 2011 fiscal years will extend this period.

Risks

The Company is subject to various risks. Factors that could cause results or events to differ materially from management's current expectations include, but are not limited to:

•: changing competitive technology and market conditions;
•: the Company's ability to successfully commercialize additional IgX PLEX tests in the autoimmune disease market;
•: the successful and timely completion of clinical validation studies at partner sites;
•: the failure to obtain requisite regulatory approvals (including the clearance of the FDA) for the Company's diagnostic tests in a timely manner, if at all, and other inherent uncertainties related to the regulatory approval process;
•: the ability to generate sufficient acceptance of the Company's platforms and sales of test kits; and,
•: the ability of the Company to fund its cash requirements from internal and external sources.

Management seeks to mitigate these risks, and others, primarily by retaining experienced employees and advisors who have expertise in the scientific, medical business, regulatory, manufacturing and operational disciplines of automated platform integration and immunoassay diagnostic test development.

The Company's SQiDworks automated analytical platform and its lead IgX PLEX RA multiplexed test kit, which have received regulatory clearances in Canada, Europe and the United States, are believed to be the first microarray technologies in the autoimmune disease market to receive such clearances. The Company has continued to build on this regulatory success with the Health Canada licensing of its IgX PLEX Celiac Qualitative test and subsequent to quarter end its IgX PLEX Celiac Quantitative test, also CE Market in Europe. With the Health Canada approval for the first second generation fully quantitative assay, the Company anticipates that its quantitative celiac product line will progress commercially, later this year with the release of a 6-plex quantitative panel that adds additional emerging biomarkers for markets in Canada, the US and Europe.

Our tests are designed to run only on the SQiDworks platform. In order to obtain approval for the SQiDworks platform and the Company's consumable tests for sale in the United States, our largest target market, the FDA typically requires the conduct of clinical validation studies to compare the performance of a new test to predicate tests currently approved for sale in the US. Upon successful completion of validation studies conducted at both SQI's labs and at multiple third party labs, the data derived are then presented to the FDA in the form of a 510(k) Pre-market Notification. It is typical for the external validation studies to take several months to complete and upon receipt of a completed 510(k) submission the FDA may take up to 180 days to render a decision on the application, not including any "time-outs" which the Company may take to prepare responses to various inquiries from the FDA. The Company believes the experience gained in obtaining the clearance of the SQiDworks and RA test, together a system, will enable it to complete and file applications for clearance of the subsequently developed pipeline of assays more efficiently. This in turn may result in shorter review periods at the FDA than was experienced with the SQiDworks-RA system. The timing of such clearances is dependent on several factors some of which are not controlled by the Company.

During the current reporting period the Company did not earn significant revenues from its test kits or SQiDworks platform. Management believes that material revenues from the sale of its test kits may be achieved in the 2011 calendar year; this is subject to certain risks including without limitation, the continued success of the development program and regulatory approvals of the products. The continuation of the Company's research, development and commercialization activities along with investment in marketing and sales is dependent upon the Company's ability to successfully manage its growth, investment in continued pipeline development and its cash requirements.

forward currency contracts or other financial derivatives to hedge foreign exchange risk. We are subject to foreign exchange rate changes that could have a material effect on future operating results or cash flows.

Management will continue to review the Company's financial needs and to seek additional capital financing as required from sources that may include equity financing, debt financing, collaborative projects and licensing arrangements. However, there can be no assurance that such additional funding will be available or if available, whether acceptable terms will be offered. Management believes that it will need to seek such additional financing during the 2011 fiscal year.

Outstanding Share Capital

As at March 31, 2011, there were 33,913,000 common shares issued and outstanding.

The following tables describe the securities that have been issued that are convertible under certain conditions into common shares:

The Company had the following warrants outstanding at March 31, 2011:

	Purchase Price		Expiry Date

1,199,000	$	4.00	December 4, 2011
237,000	$	1.90	December 23 2011
1,140,000	$	5.00	August 12, 2012
57,000	$	2.50	August 12, 2012

2,633,000

The Company had the following stock options outstanding under the Plan at March 31, 2011:

	Exercise Price		Expiry Date

33,000	$	1.20	June 29, 2011
58,000	$	1.20	August 29, 2011
143,000	$	1.74	August 7, 2012
50,000	$	1.50	October 23, 2012
758,000	$	1.60	February 15, 2013
255,000	$	1.75	August 26, 2013
78,000	$	1.30	May 21, 2014
25,000	$	3.26	November 3, 2014
57,000	$	2.25	February 22, 2015
60,000	$	2.10	May 27, 2015
175,000	$	2.50	August 16, 2015
100,000	$	2.90	October 4, 2015
75,000	$	2.85	January 31, 2016

1,867,000

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Future Prospects

least eight autoimmune microarray diagnostic panels over the next eighteen months. It further believes that successful completion of these tests in development, and collaborations with its partners, may lead to the identification and commercialization of other test panels, not currently contemplated or in development, addressing unmet medical needs in the diagnosis or therapies for autoimmune, infectious disease and allergy management.

SQI's operational objectives are straightforward: generate revenue from products in the regulatory jurisdictions for which we have acquired regulatory approvals or licenses; continued successful commercialization and continuous improvement of a menu of autoimmune test kits; and, expansion of partnerships and other strategic relationships to enhance our product offerings or revenues. Success in these steps will allow the Company to further validate its multiplexing model, value proposition and to roll-out and sell its products to customers in its target markets.

The Company plans to execute on the following components of its operational strategy:

•: Generate, maintain and grow customer sales in North America; Explore near-term revenue opportunities in Europe;
•: Complete commercialization and regulatory filings (where appropriate) for, vasculitis, lupus, IBD-Crohn's, anti-TNF and second generation product extensions for RA and celiac panels;
•: Work with our partners to enhance our product offerings and produce collaborative research identifying product strengths;
•: Provide world-class customer support and service to ensure satisfaction; and, Publish scientific papers to broaden our product value proposition.

The Company will continue to invest in research and development activities related to its core platform technologies of microarray-based assays and detection devices.

Disclosure Controls and Procedures, and Internal Control Over Financial Reporting

The accompanying financial statements have been prepared by management in accordance with Canadian generally accepted accounting principles. For quarterly reporting periods, the Company's financial statements are approved by the Audit Committee and the Board of Directors. For annual reporting periods, the Company's financial statements are approved by the Board of Directors upon recommendation by the Audit Committee. The integrity and objectivity of these financial statements are the responsibility of management. In addition, management is responsible for all other information in this report and for ensuring that this information is consistent, where appropriate, with the information contained in the financial statements.

In support of this responsibility, management maintains a system of internal controls to provide reasonable assurance as to the reliability of financial information and the safeguarding of assets.

In particular, the CEO and CFO are responsible for establishing and maintaining disclosure controls and procedures ("DC&Ps") and internal controls over financial reporting ("ICFRs") for the Company, and have:

(a): designed such DC&Ps, or caused them to be designed under supervision, to provide reasonable assurance that material information is made known during the period in which the annual and quarterly filings are being prepared;
(b): designed such ICFRs, or caused them to be designed under supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with Canadian GAAP;
(c): evaluated the design and effectiveness of the Company's DC&Ps as of the quarter ended March 31, 2011;
(d): have concluded that a material design weakness in the ICFRs may exist in terms of the inadequate segregation of certain duties, which is typical of development stage companies; mitigating factors, including dual-payment authorization policies and transparent internal financial transaction reporting

processes, serve to minimize the risk that such design weakness could result in a material misstatement of results for the quarter ended March 31, 2011; and

(e): have concluded that, other than the item described above in sub-point (d), there are no additional material design weaknesses in the DC&Ps or ICFRs, and that the effectiveness of the DC&Ps is sufficient to expect the prevention or detection of material misstatements of results.

The financial statements include amounts that are based on the best estimates and judgments of management. The Board of Directors is responsible for ensuring that management fulfills its responsibility for financial reporting and internal control. The Board of Directors exercises this responsibility principally through the Audit Committee. The Audit Committee consists of three directors, all of whom are independent and not involved in the daily operations of the Company. The Audit Committee meets with management and the external auditors to satisfy itself that management's responsibilities are properly discharged and to review the financial statements prior to their presentation to the Board of Directors for approval.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

For the purposes of this Management's Discussion and Analysis of Financial Condition and Results of Operations only, capitalized terms have the meaning given to them in this section.

This discussion and analysis covers the audited financial statements for the years ended September 30, 2010 and 2009, prepared in accordance with Canadian generally accepted accounting principles (Canadian GAAP). The fiscal year end of SQI Diagnostics Inc. ("SQI" or "Company") is September 30 of each calendar year. This discussion and analysis was prepared by management using information available as at January 11, 2011.

All amounts are expressed in Canadian dollars unless otherwise indicated.

OVERVIEW

SQI Diagnostics Inc. is a medical systems company that develops proprietary human diagnostic technology through multiplexing, miniaturization and automation. Our technologies enable laboratories to analyze multiple biomarkers simultaneously, deliver accurate and quantitative patient results in less time, significantly reduce labour costs, and increase profits when compared with current diagnostic instrumentation. The Company's proprietary SQiDworks™ instrument and IgXPLEX consumable tests together form an immunoassay system capable of providing many of the diagnostic tests currently performed in reference laboratories engaged in testing human blood for a wide range of disease markers.

The Company has been primarily involved in research, development and commercialization activities related to its core technology platform since 2003. The Company has expended significant resources to create and protect its technology platform through the filing of patents and in building an automated instrument and multiplexed IgXPLEX assay platform. The Company has invested in fostering partnerships with clinicians who are leaders in our disease areas of focus and with potential novel biomarker collaborators. The Company has also incurred costs associated with gathering market intelligence concerning prospective customers, developing a direct sales platform and in marketing and selling to prospective customers.

The Company's strategy is to develop and commercialize test kits for the autoimmune disease market as further described below, and plans to pursue commercialization of tests in infectious disease and allergen testing in the future. The Company also plans to explore in-licensing opportunities to expand its product pipeline as well as to continuously improve its in-market product through the addition of novel biomarkers to the existing diagnostic panels of tests. To execute this strategy the Company plans to seek regulatory approvals to sell these additional tests globally starting with the North American markets. Following the successful commercialization of several IgXPLEX test panels, management will evaluate selling in additional markets starting with countries in the European Union.

During the fiscal year ended September 30, 2010, the Company's strategic focus was to initiate the transition from a development Company to a commercial Company. During fiscal 2010, the Company entered into a contract with Gamma Dynacare Medical Laboratories (GDML) to supply them with a SQiDworks assay processing and analytical system and QuantiSpot RA™ test kits. GDML has also agreed to evaluate the Company's IgXPLEX Celiac test kits in the 2011 fiscal year and the Company expects to deliver validation IgXPLEX Celiac products to them in the second quarter of fiscal 2011. GDML is a key customer for the Company; it processes significant test volumes of both rheumatoid arthritis and celiac disease tests.

The Company is currently in the process of obtaining US FDA clearance of its IgXPLEX Celiac test. The Company believes the clearance of this product will significantly enhance its US market position. The Company is also following up with and is optimistic of winning additional Canadian customers based on Health Canada licensing of its IgXPLEX Celiac product during 2010.

The Company is focusing on the continued development of a pipeline of assays and SQiDworks and SQiDman assay processing and analytical platforms. The Company expects to advance additional test kits through the regulatory process during fiscal 2011 as discussed further in this document.

Status of Development Program

		Approval Status

	Development Status	Approval Status
Product	Development Status	Canada	United States	Europe
SQiDworks	Complete	Approved	Cleared as a system with IgXPLEX RA	CE Marked
SQiDman	Development RUO	Not required	Not required	Not required
IgXPLEX RA	Complete	Approved	Cleared	CE Marked
QuantiSpot RA™	Complete	Approved		CE Marked
IgXPLEX Celiac	Complete	Approved	Filed
IgXPLEX RA Quantitative	Development
IgXPLEX Celiac Quantitative	Development
IgXPLEX TNF	Development
IgXPLEX Vasculitis	Development
IgXPLEX Lupus	Development
IgXPLEX IBD	Proof of Concept

1.: The Company has developed fully automated SQiDworks and semi-automated SQiDman™ microarray-based test platforms that enable laboratory customers to generate multiple patient test results with less than one unit of traditional 'test effort'. The Company has received marketing clearance from the United States Food & Drug Administration ("FDA"), Canadian regulatory approval for, and has CE Marked its fully automated, high throughput SQiDworks platform. SQiDworks is the only such platform to achieve these regulatory clearances.

The SQiDworks platforms are to be used to run a menu of tests used to aid in the diagnosis of a wide range of diseases in targeted market segments. The Company has received clearance from the FDA, Canadian regulatory approval for, and has CE Marked its IgXPLEX RA test kits used to detect and measure a panel of biomarkers to aid in the diagnosis of rheumatoid arthritis. The Company has also received Canadian regulatory approval for, and has CE marked, its fully quantitative QuantiSpot RA™ tests kits, run on the SQiDworks platforms. The QuantiSpot RA test kits provide fully quantitative information to further aid in the diagnosis and diagnostic monitoring of rheumatoid arthritis.

The Company has received Canadian regulatory approval for its IgXPLEX Celiac test kits and filed for US FDA regulatory clearance to market this product.

2.: The Company continues to focus on its in-market tests and believes that it must continuously improve and update its products. The company has identified and has moved into development enhancements to the existing IgXPLEX RA and IgXPLEX Celiac test panels. These improvements, requiring regulatory approvals, will represent second generation, fully quantitative IgXPLEX microarray technology and include expanded biomarker content for IgXPLEX RA and IgXPLEX Celiac. All in-development tests will utilize this second generation, fully quantitative multiplexing technology; the Company believes these enhancements will provide significant market advantages compared to our competitors.
3.: The Company has completed proof of concept for a multiplexed test to measure the presence of anti-TNF-based biologic drugs used to treat a variety of autoimmune diseases. The Company believes that a test to measure these biological drugs in patient serum will provide important clinical and

treatment management tools for clinicians treating autoimmune diseases. The Company also believes that the development of thiscompanion diagnostic product will be used as a basis to develop other companion diagnostic products that could be delivered and sold as RUO or IUO kits to a broader market including but not limited to the pharmaceutical development and academic research markets. During the year, the Company completed development of the prototype of the IgXPLEX TNF and provided the prototype to its development partner, Mount Sinai Services (Toronto), to enable validation studies of the product and to provide initial performance feedback to the Company. The validation studies were completed, the performance criteria were met, and the Company's partner's feedback was received and is in the process of being implemented. The Company believes that it will deliver a commercial product to its partner during the 2011 calendar year.

4.: During the fiscal year ended September 2010, the Company entered into an OEM development agreement with Silliker Inc. to complete development of a multiplexed botulism assay. Owing to SQI project prioritization, and minor changes to the scope of the project, the Company decided to hold development of this project. The Company, in association with Silliker will re-assess the viability of the project over the coming quarter and will prioritize it relative to the other development projects that are currently being focussed on.

Status of Commercialization Activities and Other Events in the Year

During the year ended September 30, 2010, the Company invested in its sales and marketing team, its science, commercialization, and regulatory groups, and in infrastructure. The Company's sales efforts are focusing on the North American market to generate sales to targeted customers of the currently approved system, including the SQiDworks fully automated analytical platform, IgXPLEX RA panel, QuantiSpot RA panel, and IgXPLEX Celiac panel (Canada). The science, commercialization, and regulatory groups are focusing on the continued development of pipeline assays and SQiDworks and SQiDman platforms.

Following is an overview of the Company's achievements for the year to date:

(a): During the year ended 2010, the Company entered into a sales agreement with Gamma Dynacare Medical Laboratories (GDML) for the supply of its QuantiSpot RA test kits and SQiDworks platform. GDML has also requested that the Company provide to it sufficient IgXPLEX Celiac test kits upon the Company's successful validation of the product such that GDML can perform its internal review of the product's performance. The Company expects to deliver these test kits to GDML during the second quarter of 2011. Successful internal review by GDML is expected to lead to the expansion of the current contract to include IgXPLEX Celiac test kits;
(b): Subsequent to the year ended September 30, 2010 the Company executed an evaluation agreement with a significant US-based reference laboratory and technology opinion-leader. The Company believes that the conversion of this target customer will result in a very positive general market reaction and demand for its products. The Company expects to deliver the SQiDworks platform to this target customer in the second fiscal quarter of 2011;
(c): Completed an in-depth market survey of high potential target customers generating numerous high quality sales leads during the year;
(d): Completed 50 sales calls with potential customers from our target list drawn from the top 100 diagnostic labs (based on volume) during the second, third and fourth quarters. The Company believes that it has generated significant interest from these target customers and that there is a high level of interest to evaluate the SQiDworks platform and available test kits upon the clearance of its IgXPLEX Celiac test kit;
(e): Obtained the patent "Method to Measure Dynamic Internal Calibration True Dose Response Curves". Management believes this patent to be a significant achievement in its intellectual property portfolio establishing enhanced protection of in-array calibration and normalization; and,
(f): Progressed a number of pipeline diagnostic tests through our discovery and development program;

(i): the Company obtained clearance from the FDA to market and sell the IgXPLEX RA and SQiDwoks system; the first ever cleared multiplexed/microarray product. Health Canada licenses were also obtained to market the IgXPLEX RA product in addition to the previously licensed QuantiSpot RA product and SQiDworks platform;
(ii): Applied for and obtained Health Canada license to market the IgXPLEX Celiac 4-PLEX panel;
(iii): Applied for US FDA regulatory clearance of its IgXPLEX Celiac 4-PLEX panel. Subsequent to the fiscal year ended September 30, 2010, the Company received and responded to questions from the FDA regarding this panel. The questions and responses are described by the Company as those expected in the normal course of its regulatory processes.
(iv): Based on market information obtained through in-depth market surveys and sales calls with potential customers the Company has identified enhancements to its existing RA and Celiac products. These enhancements, requiring regulatory approvals, are in development and include transition from qualitative to fully quantitative reporting and the expansion of additional biomarkers that the Company believes will be relevant in the market.
(v): The IgXPLEX Vasculitis assay was advanced to the Assay Development stage and is expected to complete clinical validation in the second quarter of 2011.
(vi): Advanced the IgXPLEX Lupus test kits to the proof of concept stage and subsequent to the year end it was progressed to the assay development stage. The Company expects to initiate clinical validation of this product in the second calendar quarter of 2011, and complete regulatory filings shortly thereafter.
(vii): IgXPLEX IBD was progressed into the proof of concept stage and is being actively developed with the expectation of being completed and filed for regulatory approvals in 2011.
(viii): Continued development of IgXPLEX TNF test kits based on the expanded performance requirements requested by our partner, Mount Sinai Services. During this time, the R&D team also made significant technical improvements in the assay. The IgXPLEX TNF test is intended to be used to measure and monitor the concentration of anti-TNF-based drugs including Remicade™, Humira™ and Enbrel™ in patients with a range of autoimmune and inflammatory disorders including but not limited to rheumatoid arthritis, crohn's disease, plaque psoriasis and ankylosing spondylitis. The Company believes that the cost-effective measurement of these drugs would provide clinicians enhanced treatment options. The Company expects that it will be able to complete commercialization of an IgXPLEX TNF test that will be able to be cleared for IVD sale in Canada. It will remain as a Research Use Only (RUO) product with limited performance claims in the US until expanded clinical studies are performed. However, the Company continues to believe that, as there are no predicate tests currently approved to test for the presence and concentration of anti-TNF, there is a viable RUO market for the product in the US.
(ix): Initiated platform development for SQiDman with a target to complete development that is expected to coincide with customer requirements for potential research use collaborations. Subsequent to the year end this SQiDman platform became available for RUO/IUO applications. This platform is currently not targeted at IVD applications until the Company is actively developing infectious disease content and at that time the SQiDman platform would require additional development for regulatory requirements;

(g): Partnering Successes in 2010

During and subsequent to the year ended 2010, the Company was successful in entering into multiple collaboration agreements with the leading institutes highlighting the market interest in multiplexing and the Company's achievements to date. These collaborations significantly improve the Company's ability to progress its products through the development process through obtaining access to patient sera needed for assay development, verification of in-development products and final product clinical validation.

The following table provides an overview of our partnering collaborations and the relevant pipeline product:

Partnering Institute*	Principal Investigator	Pipeline Product	Purpose



Cleveland Clinic (i)	Dr. Tubbs	IBD	Serum Samples Collaboration

Beth Israel Deaconess Medical Center	Dr. Kelly	Celiac	Serum Samples Collaboration/Publication

Beth Israel Deaconess Medical Center	Dr. Moss	Anti-TNF	Serum Samples Collaboration/Publication

Hospital Clinic de Barcelona, Spain	Dr. Cervera	Vasculitis	Serum Samples Collaboration/Publication

Cleveland Clinic	Dr. Wang	All Rheumatoid Arthritis Various	Clinical Validation Collaboration Serum Samples

University of Maryland	Dr. Fasano	Celiac	Serum Samples

University Hospital Maastricht, the Netherlands	Dr. Damoiseaux	Vasculitis	Serum Samples Collaboration

University North Carolina Kidney Center (ii)	Dr. Falk	Vasculitis	Collaboration Serum Samples Clinical Validation

*: All Partnering Institutes are located in the USA unless otherwise annotated.

(i): Completed an "IBD Multiplex Panel Development Collaboration" agreement with Dr. Tubbs of the Department of Molecular Pathology, Cleveland Clinic. This agreement gives the Company access to a significant resource for professional collaboration of its IBD (Crohn's Disease) IgXPLEX product and next generation biomarkers as well as access to a valuable bank of characterized patient serum for development and clinical validation.
(ii): Subsequent to the fiscal year end, the Company entered into a clinical validation agreement with the University North Carolina Kidney Center (UNCKC), Chapel Hill, with Dr. Falk acting as the principal investigator. This agreement gives the Company access to a significant bank of prospective and stored patient serum samples for characterized positive vasculitis patients. These serum samples substantially improve the Company's ability to develop and validate its IgXPLEX Vasculitis product. The collaboration agreement also provides the Company professional expertise from the world leader in diagnosing vasculitis disease. The Chapel Hill Protocol is the most recognized diagnostic algorithm used to diagnose vasculitis disease. As part of the agreement, the Company is collaborating to establish a center of excellence for microarray-based multiplex testing of vasculitis with Dr. Falk through the collaboration and delivery of a SQiDworks platform at Chapel Hill. The agreement calls for co-publishing of the results of the collaborative efforts.

The Company anticipates that this platform can be used for expanded purposes alongside the collaboration with Dr. Falk including, but not limited to validation of additional products in its pipeline.

CORPORATE FINANCING TRANSACTIONS

During the fiscal year ended 2010 the Company was successful in raising significant capital to sustain its operations from the exercise of warrants and options and from two private placements, in total generating $13,997,000 in net cash.

On December 4, 2009, the Company completed a private placement resulting in the issuance of 2,398,104 units at a price of $2.75 per share for gross proceeds of $6,595,000 (net of cash costs — $6,109,000). Each unit was comprised of one common share and one half common share purchase warrant. Each whole warrant entitles the holder to purchase one additional common share at a price of $4.00, expiring December 4, 2011. The total share issuance costs were $611,000.

On August 12, 2010, the Company complete another private placement resulting in the issuance of 2,280,000 units at a price of $2.50 per unit for gross proceeds of $5,700,000 (net of cash costs — $5,399,000). Each unit was comprised of one common share and one half common share purchase warrant. Each whole warrant entitles the holder to purchase one additional common share at a price of $5.00, expiring on August 12, 2012. The total share issuance costs were $363,000.

During the fiscal year ended 2010 199,493 warrants with an expiry of April 26, 2010 were exercised resulting in the issuance of 199,493 shares and net proceeds of $120,000. During the fiscal year ended 194,200 warrants with an expiry of June 3, 2010 were exercised resulting in the issuance of 194,200 shares and net proceeds of $291,000. In addition, 576,563 warrants with an expiry date of June 29, 2010 were exercised resulting in the issuance of 576,563 shares and net proceeds of $1,384,000 the remaining 1,207,213 warrants with an expiry date of June 29, 2010 expired unexercised.

During the fiscal year ended 2010 the Company also issued 916,683 shares resulting from the exercise of options (850,017 of these option were issued under the Stock Option Plan). The exercise of these options resulted in gross proceeds of $694,000.

CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT ESTIMATES

Financial statements are prepared in accordance with Canadian GAAP.

The significant accounting policies that management believes are the most critical in fully understanding and evaluating the reported financial results include the following:

Patents and Trademarks

Research and Development Costs

Research costs are charged to earnings in the period in which they are incurred. Development costs are expensed as incurred or deferred if they meet the criteria for deferral under Canadian generally accepted accounting principles and are expected to provide future benefits with reasonable certainty. At September 30, 2010, the Company was in development of its pipeline of novel tests for its diagnostic system. Deferral criteria have not yet been met, and accordingly, all development costs have been expensed.

Stock-Based Compensation and Other Stock-Based Payments

Share Issuance Costs

Costs incurred in connection with the issuance of capital stock are netted against the proceeds received.

Income Taxes

Use of Estimates

Recent Accounting Pronouncements

Business Combinations

International Financial Reporting Standards (IFRS)

The CICA plans to converge Canadian Generally Accepted Accounting Principles with International Financial Reporting Standards ("IFRS") over a transition period expected to end in 2011, when IFRS will be fully adopted. The Company will required to adopt IFRS for its 2012 fiscal year end and will be required to provide IFRS comparative information for the previous fiscal year. The Company continues to monitor and assess the impact of the convergence of Canadian GAAP and IFRS on its financial statements. We have identified the main differences between existing Canadian GAAP and IFRS standards. The Company has a

conversion plan in place and believes it has the resources in place to meet the conversion timelines. The following are the main differences and the expected impact on our business processes and information systems:

Key Accounting Areas		Difference with potential impact on the Company



IFRS 1 First time adoption of IFRS		The Company is in the process of selecting the applicable exemptions under IFRS.
		Required reconciliations and disclosure upon the initial conversion to IFRS will be included in the initial statements presented under IFRS commencing in the first quarter of fiscal 2012.

IAS 16 Property Plant and Equipment		The Company will re-evaluate the useful life of each component of property plant and equipment and will restate, if applicable, the historic amortization expense.

IAS 36 Impairment of Assets		The Company will evaluate potential impairments using discounted cash flow analysis as required under IFRS

IAS 12 Income Tax		The Company has accumulated non-capital losses, undeducted scientific research and development costs, and investment tax credits that have not been reflected in the financial statements. These items will need to be assessed based on the IFRS criteria to ensure proper classification on the balance sheet.

IFRS 2 Share based payments		The Company will treat all options with graded vesting as separate option awards as required under IFRS 2. The Company will utilize the exemptions under IFRS 1 when converting to the new standard.

IAS 1 Financial Statement Presentation		Additional disclosure required as well as selection between presentation alternative will be addressed in the initial statements presented under IFRS.

SELECTED FINANCIAL INFORMATION

The table below summarizes annual financial information for the fiscal years ending September 30, 2010 and 2009. Certain comparative information has been reclassified to conform to the current year's presentation.

	Year ending September 30, 2010 (000s)			Year ending September 30, 2009 (000s)



Revenue	$	35		$	32

Net loss	$	8,073		$	5,910

Net loss per share	$	(0.27	)	$	(0.23	)

Weighted average shares		30,349			25,158

Total Assets	$	13,134		$	6,205

The increasing net loss trend between the year ended September 30, 2009 and the fiscal year ended September 30, 2010 was primarily related to increased development activity and expenses for the scientific discovery and development of several IgXPLEX assays, the regulatory approval, and the commercialization of the QuantiSpot RA, IgXPLEX RA and IgXPLEX Celiac test panels and SQiDworks system. In addition a number of diagnostic tests continued progression through our discovery and development program including IgXPLEX Vasculitis and, IgXPLEX SLE (Lupus), IgXPLEX TNF and initial development of SQiDman. The Company also invested in the development of its second generation fully quantitative and expanded biomarker panels for IgXPLEX RA and Celiac products as previously discussed.

Differences in the net loss for 2010 versus 2009 were also related to increased professional and consulting fees including recruiting fees for personnel additions, legal and accounting fees, increased stock-based

compensation expenses, and expansion of infrastructure resulting in increased personnel and occupancy costs in the year ended September 30, 2010.

Gross research and development ("R&D") costs, which include R&D salaries, laboratory consumables and operating expenses, clinical studies, scientific consultants and clinical partner costs were $5,354,000 for the year ending September 30, 2010 compared to $3,449,000 for the year ending September 30, 2009. The principle difference in Gross R&D expenses of $1,905,000 between the two periods was due to:

•: an expansion of development activities owing to an expanded number of autoimmune products in advanced stages of development in 2010 compared to 2009. During 2009 IgXPLEX RA and Celiac were in the development stage with 2 other panels in early discovery. During 2010 the company advanced IgXPLEX Celiac to the regulatory approval stage, obtained the regulatory approval of IgXPLEX Celiac in Canada, had 5 additional panels in the development stage (second generation IgXPLEX Celiac and RA, IgPLEX Vasculitis, IgXPLEX Lupus, and IgPLEX TNF) and one product in the early discovery stage (IgPLEX IBD);
•: Initiated development efforts toward the SQiDman platform and enhancements to the SQiDworks platform and software allowing multi-plate/multi-product runs, pick and pay capability and Lab Information Management Systems ("LIMS") integration;
•: a greater level of activity and personnel additions in 2010 to complete the required work;
•: cost related to Autoimmune assay validation services;
•: new expenditures for internal and third party clinical studies including increased acquisition costs for patient serum tested in these studies.

In the fiscal period ending 2010 the Company had a peak of 53 employees, 44 involved directly in R&D compared to the 2009 fiscal year when the Company had a peak of 36 employees with 29 involved directly in R&D. R&D salaries and payroll costs increased from $2,372,000 for the period ending September 30, 2009 to $3,159,000 for the year ending September 30, 2010. R&D consumable costs rose in proportion to the number of R&D employees and development projects being prosecuted, and these expenses increased by $1,118,000 in the year ending September 30, 2010 above the expenses incurred in the period ending September 30, 2009.

Gross R&D expenses were offset by the recognition of Scientific Research and Experimental Development ("SRED") cash refunds received in the 2009 fiscal year of $87,000 resulting in net R&D expenses of $3,362,000 and by $295,000 in the 2010 fiscal period resulting in net R&D expenses of $5,059,000.

General and administrative ("G&A") expenses include occupancy costs (rent, maintenance and utilities), office supplies as well as other general operating costs and bank charges. G&A expenses increased in the year ending September 30, 2010 compared to the period ending September 30, 2009 from $447,000 to $471,000. The primary reasons for the $24,000 increase were an increase in travel related to corporate development activities, increased occupancy costs due to the increase in the number of employees, and other costs related to the general growth of the corporate activities and related overheads to operate the business. General and administrative expenses included a $97,000 patent write down in 2009; there was no similar write down in the current year. Amounts for sales and marketing included in general and administrative expenses in the prior year have been reclassified to sales and marketing expenses.

Sales and marketing costs were primarily related to sales and marketing consultant fees and to travel related to selling activities. Sales and marketing expenses totalled $474,000 for the year ended September 30, 2010 compared to $409,000 for the year ended September 30, 2009. The increase of $65,000 was primarily a result of additional consultant costs as the company expanded its commercialization efforts.

Fourth Quarter Commentary

The table below summarizes quarterly financial information for the 3 month periods shown.

	September 30, 2010 (000s)			June 30, 2010 (000s)			March 31, 2010 (000s)			December 31, 2009 (000s)



Revenue	$	14		$	6		$	10		$	5

Net Loss	$	2,621		$	1,811		$	2,021		$	1,620

Net Loss Per Share	$	(0.08	)	$	(0.06	)	$	(0.07	)	$	(0.06	)

Weighted Average Shares		32,705			30,790			29,917			27,930

	September 30, 2009 (000s)			June 30, 2009 (000s)			March 31, 2009 (000s)			December 31, 2008 (000s)



Revenue	$	7		$	8		$	7		$	10

Net Loss	$	1,616		$	1,354		$	1,473		$	1,467

Net Loss Per Share	$	(0.06	)	$	(0.05	)	$	(0.06	)	$	(0.07	)

Weighted Average Shares		27,271			26,326			25,837			22,448

Revenue for the quarter ended September 30, 2010 was $14,000 compared to $7,000 for the quarter ended September 30, 2009. In the last quarter of 2010 the Company completed its first sale of its QuantiSpot RA test kit to a 3^rd party. Other revenue for the three month periods ending September 30, 2010 and 2009 was from service-based revenue provided to a related party.

For the quarter ended September 30, 2010, the Company recorded a net loss of $2,621,000 ($0.08 net loss per share) compared to a net loss of $1,616,000 ($0.06 net loss per share) for the quarter ended September 30, 2009. Per share values are based on the weighted average shares outstanding in the period. For the quarter ended September 30, 2010 there was an average of 32,705,000 shares outstanding.

Net loss and net loss per share were greater for the quarter ended September 30, 2010 compared to September 30, 2009. The increased loss for the three months ending September 30, 2010 was primarily related to increases in activity and expenses in the discovery efforts for and development of several IgXPLEX assays, including ordinary increases in wage and wage-related expenses owing to an increase in personnel, increased lab expenditures to support the greater number of projects, and other direct costs including serum acquisition and development and validation partner costs. Sales and Marketing expense was higher in the quarter ended 2010 owing to additional travel and contract resources in sales and marketing as the Company increase its sales effort for approved IgXPLEX panels in Canada and the United States and in anticipation of further approval.

R&D expenditures for the three month period ended September 30, 2010 were $1,621,000 compared to the $872,000 (before the effect of SR&ED tax credits) for the three month period ended September 30, 2009. The increase in R&D expense for the three month period ended September 30, 2010 compared to the three months ending September 30, 2009 resulted from increased R&D activity with an increased number of assay panels in development and to regulatory validation efforts related to the IgXPLEX Celiac assay. In the fourth quarter of 2009 the Company had 1 panel in development and one panel in the regulatory approval process. In the last quarter of 2010 in addition to the IgXPLEX Celiac assay in regulatory validation, the company had 5 panels in development and 1 additional panel in early discovery and development. The company has also expended developments efforts toward the SQiDman platform and enhancements to the SQiDworks platform and software. The company also incurred costs related to autoimmune assay validation services and expenditures for internal and third party clinical studies.

Corporate expenses include, primarily, all salaries and related expenses (including benefits and payroll taxes) of the Company other than salaries and related expenses paid to personnel engaged in research and development. General and Administrative expenses include facility costs, insurance costs, and foreign exchange expenses. Corporate and general expenses totalled $299,000 for the quarter ended September 30, 2010 compared to $290,000 for the quarter ended September 30, 2009. During the fourth quarter of 2010 corporate

expenses increase as a result of higher salary costs, including bonuses and increased personnel and increased occupancy costs. Corporate expenses included a write down for abandoned patents in the quartered ended September 30, 2009, there was no similar write down in 2010.

Professional consulting (legal, accounting, Board of Directors compensation, recruiting, administrative contractor, and investor relations) costs in the quarter ended September 30, 2010 were $223,000 compared to $179,000 from the quarter ended September 30, 2009. The increase in professional and consulting costs in the quarter ended September 30, 2010 were primarily related to the use of multiple experts in the areas of professional recruiting for science, regulatory, engineering and technical professionals, laboratory cost analysis, competitive and product intelligence, and work-flow management. Professional recruiting costs were incurred primarily to increase staffing to support product pipeline and commercialization efforts. Amounts for sales and marketing included in professional and consulting expenses in 2009 been reclassified to sales and marketing expenses to conform with the current year's presentation.

Operational expenses were partially offset by interest income earned on short-term investments. The interest income was $32,000 and $12,000 for the year and quarter ended September 30, 2010 respectively. The interest earned for the year and quarter ended September 30, 2009 was $121,000 and $3,000. Interest in 2009 included interest earned on ITC credits outstanding. The Company invests its cash in variable term cashable government investment certificates and short-term money market deposits.

Non-cash stock based compensation charges totalled $218,000 for the quarter ended September 30, 2010 ($402,000 — year ended September 30, 2010) compared to $89,000 for the quarter ended September 30, 2009 ($380,000 — year ended September 30, 2009). The related stock option issuances are described further below in the Outstanding Share Capital section.

Outlook

Management expects losses to continue for the current fiscal year as investment continues in product development and commercialization efforts on its pipeline of autoimmune test kits as well as investment in sales and marketing. During the 2011 fiscal year the Company will focus on sales and placing SQiDworks systems in Canadian and US-based customers for system evaluation and expects that of the majority of these evaluation placements will lead to commercial acceptance and revenues from sales of consumable test kits. The Company delivered one such evaluation placement in January 2010 to GDML. This system was installed and handed off to the customer in February following training of its operational personnel. From the date of hand-off the customer was provided 90 days to run its internal acceptance validation. During the quarter ending June 30, 2010, the Company converted the positive validation of the platform to a commercial agreement for commercial use by the customer, and generated revenue to the Company in the quarter ended Sept 30, 2010.

During the 2010 fiscal year the Company utilized its significant positive customer feedback relating to the commercial feasibility of its system and consumable tests from this market survey generated in the first two quarters of the 2010 fiscal year to focus on high-value customers with higher volumes of rheumatoid arthritis testing. Based on this market feedback, the Company believes that its strategy of focusing development, commercialization and marketing efforts on panels of autoimmune assays targeted at medium and large reference laboratory customers continues to be sound and aligns with customer demand. As well, the Company generated a significant number of qualified sales leads from its survey activity and is in the process of conducting both initial and follow-up sales meetings with approximately 50 qualified prospective customers.

the company will be well-positioned for wider scale commercial acceptance of our platforms during the 2011 fiscal year, and beyond. Management believes the number of potential customers upon regulatory clearance of multiple IgXPLEX products (ex IgXPLEX RA and IgXPLEX Celiac) in the US, to greatly exceed those currently targeted with only one approved product in the US. Further, completion of SQiDworks Lite in 2011 for IVD and RUO/IUO applications will greatly enhance the addressable market into the 1,000s of potential customers.

Based on its successful FDA clearance, its Health Canada licenses and EU authorization, management increased the intensity of the development and commercialization of several new IgXPLEX test kits in 2010 and expects this development to result in the submission of a continuous flow of autoimmune test kit applications to the US, Canadian and EU regulatory bodies during the 2011 calendar year. This activity will generate similar R&D expenses in 2011 as was experienced in the second half of the 2010 fiscal year related to internal development, internal verification and validation studies and third party validation studies. This activity is expected to continue in the foreseeable future as the company completes the autoimmune pipeline, continues to improve in-market tests and initiates development in new clinical areas.

During the 2011 calendar year the Company believes it to be strategic to expand its marketing and sales program to RUO/IUO customers that conduct research in the relevant disease markets or that have an interest in companion testing during drug development and that are targeted in our clinical areas of interest. The Company would target lower throughput customers conducting research with SQiDman platform and RUO/IUO products, higher throughput customers with our SQiDworks platform or SQiDworks Lite, the Company's intermediate platform expected to start in development in the first half of calendar 2011 and anticipated to be completed with nine months after initiation. Management believe that SQiDworks Lite will be an important system for future clinical areas and non-reference lab customers. SQiDworks Lite is expected to be fully automated, allow smaller batch sizes and to have equivalent analytical performance when compared to the current fully automated SQiDworks Platform.

It will also be necessary to invest in expanding the Company's customer service and administrative elements to support our customers and sales, as we are successful in growing our placement of SQiDworks platforms across Canada and the United States, and increase our product menu available to our customers. Management will add these expenses as needed to support forecasted customer installations of SQiDworks platforms and sales of consumable kits.

Management will continue to monitor the cash burn rate in relation to the capital available to it and will manage cash flows as required in the context of the capital markets. Management believes that it may, at some point, seek additional capital to advance and accelerate the number of tests under development and being validated for regulatory submissions, to expand our areas of focus beyond autoimmune disease at the appropriate times, expand our fully marketed analytical platform system portfolio enabling us to address a broader market, to build SQiDworks platforms to address customer demand, as well as to expand our sales team and its efforts in the United States and other jurisdictions as appropriate.

Related Party Transactions

Included in general and administrative expense for the year ended September 30, 2010 is $49,000 (September 30, 2009 — $50,000), related to recovery of occupancy costs, from a corporation in which an officer of the Company was also an officer. Consulting fee revenue of $30,000 for the year ended September 30, 2010 (year ended September 30, 2009 — $27,000) was earned from this corporation. At year end, $1,000 (September 30, 2008 — $6,000) due from this corporation is included in amounts receivable.

Sources and Uses of Cash

Operational activities for the year ended September 30, 2010 were financed by cash on hand.

During the year ended September 30, 2010 the Company:

1.: Completed two non-brokered private placement for combined gross proceeds of $12,295,000 through the issuance of 4,678,000 shares; and,
2.: Received net proceeds of $1,795,000 following the exercise 970,256 warrants resulting in the issuance of 970,256 shares.
3.: Received $694,000 for new shares issued upon the exercise of 916,684 options.

At September 30, 2010, current assets were $9,902,000 compared to $3,649,000 at September 30, 2009. Working capital as at September 30, 2010 was $8,928,000 compared to $3,280,000 at September 30, 2009.

Management believes that cash on hand at September 30, 2010, and cash generated from revenues will be sufficient to fund Company operations for at least 12 months. The continued successful commercial launch and generation of revenue in the 2011 fiscal years will extend this period.

Risks

The Company is subject to various risks. Factors that could cause results or events to differ materially from management's current expectations include, but are not limited to:

•: changing competitive technology and market conditions;
•: the Company's ability to successfully commercialize additional IgXPLEX tests in the autoimmune disease market;
•: the successful and timely completion of clinical validation studies at partner sites;
•: the failure to obtain requisite regulatory approvals (including the clearance of the FDA) for the Company's diagnostic tests in a timely manner, if at all, and other inherent uncertainties related to the regulatory approval process;
•: the ability to generate sufficient acceptance of the Company's platforms and sales of test kits; and,
•: the ability of the Company to fund its cash requirements from internal and external sources.

The Company's SQiDworks automated analytical platform and its lead IgXPLEX RA test kit used to detect and quantify a panel of biomarkers to aid in the diagnosis of rheumatoid arthritis was cleared and licensed to be sold and marketed in Canada during the quarter ended December 31, 2008 and in the United States in November of 2009, and in the quarter ended March 31, 2009 were authorized to be CE Marked and to be sold in Europe. To the best of the Company's knowledge, this was the first and remains the only multiplexed microarray test in the autoimmune disease market to have been successfully cleared by the FDA or, in combination with IgXPLEX Celiac, the only tests of this nature licensed in Canada. The Company sought regulatory approvals and clearances for its IgXPLEX Celiac test kit in the fourth quarter and received Health Canada approval prior to year end. The Company is awaiting FDA clearance.

IgXPLEX and QuantiSpot tests are designed to run only on the SQiDworks platform. In order to obtain approval for the SQiDworks platform and the Company's consumable tests for sale in the United States, our largest target market, the FDA typically requires the conduct of clinical validation studies to compare the performance of a new test to predicate tests currently approved for sale in the US. Upon successful completion of validation studies conducted at both SQI's labs and at multiple third party labs, the data derived are then presented to the FDA in the form of a 510(k) Pre-market Notification. It is typical for the external validation studies to take several months to complete and upon receipt of a completed 510(k) submission the FDA may take up to 180 days to render a decision on the application, not including any "time-outs" which the Company may take to prepare responses to various inquiries from the FDA. The Company believes the experience gained in obtaining the clearance of the SQiDworks-IgXPLEX RA system will enable it to complete and file

applications for clearance of subsequently developed pipeline IgXPLEX assays more efficiently. This in turn may result in shorter review periods at the FDA than was experienced with the SQiDworks-IgXPLEX RA system. The timing of such clearances is dependent on several factors some of which are not controlled by the Company.

The IgXPLEX multiplexed test panels used to detect and quantify a panel of biomarkers to aid in the diagnosis of lupus, vasculitis, and Crohn's disease, are currently in the Company's discovery and development pipeline along with the IgXPLEX TNF panel to detect the drug, anti-TNF, that is used in the management of multiple autoimmune diseases. The IgXPLEX TNF panel is used to measure the quantity of therapeutic agents in the body and the information from this test could be used by clinicians in the management of several autoimmune diseases, including but not limited to rheumatoid arthritis, vasculitis and irritable bowel disease.

The Company is expecting one, or all of its pipeline of new multiplexed test panels in the autoimmune disease market under development (Vasculitis, Lupus, IBD (Crohn's), and the second generation and expanded IgXPLEX RA and Celiac tests, and the SQiDworks platform, together each a system, to be commercially ready to file applications with the applicable regulatory jurisdictions in calendar 2011. Management believes that the IgXPLEX TNF test kits will be available for commercial sale for diagnostic use in Canada and research use in the US prior to the end of the 2011 calendar year.

During the current reporting period the Company did not earn material revenues from its test kits or SQiDworks platform. The continuation of the Company's research, development and commercialization activities along with investment in marketing and sales is dependent upon the Company's ability to successfully manage its growth, investment in continued pipeline development and its cash requirements. Management believes that it has sufficient cash reserves to support the development, validation and commercialization of Vasculitis, Lupus, IBD (Crohn's), and the second generation and expanded IgXPLEX RA and Celiac tests and SQiDworks in North America.

We are exposed to market risks related to changes in interest rates and foreign currency exchange rates, which could affect the value of our current assets and liabilities. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our cash investment, due to the prime interest rate based nature of the investment. We have not entered into any forward currency contracts or other financial derivatives to hedge foreign exchange risk. We are subject to foreign exchange rate changes that could have a material effect on future operating results or cash flows.

Outstanding Share Capital

As at September 30, 2010, there were 33,758,000 common shares issued and outstanding.

The following tables describe the securities that have been issued that are convertible under certain conditions into common shares:

The Company had the following warrants outstanding at September 30, 2010:

	Purchase Price		Expiry Date

144,000	$	2.750	December 4, 2010
107,000	$	1.250	January 22, 2011
1,199,000	$	4.000	December 4, 2011
237,000	$	1.900	December 23, 2011
1,140,000	$	4.000	August 12, 2012
57,000	$	2.500	August 12, 2012

2,884,000

The Company had the following stock options outstanding under the Plan at September 30, 2010:

	Exercise Price		Expiry Date

33,000	$	1.200	June 29, 2011
67,000	$	1.200	August 29, 2011
180,000	$	1.740	August 7, 2012
50,000	$	1.500	October 23, 2012
758,000	$	1.600	February 15, 2013
269,000	$	1.750	August 26, 2013
80,000	$	1.300	May 21, 2014
25,000	$	3.260	November 3, 2014
68,000	$	2.250	February 22, 2015
60,000	$	2.100	May 27, 2015
175,000	$	2.500	August 16, 2015

1,764,000

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Future Prospects

In its current state of evolution, management believes that the Company has assembled the necessary intellectual, financial, and human capital to advance its current pipeline of autoimmune test panels and the SQiDworks system through the completion of clinical validation studies and regulatory filings in Canada, the U.S. and Europe. The Company believes that completion of its lead product IgXPLEX RA and its clearance in the United States plus the filing for clearance in the United States of IgXPLEX Celiac, the licensing in Canada of QuantiSpot RA, IgXPLEX RA and IgXPLEX Celiac, and authorization to CE Mark it in Europe of QuantiSpot RA justifies the current intensified investment in development and commercialization of its pipeline of an additional group of at least eight autoimmune microarray diagnostic panels over the next eighteen months, with four novel and two second generation tests currently in the Company's discovery or assay development processes. It further believes that successful completion of these pipeline tests may lead to the development and commercialization of other test panels addressing unmet medical needs in the detection of known analytes used in the diagnosis or therapies for autoimmune, infectious disease and allergy management.

The Company plans to execute on the following components of its operational strategy:

•: Generate, maintain and grow customer sales in North America;
•: Complete commercialization and regulatory filings (where appropriate) for, vasculitis, lupus, IBD, anti-TNF and second generation product extensions for RA and Celiac panels;
•: Work with our partners to enhance our product offerings;
•: Provide world-class customer support and service to ensure satisfaction; and,
•: Publish scientific papers to broaden our product value proposition.

The Company will continue to invest in research and development activities related to its core platform technologies of microarray-based assays and detection devices.

Disclosure Controls and Procedures, and Internal Control Over Financial Reporting

In support of this responsibility, management maintains a system of internal controls to provide reasonable assurance as to the reliability of financial information and the safeguarding of assets.

(a): designed such DC&Ps, or caused them to be designed under supervision, to provide reasonable assurance that material information is made known during the period in which the annual and quarterly filings are being prepared;
(b): designed such ICFRs, or caused them to be designed under supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with Canadian GAAP;
(c): evaluated the design and effectiveness of the Company's DC&Ps as of the quarter ended September 30, 2010;
(d): have concluded that a material design weakness in the ICFRs may exist in terms of the inadequate segregation of certain duties, which is typical of development stage companies; mitigating factors, including dual-payment authorization policies and transparent internal financial transaction reporting processes, serve to minimize the risk that such design weakness could result in a material misstatement of results for the quarter ended September 30, 2010; and
(e): have concluded that, other than the item described above in sub-point (d), there are no additional material design weaknesses in the DC&Ps or ICFRs, and that the effectiveness of the DC&Ps is sufficient to expect the prevention or detection of material misstatements of results.

DIRECTORS AND OFFICERS

The following table sets forth the names, municipalities of residence, positions held with us and principal occupations of our directors and executive officers and, if a director, the month and year in which the person became a director. Our directors hold office until the next annual meeting of our shareholders or until their successors are appointed.

Name, Place of Residence and Director Since (if applicable)	Principal Occupation

Claude Ricks Barrie, ON May, 2007	Currently and since May 2007, Mr. Ricks has been the President, Chief Executive Officer and a director of the Company Prior to that, Mr. Ricks was the Chief Executive Officer of SQI Diagnostics Systems Inc., a wholly-owned subsidiary of the Company.	1,992,157	5.87%
Dr. Peter Lea Toronto, ON May, 2007	Currently and since May 2007, Dr. Lea has been the Chief Science Officer and a director of the Company. Prior to that, Dr. Lea was Chief Science Officer and director of SQI Diagnostics Systems Inc., a wholly-owned subsidiary of the Company.	2,173,904	6.40%
Eric Schneider⁽²⁾⁽³⁾ Waterloo, ON May, 2007	Currently and for the past five years, Mr. Schneider is a partner in the law firm Miller Thomson LLP and its predecessors.	380,585	1.12%
Saied Nadjafi⁽³⁾ Toronto, ON May, 2007	Currently and for the past five years Mr. Nadjafi is an independent business man.	1,931,475	5.69%
David Williams⁽²⁾ Toronto, ON May, 2007	Currently and for the past five years, Mr. Williams is the President of Roxborough Holdings Limited, a Toronto based investment company.	477,225	1.40%
Paul J. Mountain⁽³⁾ Welland, ON August, 2007	Currently and since August 2007, Mr. Mountain has been an independent consultant. Prior to that and since January 1990 Mr. Mountain was Vice President of Science and Technology at MDS Inc., a Toronto-based diversified healthcare company.	—	—
Peter Winkley⁽²⁾ Mississauga, ON November, 2007	Currently and since September 2010, Mr. Winkley is the Vice President and Chief Financial Officer of Algoma Capital Corporation. Prior to that, Mr. Winkley was the Chief Financial Officer of Therapure Biopharma Inc. a Mississauga-based biologics contract manufacturer. Prior to this, Mr. Winkley was Vice-President, Corporate Finance at MDS Inc.	—	—
Andrew Morris Oakville, ON	Currently and since 2004, Mr. Morris has been the Chief Financial Officer of the Company or SQI Diagnostics Systems Inc., a wholly-owned subsidiary of the Company.	283,340	0.83%
Catherine Smith Toronto, ON	Currently and since January 2005, Ms. Smith is the Vice President, Technology of the Company.	42,168	0.12%
Jaymie R. Sawyer Thornhill, ON	Currently and since October 2010, Ms. Sawyer is the Vice President, R&D of the Company. Prior to that and since 2002, Ms. Sawyer was the Director, R&D at BD Biosciences	—	—

(1): As of July 5, 2011. Options not included.
(2): Member of the audit committee (the "Audit Committee") (appointed annually).

(3): Member of the compensation committee (the "Compensation Committee") (appointed annually).
(4): Member of the Nominating and Corporate Governance Committee (appointed annually).

As of July 5, 2011 as a group, our directors and executive officers beneficially owned, directly or indirectly, or exercised control over, 7,280,854 common shares, which represented 21.45% of the outstanding common shares. Additionally, as of July 5, 2011 as a group, our directors and executive officers beneficially owned, directly or indirectly, or exercised control over, options to purchase up to 841,669 common shares.

Except as disclosed below, each of our directors and executive officers has been engaged for five years in his present principal occupation or in other capacities with the company or organization (or predecessor thereof) in which he currently holds his principal occupation. The information provided below has been provided to us by the individuals themselves and has not been independently verified by us.

Board Committees

Our board of directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee to assist the directors in efficiently carrying out their responsibilities. The below descriptions of our board policies reflects the policies which we have adopted and will have effect upon the closing of the offering.

Audit Committee

Our board of directors has appointed an Audit Committee consisting of three directors, being Eric Schneider, David Williams and Peter Winkley, the Chair of the Audit Committee, all of whom are "financially literate" within the meaning of Multilateral Instrument 52-110 (Audit Committees) and applicable U.S. securities laws, have accounting or related financial expertise, and are "independent" within the meaning of applicable Canadian and United States securities laws and as may be defined by the TSXV and the NYSE Amex. The responsibilities and mandate of the Audit Committee are set out in an Audit Committee Charter. The primary purposes of the Audit Committee are to:

(a)

assist the board of directors in fulfilling its oversight of our financial integrity, specifically by assisting the board of directors' oversight of:

(i): the integrity of our financial statements and other financial reporting;
(ii): the external auditor's qualifications and independence;
(iii): the performance of our internal audit function and internal auditor, if and when one is appointed;
(iv): our compliance with legal and regulatory requirements;
(v): the process by which we assess and manage risk; and
(vi): any other matters as defined by the board of directors;

(b)

manage, on behalf of the shareholders, the relationship between our company and the external auditor by:

(i): having direct responsibility for appointing, retaining and determining the compensation of the external auditor (in the Audit Committee's capacity as a committee of the board of directors and subject to the rights of shareholders and applicable law);
(ii): overseeing the work of the external auditor engaged for the purpose of preparing or issuing an auditor's report or performing other audit, review or attest services for our company, including the resolution of any disagreements between management and the external auditor regarding financial reporting;
(iii): determining and approving compensation for all audit and audit-related services and pre-approving all audit and permitted non-audit services to be provided to us or our subsidiaries by our external auditor;

(iv): ensuring that the external auditor reports directly to the Audit Committee and meets with the Audit Committee or the board of directors without management present at each regularly scheduled meeting of the Audit Committee or the board of directors;
(v): facilitating communication between our company and the external auditor; and
(vi): overseeing the preparation of any report that is required by any applicable securities regulatory authority to be included in the annual proxy statement, annual information form or any other public disclosure document of our company.

Compensation Committee

Our board of directors has appointed a Compensation Committee consisting of three directors, being Saied Nadjafi, Paul Mountain and Eric Schneider, the Chair of the Compensation Committee, who are "independent" within the meaning of applicable Canadian and United States securities laws and as may be defined by the TSXV and the NYSE Amex.

The responsibilities and mandate of the Compensation Committee are set out in a Compensation Committee Charter. The primary purpose of the Compensation Committee is to assist the board of directors in discharging its oversight responsibilities for the executive compensation programs of the Company and determining compensation for the Company's directors and elected officers. The Compensation Committee is responsible for:

(a): evaluating and providing recommendations to the board of directors regarding our equity-based and incentive compensation plans and programs;
(b): evaluating and providing recommendations to the board of directors regarding compensation, incentive compensation and equity-based plans and programs for our executive officers and directors;
(c): evaluating and providing recommendations to the board of directors regarding executive development and succession planning for our senior executives; and
(d): producing an annual report on executive compensation for inclusion in our management proxy circular.

Nominating and Corporate Governance Committee

Our board of directors has appointed a Nominating and Corporate Governance Committee consisting of two directors, being David Williams and Eric Schneider, who are "independent" within the meaning of applicable Canadian and United States securities laws and as may be defined by the TSXV and the NYSE Amex.

The responsibilities and mandate of the Nominating and Corporate Governance Committee are set out in a Nominating and Corporate Governance Committee Charter. The primary purpose of the Nominating and Corporate Governance Committee is to discharge the responsibilities of the board of directors with respect to certain nominating and corporate governance matters. The Nominating and Corporate Governance Committee will also:

(a): evaluate and make recommendations regarding the composition and governance of the board of directors and its committees;
(b): assess the performance of members of the board and committee members;
(c): recommend desired qualifications for board of director membership and conduct searches for potential board of directors members; and
(d): review and make recommendations with regard to our corporate governance policies and procedures.

Corporate Cease Trade Orders, Penalties and Bankruptcies

Other than as disclosed below, to our knowledge, no proposed director:

(i)

is, as at the date of this prospectus, or has been, within 10 years before the date of this prospectus, a director or executive officer of any company (including our company) that, while that person was acting in that capacity,

(A): was the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than 30 consecutive days;
(B): was subject to an event that resulted, after the director or executive officer ceased to be a director or executive officer, in the company being the subject of a cease trade or similar order or an order that denied the relevant company access to any exemption under securities legislation, for a period of more than 30 consecutive days; or
(C): within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets; or

(ii)

has, within the 10 years before the date of this prospectus, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director.

•

Mr. Nadjafi was a director and officer of TelcoPlus Enterprises Inc. when the British Columbia and Alberta securities commissions issued a cease trade order against the company in June, 2003. The cease trade order was issued due to the fact that the company was a shell company that had no operating business. The cease trade order was revoked in December 2003.

•

Mr. Williams was a director of Octagon Industries Inc. ("Octagon") from November 1993 to 2005. Octagon was subject to cease trade orders issued by the British Columbia Securities Commission ("BCSC") on May 29, 2001 (revoked on August 28, 2001) and on June 24, 2004, and by the Alberta Securities Commission on June 8, 2004, for failure to file its required financial statements. Octagon was delisted from the NEX (a separate exchange from the TSXV) for default of paying its listing fees for the third quarter of 2004. On August 12, 2001, the trustees of Octagon sent a proposal to unsecured creditors of Octagon pursuant to theBankruptcy and Insolvency Act (Canada). A majority of the unsecured creditors approved the proposal at a general meeting of the creditors held on August 25, 2001.

•

Mr. Williams also served as a director of RoaDor Industries Inc. ("RoaDor"), a reporting issuer in the Provinces of British Columbia, Alberta and Ontario, when on February 18, 2011, the BCSC and the Ontario Securities Commission each issued a cease trade order against RoaDor for failure to file its financial statements and management's discussion and analysis related thereto for the year ended September 30, 2010. The cease trade orders remain in effect as of the date of this prospectus.

•

Mr. Winkley became a director and the corporate secretary of 1608557 Ontario Inc. ("1608557") (formerly Hemosol Corp.) in November 2008 as a part of that company's emergence from protection under theCompanies' Creditors Arrangement Act (Canada). In December 2008 and March 2009, the applicable Canadian securities regulatory authorities issued cease trade orders against that company as a result of the failure to file financial statements for periods during the 2005, 2006, 2007 and 2008 fiscal years. Mr. Winkley ceased to be a director and officer of 1608557 in December 2009.

Personal Bankruptcies

To our knowledge, none of our existing or proposed directors have, within the 10 years before the date of this prospectus, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or been subject to or instituted any proceedings, arrangements or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of that person.

Executive Compensation for the Fiscal Year Ended September 30, 2010

Detailed information concerning the compensation of our executive officers and directors for the fiscal year ended September 30, 2010 is contained in pages 11 to 16 of our Management Circular, which is incorporated by reference into this prospectus. For ease of reference, we have set out below the key tables relating to the compensation for the fiscal year ended September 30, 2010 for our Chief Executive Officer, our Chief Financial Officer, and our Chief Science Officer (collectively, the "Named Executive Officers" or "NEOs"). These tables have been extracted from our Management Circular.

Summary Compensation Table

The following table sets forth all compensation earned by the Named Executive Officers during our last two fiscal years.

			Annual Compensation					Long Term Compensation

								Awards
								Securities Under Option/ SARs Granted (#)
							Other Annual Compen- sation ($)		Shares/Units Subject to Resale Restrictions ($)	Payouts
										Payouts	All Other Compen- sation ($)
NEO Name and Principal Position	Year		Salary ($)		Bonus ($)					LTIP Payouts ($)	All Other Compen- sation ($)
Claude Ricks⁽¹⁾ President and Chief Executive Officer		2010 2009		182,308 171,923		12,308 Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil
Andrew Morris⁽²⁾ Chief Financial Officer		2010 2009		166,731 160,961		9,231 22,500	Nil Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil
Dr. Peter Lea⁽³⁾ Chief Science Officer		2010 2009		151,154 150,000		6,154 Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil

(1): Mr. Ricks was appointed Chief Executive Officer of the Company in April, 2007. Prior to that, Mr. Ricks was the Chief Executive Officer of SQI Diagnostics Systems Inc., the wholly-owned subsidiary of the Company.
(2): Mr. Morris was appointed Chief Financial Officer of the Company in April, 2007. Prior to that, Mr. Morris was the Chief Financial Officer of SQI Diagnostics Systems Inc., the wholly-owned subsidiary of the Company.
(3): Mr. Lea was appointed Chief Science Officer of the Company in April, 2007. Prior to that, Mr. Lea was the Chief Science Officer of SQI Diagnostics Systems Inc., the wholly-owned subsidiary of the Company.

Outstanding Option-Based Awards

We had the following option-based awards outstanding for Named Executive Officers at September 30, 2010.

Name			Option Expiration Date

Claude Ricks	150,000	1.60	February 26, 2013	198,000
Andrew Morris	250,000	1.60	February 26, 2013	330,000
Peter Lea	150,000	1.60	February 26, 2013	198,000

(1): Closing market value on September 30, 2010 was $2.92.

Incentive Plan Awards — Value Vested or Earned During Year Ended September 30, 2010

The following incentive plan awards for Named Executive Officers vested during the year ended September 30, 2010.

Name	Option-Based Awards — Value Vested During the Year ended September 30, 2010⁽¹⁾

Claude Ricks	$	66,000
Andrew Morris	$	49,500
Peter Lea	$	66,000

(1): Closing market value on September 30, 2010 was $2.92.

Securities Authorized for Issuance under Equity Compensation Plans

The following table gives certain information as of September 30, 2010, being the our most recently completed financial year, with respect to our stock option plan under which our equity securities are authorized for issuance (see "Capitalization").

Plan Category		Number of securities to be issued upon exercise of outstanding options			Weighted-average exercise price of outstanding options			Number of securities remaining available for future issuance under equity compensation plans

Equity compensation plans approved by security holders			1,764,000		$	1.75			424,701

DESCRIPTION OF CAPITAL STRUCTURE

Common Shares

We are authorized to issue an unlimited number of common shares. The holders of common shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared by our board of directors and to receive the remaining property and assets of our company upon our dissolution or winding up. The common shares are not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such shares.

Warrants

As of May 31, 2011, we had outstanding warrants to purchase an aggregate of 2,632,852 common shares at exercise prices ranging from $1.90 per share to $5.00 per share. These warrants will expire at various times between December 4, 2011 and August 12, 2012. In the event of a distribution of dividends, a share split, a reorganization, a reclassification, a consolidation, or a similar event, each warrant provides for adjustment of the exercise price and the number of shares issuable upon exercise.

Options

We maintain a stock option plan for the benefit of directors, officers, employees and consultants. The aggregate number of common shares reserved for issuance under the plan, together with any other employee stock option plans, options for services and employee share purchase plans, may not exceed 10% of the issued and outstanding common shares at the time of the option grant (on a non-diluted basis). Options granted pursuant to the plan must have terms not to exceed five years, and are granted at an option price that may not be less than the fair market price at the time the options are granted. All options granted to individual optionees, other than consultants, generally vest in three equal installments over a period of 36 months.

DIVIDEND POLICY

MARKET FOR SECURITIES

Trading Price and Volume

Our common shares are listed and posted for trading on the TSXV under the symbol "SQD". The following table sets out, for the periods indicated, the reported high and low sales prices and aggregate volume of trading of our common shares on the TSXV for the periods indicated.

2010

Month

January	169,691	2.60	2.25
February	438,181	2.40	2.12
March	153,377	2.27	1.60
April	315,620	2.47	2.21
May	199,865	2.41	2.05
June	1,097,152	2.47	2.00
July	354,891	2.42	2.21
August	644,310	3.13	2.30
September	604,825	3.18	2.76
October	744,468	2.97	2.65
November	193,705	2.70	2.42
December	104,220	2.75	2.50

2011

Month

January	253,844	3.20	2.70
February	442,792	3.42	2.90
March	177,537	3.38	3.00
April	100,731	3.25	2.95
May	414,333	3.45	3.09
June	138,626	3.60	3.31
July⁽¹⁾	38,815	3.60	3.35

(1): As at market close July 4, 2011.

Our common shares have been approved for listing on NYSE Amex under the trading symbol "SQD".

Prior Sales

Common Shares

On August 12, 2010, pursuant to a private placement, we issued 2,280,000 units, each comprised of one common share and one-half common share purchase warrant, at a price of $2.50 per unit, resulting in gross proceeds of $5,700,000.

On December 4, 2009, pursuant to a private placement, we issued 2,398,104 units, each comprised of one common share and one-half common share purchase warrant, at a price of $2.75 per unit, resulting in gross proceeds of $6,595,000.

During the 24-month period prior to July 5, 2011, we issued the following common shares upon the exercise of warrants.

Date of Issue		Purchase Price per Common Share

July 27, 2009	777,622	$	0.60
November 9, 2009	5,000	$	2.40
November 16, 2009	1,563	$	2.40
November 23, 2009	2,500	$	2.40
January 18, 2010	13,288	$	0.60
April 12, 2010	30,000	$	2.40
April 23, 2010	186,205	$	0.60
May 06, 2010	101,000	$	2.40
May 14, 2010	65,000	$	2.40
June 3, 2010	194,200	$	1.50
June 22, 2010	15,000	$	2.40
June 25, 2010	217,500	$	2.40
June 29, 2010	139,000	$	2.40
January 21, 2011	106,520	$	1.25

During the 24-month period prior to July 5, 2011, we issued the following common shares upon the exercise of stock options.

Date of Issue		Exercise Price

April 14, 2010	141,670	$	1.20
April 14, 2010	166,670	$	0.60
April 21, 2010	5,000	$	1.74
June 18, 2010	16,667	$	1.20
August 23, 2010	10,000	$	1.75
September 1, 2010	10,000	$	1.75
December 17, 2010	7,500	$	1.74
January 21, 2011	2,500	$	1.30
Feb 14, 2011	8,334	$	1.20
March 30, 2011	30,000	$	1.74
April 26, 2011	33,334	$	1.20

Options

The following table sets forth the details for all options that we granted under our stock option plan during the 24-month period prior to July 5, 2011.

Date of Grant		Exercise Price

November 4, 2009	25,000	$	3.26
February 22, 2010	124,000	$	2.25
May 27, 2010	60,000	$	2.10
August 16, 2010	175,000	$	2.50
October 4, 2010	100,000	$	2.90
January 31, 2011	75,000	$	2.85

Warrants

The following table sets forth the details for all warrants that we issued during the 24-month period prior to July 5, 2011.

Date of Issue		Exercise Price

December 4, 2009	143,886	$	2.75
December 4, 2010	1,199,052	$	4.00
August 12, 2010	1,140,000	$	5.00
August 12, 2010	57,000	$	2.50

PRINCIPAL SHAREHOLDERS

The following table shows information known to us with respect to the beneficial ownership of our common shares as of July 5, 2011, as adjusted, where applicable, to reflect the sale of common shares offered hereby, by:

•: each of our directors;
•: the Named Executive Officers who remain employees as of the date of this prospectus; and
•: all of our directors and Named Executive Officers as a group.

	Beneficial Ownership Prior to the Offering†				Beneficial Ownership After the Offering*†

Name of Beneficial Owner	Shares		Percentage		Shares		Percentage
Directors and Named Executive Officers
Dr. Peter Lea		2,173,904		6.40%		•		•
Andrew Morris		283,340		0.83%		•		•
Paul J. Mountain		—		—
Saied Nadjafi		1,931,475		5.69%		•		•
Claude Ricks		1,992,157		5.87%		•		•
Eric Schneider		380,585		1.12%		•		•
David A. Williams		477,225		1.40%		•		•
Peter Winkley		—		—
All Directors and Named Executive Officers as a Group		7,238,686		21.32%		•		•

†: Options not included.
*: Assumes the over-allotment option is exercised in full.

Conflicts of Interest

Our directors are required by law to act honestly and in good faith with a view to our best interests and to disclose any interests that they may have in any project or opportunity of SQI. If a conflict of interest arises at a meeting of the board, any director in a conflict must disclose his interest and abstain from voting on such matter.

To the best of our knowledge, and other than disclosed herein, there are no known existing or potential conflicts of interest among SQI, our promoters, directors and officers or other members of management of SQI or of any proposed promoter, director, officer or other member of management as a result of their outside business interests, except that certain of the directors and officers serve as directors and officers of other companies, and therefore it is possible that a conflict may arise between their duties to SQI and their duties as a director or officer of such other companies.

PLAN OF DISTRIBUTION

Subject to the terms and conditions of the underwriting agreement, dated July • , 2011, between us and Leerink Swann LLC, as representative for each of the underwriters named below, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of common shares indicated opposite its name in the table below at the offering price, on or about the date of closing:

Underwriter		Number of Common Shares

Leerink Swann LLC			•
Rodman & Renshaw, LLC			•
Kingsdale Capital Markets Inc.			•

Total			•

The underwriters are offering the common shares subject to their acceptance of the common shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent, such as the receipt by the underwriters of officers' certificates and legal opinions and approval of certain legal matters by their counsel, including the validity of the common shares. The underwriting agreement provides that the underwriters have agreed, severally and not jointly, to take up and pay for all of the shares if any of them are purchased. However, the underwriters are not obligated to purchase any common shares covered by the underwriters' over-allotment option described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated. The obligations of the underwriters under the underwriting agreement may be terminated at the discretion of the representative of the underwriters on the basis of its assessment of the effect that certain changes in the United States', Canada's or international political, financial or economic conditions may have on the market for the common shares. The obligations of the underwriters may also be terminated upon the occurrence of certain stated events.

We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under applicable securities legislation, or to contribute to payments that the underwriters may be required to make in respect of those liabilities.

The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary authority.

The offering is being made concurrently in the United States and Canada pursuant to the multi-jurisdictional disclosure system. The common shares will be offered in the United States through Leerink Swann LLC and Rodman & Renshaw, LLC, and in Ontario through Kingsdale Capital Markets Inc. either directly or through their respective broker-dealer affiliates or agents, as applicable. No securities will be offered or sold in any jurisdiction except by or through brokers or dealers duly registered under the applicable securities laws of that jurisdiction, or in circumstances where an exemption from such registered dealer requirements is available. Subject to applicable law, the underwriters may offer the common shares outside of the United States and Canada pursuant to prospectus exemptions.

The offering price of the common shares will be determined by negotiation between us and the underwriters.

The offering price of the common shares for investors in the United States will be payable in U.S. dollars and the offering price of the common shares for investors in Canada will be in Canadian dollars unless the underwriters otherwise agree.

Subscriptions for the common shares will be received subject to rejection or allotment, in whole or in part, and the right is reserved to close the subscription books at any time without notice. We expect to arrange for an instant deposit of the common shares to or for the account of the underwriters with CDS Clearing and Depository Services Inc. and The Depository Trust Company on the date of closing, which is expected to take

place on or about • , 2011, or such other date as may be agreed upon by us and the underwriters, but in any event no later than • , 2011. In any event, the common shares are to be taken up by the underwriters, if at all, on or before a date not later than 42 days after the date of the receipt of the final prospectus.

Commission and Expenses

The representative has advised us that the underwriters propose initially to offer the common shares to the public at the offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of US$ • per common share. The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of US$ • per common share to certain brokers and dealers. After the initial offering, the offering price, concession and reallowance to dealers may be reduced by the representative. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. The offering price has been determined by negotiation between us and the underwriters.

We offer no assurances that the offering price will correspond to the price at which the common shares will trade in the public market subsequent to the offering.

For purposes of the offering, if all of the common shares have not been sold after the underwriters have made a reasonable effort to sell the common shares at the offering price disclosed in this prospectus, the underwriters may from time to time decrease or change the offering price and the other selling terms provided that the price for the common shares shall not exceed the offering price and further provided that the compensation that is realized by the underwriters will be decreased by the amount that the aggregate price paid by the purchasers for the common shares is less than the gross proceeds paid by the underwriters to us. Any such reduction in the offering price will not affect the proceeds received by us.

The following table shows the offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters' option to purchase additional shares described below.

	Per Share				Total

	Without Option to Purchase Additional Shares		With Option to Purchase Additional Shares		Without Option to Purchase Additional Shares		With Option to Purchase Additional Shares
Public offering price	US$	•	US$	•	US$	•	US$	•
Underwriting discounts and commissions paid by us	US$	•	US$	•	US$	•	US$	•
Proceeds to us, before expenses	US$	•	US$	•	US$	•	US$	•

We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately US$ • .

Listing

Our common shares are listed on the TSXV under the trading symbol "SQD". Our common shares have been approved for listing on NYSE Amex under the trading symbol "SQD".

Option to Purchase Additional Shares

We have granted to the underwriters an option, exercisable for 30 days from the closing of the offering, to purchase up to an aggregate of • additional common shares at the offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase the number of additional common shares proportionate to that underwriter's initial purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more common shares than the total number set forth on the cover page of the prospectus. We will pay the expenses associated with the exercise of this option.

No Sales of Similar Securities

We and certain of our officers and directors have agreed, subject to specified exceptions, not to directly or indirectly:

•: issue, offer, sell, agree to issue, offer or sell, solicit offers to purchase, grant any call option, warrant or other right to purchase, purchase any put option or other right to sell, pledge, borrow or otherwise dispose of any common shares;
•: will not establish or increase any "put equivalent position" or liquidate or decrease any "call equivalent position" (in each case within the meaning of Section 16 of the Exchange Act and the Rules and Regulations) with respect to any common shares; or
•: otherwise enter into any swap, derivative or other transaction or arrangement that transfers to another, in whole or in part, any economic consequence of ownership of common shares; or
•: publicly announce an intention to do any of the foregoing without the prior written consent of Leerink Swann LLC.

This restriction terminates after the close of trading of the common shares on and including the 90th day after the date of the final prospectus. However, subject to certain exceptions, in the event that either:

•: during the last 17 days of the 90-day restricted period, we issue an earnings release or material news or a material event relating to us occurs, or
•: prior to the expiration of the 90-day restricted period, we announce that we will release earnings results during the 16-day period beginning on the last day of the 90-day restricted period,

then in either case the expiration of the 90-day restricted period will be extended until the expiration of the 18-day period beginning on the date of the issuance of an earnings release or the occurrence of the material news or event, as applicable, unless Leerink Swann LLC waives, in writing, such an extension.

Leerink Swann LLC may, in its sole discretion and at any time or from time to time before the termination of the 90-day period, without public notice, release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our officers, directors or shareholders who will execute a lock-up agreement, providing consent to the sale of shares prior to the expiration of the lock-up period.

Stabilization

In connection with the sale of our common shares in the United States, the underwriters may sell more common shares than they are required to purchase in this offering or effect transactions which stabilize or maintain the market price of the common shares at levels other than those which otherwise might prevail on the open market. The underwriters have advised us that, pursuant to Regulation M under the Exchange Act, certain persons participating in the offering may engage in transactions, including over-allotment, stabilizing bids, syndicate covering transactions or the imposition of penalty bids, which may have the effect of stabilizing or maintaining the market price of the common shares at a level above that which might otherwise prevail in the open market. Over-allotment involves syndicate sales in excess of the offering size, which creates a syndicate short position.

Until the distribution of the common shares is completed, SEC rules may limit the underwriters from bidding for and purchasing the common shares sold in the offering. However, the representative may engage in transactions that stabilize the market price of the common shares, such as bids or purchases to peg, fix or maintain that price so long as stabilizing transactions do not exceed a specified maximum.

In accordance with the rules of the Ontario Securities Commission and the Universal Market Integrity Rules for Canadian Marketplaces administered by the Investment Industry Regulatory Organization of Canada, the underwriters may not, at any time during the period of distribution, bid for or purchase common shares. This restriction is, however, subject to exceptions where the bid or purchase is not made for the purpose of creating actual or apparent active trading in, or raising the price of, the common shares. These exceptions include a bid

or purchase permitted under the Universal Market Integrity Rules for Canadian Marketplaces relating to market stabilization and passive market making activities and a bid or purchase made for and on behalf of a customer where the order was not solicited during the period of distribution.

"Covered" short sales are sales made in an amount not greater than the underwriters' option to purchase additional common shares in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional common shares or purchasing common shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase additional shares.

"Naked" short sales are sales in excess of the option to purchase additional common shares. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common shares in the open market after pricing that could adversely affect investors who purchase in this offering.

A stabilizing bid is a bid for the purchase of common shares on behalf of the underwriters for the purpose of fixing or maintaining the price of the common shares. A syndicate covering transaction is the bid for or the purchase of common shares on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common shares originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member.

Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common shares. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time.

Electronic Offer, Sale and Distribution of Common Shares

In connection with the offering, a prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of common shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters' web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, and should not be relied upon by investors.

Affiliations

The underwriters and certain of their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and certain of their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and commissions.

In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments of ours or our affiliates.

The underwriters and certain of their respective affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any

time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

DOCUMENTS INCORPORATED BY REFERENCE

Information has been incorporated by reference into this prospectus from documents filed with securities commissions or similar regulatory authorities in Canada. Copies of the documents incorporated by reference may be obtained on request without charge from our Chief Financial Officer at 36 Meteor Drive, Toronto, ON M9W 1A4, telephone: (416) 674-7500. These documents are also available through the Internet on SEDAR, which can be accessed at www.sedar.com.

We file annual and quarterly financial information, material change reports and other information with the securities commissions or similar regulatory authorities in Canada, which allow us to "incorporate by reference" the information we file with them, which means that we can disclose important information to you by referring you to those documents. Information that is incorporated by reference is an important part of this prospectus. The following documents previously filed with the securities commissions or similar regulatory authorities in Canada are specifically incorporated by reference into and form an integral part of this prospectus:

(a): our annual information form dated June 15, 2011;
(b): our management proxy circular dated June 8, 2011 prepared in connection with the annual and special meeting of our shareholders held on July 7, 2011;
(c): our audited consolidated financial statements for the years ended September 30, 2010 and 2009, together with the auditors' report thereon;
(d): the supplemental note regarding the reconciliation of our audited consolidated financial statements for the years ended September 30, 2010 and 2009 with U.S. GAAP, together with the auditors' report thereon;
(e): our management's discussion and analysis of consolidated results of operations and financial condition for the fiscal year ended September 30, 2010;
(f): our unaudited interim consolidated financial statements for the three and six months ended March 31, 2011;
(g): the supplemental note regarding the reconciliation of our unaudited interim consolidated financial statements for the three and six month periods ended March 31, 2011 and 2010 with U.S. GAAP;
(h): our management's discussion and analysis of consolidated results of operations and financial condition for the three and six months ended March 31, 2011; and
(i): our material change report dated July 5, 2011 in respect of the proposed acquisition of Scienion.

Any annual information form, annual or interim financial statements and related management's discussion and analysis, material change report (other than a confidential material change report), business acquisition report, information circular or disclosure document filed by us with any securities commission or similar regulatory authority in Canada subsequent to the date of this prospectus and prior to the termination of the offering shall be deemed to be incorporated by reference into this prospectus, as well as any other document so filed by us that expressly states it to be incorporated by reference into this prospectus. Any report filed by us with the SEC or Report of Foreign Private Issuer on Form 6-K furnished by us to the SEC after the date of this prospectus until the termination of the distribution under this prospectus shall be deemed to be incorporated by reference as an exhibit to the registration statement of which this prospectus forms a part, if and to the extent expressly provided in such report. The documents incorporated or deemed to be incorporated by reference into this prospectus contain meaningful and material information relating to us and you should review all information contained in this prospectus and the documents incorporated or deemed to be incorporated by reference into this prospectus.

Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus shall be deemed to be modified or superseded, for purposes of this prospectus, to

the extent that a statement contained in this prospectus or in any other subsequently filed document that also is or is deemed to be incorporated by reference into this prospectus modifies or supersedes that statement. Any such modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other information set forth in the document that it modifies or supersedes. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation, an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded shall not be considered in its unmodified or superseded form to constitute part of this prospectus; rather only such statement as so modified or superseded shall be considered to constitute part of this prospectus.

WHERE YOU CAN FIND MORE INFORMATION

This prospectus does not contain all of the information contained in the registration statement we have filed with the SEC, certain items of which are contained in the exhibits to the registration statement as permitted by the rules and regulations of the SEC. Statements included or incorporated by reference in this prospectus about the contents of any contract, agreement or other documents referred to are not necessarily complete, and in each instance, if such document is filed as an exhibit, you should refer to the exhibits for a more complete description of the matter involved. Each such statement is qualified in its entirety by such reference. Upon effectiveness of the registration statement, we will become subject to the informational requirements of the Exchange Act and in accordance therewith will be required to file reports and other information with the SEC. Under the MJDS adopted by the United States and Canada, we may prepare our reports and other information in accordance with the disclosure requirements of Canada, which are different from those of the United States. Prospective investors may read any document we file or furnish to the SEC, including those documents that are incorporated by reference in this prospectus, which are filed as exhibits to our registration statement on Form F-10, at the SEC's website at www.sec.gov. You may also read and copy any document we file at the SEC's Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. We are also subject to filing requirements prescribed by the securities legislation of British Columbia, Alberta, and Ontario. These filings are electronically available from SEDAR at www.sedar.com.

As a "foreign private issuer" under the Exchange Act, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and "short-swing profit" recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required to publish financial statements as promptly as United States companies.

AUDITORS, TRANSFER AGENTS AND REGISTRARS

Our auditors are Collins Barrow Toronto LLP. The transfer agent and registrar for the common shares is Computershare Investor Services Inc. at its principal offices located in Toronto, Ontario.

CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS

The following summary describes the principal Canadian federal income tax considerations generally applicable to a prospective investor who, for purposes of the Income Tax Act (Canada) (the "Tax Act") and at all relevant times, acquires common shares ("Shares") of the Company pursuant to the offering described in this prospectus and holds its Shares as capital property, deals at arm's length with the Company, and is not affiliated with the Company (a "Shareholder"). Generally, Shares will be capital property to a shareholder unless the Shares are held or were acquired in the course of carrying on a business of buying and selling securities or as part of an adventure or concern in the nature of trade. Certain shareholders who are residents of Canada for purposes of the Tax Act and whose Shares might not otherwise be capital property may, in some circumstances, be entitled to make an irrevocable election in accordance with subsection 39(4) of the Tax Act to have such Shares and every other "Canadian security" (as defined in the Tax Act) owned by them deemed to be capital property in the taxation year of the election and in all subsequent taxation years. Such shareholders should

100

consult their own tax advisors for advice with respect to whether an election under subsection 39(4) of the Tax Act is available or advisable in their particular circumstances.

This summary is not applicable to a Shareholder (a) that is a "financial institution" for purposes of the mark-to-market property rules contained in the Tax Act; (b) that is a "specified financial institution" (as defined in the Tax Act); (c) that has elected to report its tax results in a functional currency (which excludes Canadian currency); or (d) an interest in which is a "tax shelter investment" (as defined in the Tax Act). Such Shareholders should consult their own tax advisors.

This summary is based upon the current provisions of the Tax Act, the regulations thereunder (the "Regulations"), all specific proposals to amend the Tax Act and the Regulations publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the "Proposed Amendments"), and an understanding of the current administrative policies and assessing practices published in writing by the Canada Revenue Agency ("CRA") prior to the date hereof. This summary assumes that all Proposed Amendments will be enacted in the form proposed. However, no assurances can be given that the Proposed Amendments will be enacted as proposed, or at all. This summary does not otherwise take into account or anticipate any changes in law or administrative policies or assessing practices, whether by legislative, regulatory, administrative or judicial action or decision, nor does it take into account other federal or provincial, territorial or foreign tax legislation or considerations, which may differ materially from those described in this summary. This summary assumes that, at all relevant times, the Shares will be listed on a designated stock exchange (as defined in the Tax Act), which currently includes the TSXV.

This summary is of a general nature only and is not, and is not intended to be, and should not be construed to be, legal or tax advice to any particular Shareholder. This summary is not exhaustive of all Canadian federal income tax considerations. Accordingly, Shareholders should consult their own tax advisors with respect to the Canadian federal income tax consequences of acquiring, holding and disposing of Shares having regard to their own particular circumstances.

Residents of Canada

The following portion of this summary is generally applicable to a Shareholder who, for purposes of the Tax Act and any applicable income tax treaty, at all relevant times, is or is deemed to be resident in Canada (a "Resident Shareholder").

Dividends

Dividends (including deemed dividends) received on the Shares by an individual Resident Shareholder (other than certain trusts) will be included in the individual's income and will be subject to the gross-up and dividend tax credit rules applicable to taxable dividends received by individuals from taxable Canadian corporations, including the enhanced dividend tax credit rules applicable to any dividends designated by the Company as "eligible dividends" in accordance with the Tax Act. Dividends received by an individual may give rise to alternative minimum tax.

Dividends (including deemed dividends) received on the Shares by a Resident Shareholder that is a corporation will be included in computing its income and will generally be deductible in computing its taxable income. A Resident Shareholder that is a "private corporation" or a "subject corporation", each as defined in the Tax Act, may be liable to pay a 33¹/3% refundable tax under Part IV of the Tax Act on dividends received (or deemed to be received) on the Shares to the extent such dividends are deductible in computing taxable income.

Disposition of Common Shares

A disposition or deemed disposition of a Share by a Resident Shareholder will generally give rise to a capital gain (or capital loss) equal to the amount by which the proceeds of disposition of the Share exceed (or are less than) the aggregate of the adjusted cost base of the Share to the Resident Shareholder and any reasonable costs of disposition. For this purpose, the adjusted cost base to a Resident Shareholder of a Share will be determined by averaging the cost of such Share with the adjusted cost base of any other Shares owned by

101

the Resident Shareholder as capital property. Such capital gain (or capital loss) will be subject to the treatment described below under "Taxation of Capital Gains and Capital Losses".

Taxation of Capital Gains and Capital Losses

Generally, one-half of any capital gain (a taxable capital gain) realized by a Resident Shareholder in a taxation year must be included in a Resident Shareholder's income for that year and one-half of any capital loss (an allowable capital loss) realized by a Resident Shareholder in a taxation year is required to be deducted against taxable capital gains realized by the Resident Shareholder in that year. Allowable capital losses in excess of taxable capital gains for a particular taxation year generally may be carried back and deducted in any of the three (3) preceding taxation years or carried forward and deducted in any subsequent taxation year against net taxable capital gains realized by the Resident Shareholder in such years, to the extent and in the circumstances described in the Tax Act.

The amount of any capital loss realized by a Resident Shareholder that is a corporation on the disposition of a Share may be reduced by the amount of any dividends received (or deemed to be received) by it on such Share to the extent and under the circumstances described in the Tax Act. Similar rules may apply where a Share is owned by a partnership or trust of which a corporation, trust or partnership is a member or beneficiary.

A Resident Shareholder that is throughout the year a "Canadian-controlled private corporation" (as defined in the Tax Act) may be liable for a refundable tax of 6²/3% on its "aggregate investment income", which is defined to include an amount in respect of taxable capital gains.

Capital gains realized by an individual or a trust, other than certain trusts, may give rise to alternative minimum tax.

Non-Resident Shareholders

The following portion of this summary is applicable to a Shareholder who, for purposes of the Tax Act and at all relevant times, (i) has not been and is not resident or deemed to be resident in Canada, and (ii) does not use or hold and is not deemed to use or hold Shares in connection with carrying on a business in Canada (a "Non-Resident Shareholder"). Special rules, which are not discussed in this summary, may apply to a Non-Resident Shareholder that is either an insurer carrying on business in Canada and elsewhere or an "authorized foreign bank" (as defined in the Tax Act). Such Non-Resident Shareholders should consult their own tax advisors.

Dividends

Dividends paid or credited (or deemed to be paid or credited) to a Non-Resident Shareholder by the Company will be subject to Canadian withholding tax at the rate of 25%, subject to reduction under the terms of an applicable tax treaty or convention. In the case of a Non-Resident Shareholder who is a resident of the United States for purposes of the Canada-U.S. Income Tax Convention (the "Convention"), who is the beneficial owner of the dividend, and who qualifies for the benefits of such Convention the rate of such withholding tax generally will be reduced to 15%. Not all persons who are residents of the U.S. for the purposes of the Convention will qualify for the benefits of the Convention. Non-Resident Shareholders are urged to consult their own tax advisors to determine their entitlement to any tax treaty relief as well as their ability to claim foreign tax credits with respect to any Canadian withholding tax, based on their particular circumstances.

Disposition of Common Shares

A Non-Resident Shareholder will not be subject to tax under the Tax Act on any capital gain realized on a disposition or deemed disposition of Shares unless the Shares constitute "taxable Canadian property" (within the meaning of the Tax Act) to the Non-Resident Shareholder at the time of the disposition and such gain is not otherwise exempt from tax under the Tax Act pursuant to the provisions of an applicable tax treaty or convention.

102

Shares acquired pursuant to the offering described herein, generally, will not constitute taxable Canadian property to a Non-Resident Shareholder at the time of the disposition provided that the Shares are listed on a designated stock exchange (which currently includes the TSXV) at that time, and the Non-Resident Shareholder, persons with whom the Non-Resident Shareholder does not deal at arm's length, or the Non-Resident Shareholder together with all such persons, has not owned 25% or more of the issued shares of any class or series of the capital stock of the Company at any time during the sixty (60) month period that ends at the time of the disposition. Notwithstanding the foregoing, Shares may be deemed to be taxable Canadian property in certain circumstances specified in the Tax Act.

In the event that the Shares constitute or are deemed to constitute taxable Canadian property to a Non-Resident Shareholder, such Non-Resident Shareholder will generally be subject to tax as described above under the heading "Residents of Canada — Disposition of Common Shares" unless the Non-Resident Shareholder is entitled to relief under an applicable tax treaty or convention. Non-Resident Shareholders whose Shares may be taxable Canadian property should consult their own tax advisors.

CERTAIN MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

This section describes the material United States federal income tax considerations of the acquisition, ownership and disposition of the common shares. This summary addresses only persons or entities that are "U.S. holders" (as defined below). This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax consequences that may apply to a U.S. holder arising from or relating to the acquisition, ownership, and disposition of the common shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. holder that may affect the U.S. federal income tax consequences to such U.S. holder. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. holder. This summary does not address the U.S. state and local, U.S. federal estate and gift, or foreign tax consequences or the alternative minimum tax provisions of the Code (as defined below). Each U.S. holder should consult its own financial advisor, legal counsel, or accountant regarding the U.S. federal income, U.S. state and local, and foreign tax consequences arising from and relating to the acquisition, ownership, and disposition of common shares.

This section does not apply to you if you are a member of a class of holders subject to special rules, including, but not limited to:

•: U.S. holders that are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts;
•: U.S. holders that are financial institutions, insurance companies, real estate investment trusts, or regulated investment companies;
•: U.S. holders that are dealers in securities or currencies or U.S. holders that are traders in securities that elect to apply a mark-to-market accounting method;
•: U.S. holders that have a "functional currency" other than the US dollar;
•: U.S. holders that own common shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position;
•: U.S. holders who use common shares as security for a loan;
•: U.S. holders that acquired common shares in connection with the exercise of employee stock options or otherwise as compensation for services;
•: U.S. holders that hold common shares other than as capital assets within the meaning of Section 1221 of the Code;
•: U.S. expatriates or former long-term residents of the U.S.; and
•: U.S. holders that own (directly, indirectly, or by attribution) 10% or more of the total combined voting power of our outstanding shares.

103

This section is based on the Internal Revenue Code of 1986, as amended (the "Code"), its legislative history, existing and proposed regulations under the Code, published rulings and court decisions, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the "Canada-U.S. Tax Convention"), all as in effect on the date of this offering, and all of which are subject to change, possibly with retroactive effect. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive basis.

This summary is not binding upon the Internal Revenue Service (the "IRS") and no rulings have been or will be sought from the IRS regarding any matters discussed in this summary. In that regard, there can be no assurance that one or more of the tax considerations described in this summary will not be challenged by the IRS or a U.S. court.

If a partnership (or other entity or arrangement treated as a partnership for United States federal income tax purposes) holds the common shares, the United States federal income tax treatment of a partner (or member) will generally depend on the status of the partner and the tax treatment of the partnership (or other entity). This summary does not address the tax consequences to any such partner. A partner in a partnership (or member of such other entity) holding the common shares should consult its own tax advisor with regard to the U.S. federal income tax treatment of an investment in the common shares.

You are a U.S. holder if you are a beneficial owner of a common share and you are:

•: an individual who is a citizen or resident (including a lawful permanent resident alien holding a green card) of the United States as determined for U.S. federal income tax purposes;
•: a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States or any state thereof or the District of Columbia;
•: an estate whose income is subject to U.S. federal income tax regardless of its source; or
•: a trust if it (1) is subject to the primary supervision of a federal, state or local court within the United States and one or more United States persons are authorized to control all substantial decisions of the trust or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.

The United States federal income tax consequences of the acquisition, ownership and disposition of the common shares can be very complex and, in certain cases, uncertain or potentially unfavorable to a U.S. holder. Accordingly, each prospective investor considering an acquisition of, or who acquires common shares pursuant to this offering, is strongly urged to consult its own tax advisor with respect to the United States federal, state or local income and alternative minimum tax, estate or gift, or foreign tax consequences of such acquisition, ownership and disposition of common shares in light of its own particular facts and circumstances.

U.S. Holders

Taxation of Distributions

Under the U.S. federal income tax laws, and subject to the passive foreign investment company ("PFIC") rules discussed below, if you are a U.S. holder, a distribution of cash, if any, paid on a common share, including a constructive distribution, generally will be included in your gross income as a dividend (without reduction for any amounts withheld in respect of Canadian federal income tax) to the extent of our current or accumulated "earnings and profits" (as computed under United States federal income tax rules). We do not intend to calculate our earnings and profits under United States federal income tax rules. Accordingly, U.S. holders should expect that a distribution generally will be treated as a dividend for United States federal income tax purposes. U.S. holders should consult their own tax advisors with respect to the appropriate U.S. federal income tax treatment of any distribution received from us.

If you are a non-corporate U.S. holder, dividends paid to you in taxable years beginning before January 1, 2013 that constitute "qualified dividend income" will be taxable to you at a maximum federal tax rate of 15%, provided that you hold the common shares for more than 60 days during the 121-day period beginning 60 days

104

before the ex-dividend date and meet other requirements. Dividends we pay with respect to the common shares should be qualified dividend income provided that we are not a PFIC in the year the dividend is paid or the previous taxable year.

You must include any Canadian tax withheld from the dividend payment in this gross amount even though you do not in fact receive the withheld amount. The dividend is taxable to you when you receive the dividend, actually or constructively. The dividend will not be eligible for the dividends-received deduction generally allowed to U.S. corporations in respect of dividends received from other U.S. corporations. The amount of the dividend distribution that you must include in your income as a U.S. holder will be the U.S. dollar value of the Canadian dollar payments made, determined at the spot Canadian dollar/U.S. dollar rate on the date the dividend distribution is includible in your income, regardless of whether the payment is in fact converted into U.S. dollars. Generally, any gain or loss resulting from currency exchange fluctuations during the period from the date you include the dividend payment in income to the date you convert the payment into U.S. dollars will be treated as ordinary income or loss. The gain or loss generally will be income or loss from sources within the United States for foreign tax credit limitation purposes.

To the extent that a distribution paid on the common shares is in excess of our current and accumulated "earnings and profits" (as determined for U.S. federal income tax purposes), such distribution generally will be treated as a non-taxable return of capital to the extent of your adjusted tax basis in the common shares, with any excess treated as a gain from the sale or exchange of the Shares.

A U.S. holder that pays (whether directly or through withholding) Canadian income tax with respect to distributions by us generally will be entitled, at the election of such U.S. holder, to receive either a deduction or a credit for such Canadian income tax paid. Complex limitations apply to the foreign tax credit, including the general limitation that the credit cannot exceed the proportionate share of a U.S. holder's U.S. federal income tax liability that such U.S. holder's "foreign source" taxable income bears to such U.S. holder's worldwide taxable income. In applying this limitation, a U.S. holder's various items of income and deduction must be classified, under complex rules, as either "foreign source" or "U.S. source." Special rules apply in determining the foreign tax credit limitation with respect to dividends that are subject to the maximum 15% tax rate.

For foreign tax credit purposes, dividends will be income from sources outside the United States and will, depending on your circumstances, be either "passive category" or "general category" income for purposes of computing the foreign tax credit allowable to you. However, the amount of a distribution with respect to the common shares that is treated as a "dividend" may be lower for U.S. federal income tax purposes than it is for Canadian federal income tax purposes, potentially resulting in a reduced foreign tax credit allowance to a U.S. holder. The foreign tax credit rules are complex, and each U.S. holder should consult its own U.S. tax advisor regarding the foreign tax credit rules.

Taxation of Sale, Exchange or other Taxable Disposition

Subject to the PFIC rules discussed below, if you are a U.S. holder and you sell or otherwise dispose of your common shares, you will recognize gain or loss for United States federal income tax purposes equal to the difference between the United States dollar value of the amount that you realize and your tax basis, determined in United States dollars, in your common shares. Any such gain or loss will be capital gain or loss if the common shares are held by you as capital assets. Any such gain or loss generally will be United States source income or loss for purposes of applying the United States foreign tax credit rules unless the gain is subject to tax in Canada and is re-sourced as "foreign source" under the Canada-U.S. Tax Convention and such U.S. holder elects to treat such gain as "foreign source." Capital gain of a non-corporate U.S. holder that is recognized in taxable years beginning before January 1, 2013 is generally taxed at a maximum federal rate of 15% where the U.S. holder has a holding period greater than one year. Deductions for capital losses are subject to limitations.

New Healthcare Legislation

Under newly enacted legislation, certain U.S. holders who are individuals, estates or trusts will be required to pay an additional 3.8% tax on, among other things, dividends on and capital gains from the sale or other disposition of stock for taxable years beginning after December 31, 2012. U.S. holders should consult their own

105

tax advisors regarding the effect, if any, of this legislation on their ownership and disposition of the common shares.

PFIC Rules

If we are considered to be a PFIC, as that term is defined in Section 1297 of the Code, at any time during a U.S. holder's holding period, the following sections will generally describe the United States federal income tax consequences to a U.S. holder in relation to the acquisition, ownership and disposition of common shares.

We generally will be regarded as a PFIC for United States federal income tax purposes if, for a taxable year, either (i) 75% or more of our gross income for such taxable year is passive income or (ii) on the basis of a quarterly average, 50% or more of the assets held by us either produce passive income or are held for the production of passive income, based on the fair market value of such assets. "Passive income" includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions. If a foreign corporation (such as SQI) owns, directly or indirectly, at least 25% by value of the stock of another corporation, the foreign corporation is treated for purposes of the PFIC tests described above as owning its proportionate share of the assets of the other corporation, and as receiving directly its proportionate share of the other corporation's income. In addition, under certain attribution rules, if we are a PFIC, U.S. holders will be deemed to own their proportionate share of the stock of our subsidiaries which are PFICs (such subsidiaries referred to as "Subsidiary PFICs"), and will be subject to U.S. federal income tax on (i) a distribution on the shares of a Subsidiary PFIC and (ii) a disposition of shares of a Subsidiary PFIC, both as if the holder directly held the shares of such Subsidiary PFIC.

Based on current business plans and financial expectations, we believe that the common shares should not be treated as interests in a PFIC for U.S. federal income tax purposes for the taxable year ending September 30, 2011. However, PFIC classification is fundamentally factual in nature, generally cannot be determined until the close of the taxable year in question, and is determined annually. In addition, whether any corporation will be a PFIC for any taxable year depends on the assets and income of such corporation over the course of each such taxable year. Consequently, there can be no assurance that we will not become a PFIC for any taxable year during which U.S. holders hold common shares. In any given taxable year for which we are classified as a PFIC, during which a U.S. holder holds common shares, a U.S. holder would be subject to increased tax liability (possibly including a non-deductible interest charge) (i) with respect to gain realized upon the sale or other disposition of the common shares or (ii) upon the receipt of certain distributions treated as "excess distributions," unless such U.S. holder elects to be taxed currently, by making a Mark-to-Market or a Qualified Electing Fund ("QEF") Election. An excess distribution generally would be any distribution to a U.S. holder with respect to common shares during a single taxable year that is greater than 125% of the average annual distributions received by such U.S. holder with respect to the common shares during the three preceding taxable years or, if shorter, during such U.S. holder's holding period for the common shares. In addition, certain special, generally adverse rules would apply to the common shares if we are a PFIC. For example, under certain proposed Treasury regulations, a "disposition" for this purpose may include, under certain circumstances, transfers at death, gifts, pledges, transfers pursuant to tax-deferred reorganizations and other transactions with respect to which gain ordinarily would not be recognized. In addition, if we are treated as a PFIC, dividends paid by us will not be eligible for taxation at the preferential tax rates described above under the heading "Taxation of Distributions."

If a U.S. holder owns the common shares during any year in which we are a PFIC, such U.S. holder must also file an annual report with the IRS (on IRS Form 8621 or other form specified by the U.S. Department of Treasury) regardless of whether such holder makes a Mark-to-Market or QEF Election.

Under the PFIC rules:

•: the gain or excess distribution will be allocated rateably over your holding period for the common shares;
•: the amount allocated to the taxable year in which you realized the gain or excess distribution and the amount allocated to any taxable year prior to the first taxable year in which the company is a PFIC will be taxed as ordinary income; and

106

•: the amount allocated to each prior year during which we were classified as a PFIC, with certain exceptions, will be taxed at the highest tax rate in effect for that year and an interest charge generally applicable to underpayments of tax will be imposed in respect of the tax attributable to each such year. A U.S. holder that is not a corporation must treat such interest as non-deductible personal interest.

If we were a PFIC, a U.S. holder might be able to make a Mark-to-Market Election with respect to the common shares to mitigate some of these adverse tax consequences. A U.S. holder that holds stock of a PFIC generally may make a Mark-to-Market Election with respect to its stock if the stock constitutes "marketable stock." Marketable stock is stock that is regularly traded (other than in de minimis quantities) on a U.S. exchange that is registered with the SEC or the national market system, or a non-U.S. exchange or other market that the U.S. Treasury Department determines has trading volume, listing, financial disclosure, and other rules adequate to carry out the purposes of the Mark-to-Market Election. The common shares should constitute marketable stock with respect to which a Mark-to-Market Election could be made. The common shares are expected to be traded on the NYSE Amex, which should be a "qualified exchange" for purposes of the Mark-to-Market Election. In such case, a U.S. holder would generally include as ordinary income or loss the difference between the fair market value of the U.S. holder's common shares at the end of the taxable year and the U.S. holder's adjusted tax basis in the common shares (but loss could only be included to the extent of the net amount of previously included income as a result of the Mark-to-Market Election). If a U.S. holder made the Mark-to-Market Election, the U.S. holder's tax basis in the common shares would be adjusted to reflect any such income or loss amounts. Any gain recognized on the sale or other disposition of common shares would be treated as ordinary income, and any losses incured on the sale or other disposition of the common shares would be treated as ordinary losses to the extent of any net mark-to-market gains for prior taxable years. A U.S. holder should consult its own tax advisors regarding the availability and advisability of making a Mark-to-Market Election with respect to the common shares in its particular circumstances in the event that we are or become a PFIC. A Mark-to-Market Election would not be available for any stock of a Subsidiary PFIC that a U.S. holder is deemed to own.

A Mark-to-Market Election will be effective for the taxable year for which the election is made and all subsequent taxable years. The election cannot be revoked without the consent of the IRS unless the common shares cease to be marketable, in which case the election is automatically terminated. If we are classified as a PFIC for any taxable year in which a U.S. holder owns common shares but before a Mark-to-Market Election is made, the interest charge rules described above will apply to any mark-to-market gain recognized in the year the election is made.

The QEF Election, if available, generally would allow a U.S. holder to avoid the consequences of the PFIC rules but would require such holder to include its pro rata share of our ordinary income and net capital gain in income currently, whether or not distributed. However, we do not intend to provide U.S. holders with such information as may be required to make a QEF Election effective in the event we are a PFIC.

The PFIC rules are complex and in certain cases, uncertain. Each U.S. holder should consult its own tax advisor regarding the application and operation of the PFIC rules, including the availability and advisability of, and procedure for, making the Mark-to-Market and/or QEF Elections.

Backup Withholding and Information Reporting

Under U.S. federal income tax law and Treasury regulations, certain categories of U.S. holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. Penalties for failure to file certain of these information returns are substantial. U.S. holders who acquire common shares through the offering and hold common shares should consult with their own tax advisors regarding the requirements of filing information returns, and if applicable, any Mark-to-Market Election or QEF Election.

If the holder is a non-corporate U.S. holder, then payments to it made within the United States, or by a United States payor or United States middleman, of dividends on and/or proceeds arising from the sale or other taxable disposition of common shares, generally will be subject to information reporting and backup withholding (currently at the rate of 28%), where such U.S. holder fails to furnish its correct United States taxpayer identification number (generally on IRS Form W-9), and to make certain certifications, or otherwise fails to establish an exemption from backup withholding. Any amounts withheld under the backup withholding rules

107

from a payment to a U.S. holder generally may be refunded (or credited against its United States federal income tax liability, if any) provided the required information is furnished to the IRS in a timely manner. Each U.S. holder should consult its own tax advisor regarding the backup withholding tax.

DOCUMENTS FILED AS PART OF THE U.S. REGISTRATION STATEMENT

We have filed or will file the following documents with the SEC as part of the registration statement of which this prospectus forms a part: the documents listed under the heading "Documents Incorporated by Reference"; consents of auditors and counsel; powers of attorney; and the form of underwriting agreement.

ENFORCEABILITY OF CIVIL LIABILITIES

We are a corporation existing under theCanada Business Corporations Act. All of our directors and officers and the experts named in this prospectus are residents of Canada, and all or a substantial portion of their assets, and a substantial portion of our assets, are located outside the United States. We have appointed an agent for service of process in the United States (as set forth below), but it may be difficult for holders of common shares who reside in the United States to effect service within the United States upon those directors, officers and experts who are not residents of the United States. It may also be difficult for holders of common shares who reside in the United States to realize in the United States upon judgments of courts of the United States predicated upon our civil liability and the civil liability of our directors, officers and experts under the United States federal securities laws.

We filed with the SEC, concurrently with our registration statement on Form F-10 of which this prospectus is a part, an appointment of agent for service of process on Form F-X. Under the Form F-X, we appointed Puglisi & Associates as our agent for service of process in the United States in connection with any investigation or administrative proceeding conducted by the SEC, and any civil suit or action brought against or involving us in a United States court, arising out of or related to or concerning the offering of the common shares under this prospectus and the registration statement.

108

EXPERTS

Our consolidated financial statements for the fiscal years ended September 30, 2010 and September 30, 2009 have been audited by Collins Barrow Toronto LLP, chartered accountants, as stated in their report dated November 19, 2010 (except as to the supplemental note regarding the reconciliation of such financial statements for the years ended September 30, 2010 and 2009 with U.S. GAAP, which is dated July 4, 2011).

LEGAL MATTERS

Certain legal matters related to the common shares are being passed upon on our behalf by McCarthy Tétrault LLP, with respect to Canadian legal matters and Dorsey & Whitney LLP, with respect to U.S. legal matters, and on behalf of the underwriters by Borden Ladner Gervais LLP with respect to Canadian legal matters and by Ropes & Gray LLP with respect to U.S. legal matters. As of the date hereof, the partners and associates of each of McCarthy Tétrault LLP, Dorsey & Whitney LLP, Borden Ladner Gervais LLP and Ropes & Gray LLP, in each case as a group, beneficially own, directly or indirectly, less than 1%, respectively, of our outstanding securities.

MATERIAL CONTRACTS

The only material contracts entered into by us to which we are or will become a party on or prior to the closing of this offering are as follows:

1.: the purchase agreement referred to under "Acquisition of Scienion AG"; and
2.: the underwriting agreement referred to under "Plan of Distribution".

109

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS


1.	Unaudited interim consolidated financial statements for the three and six months ended ended March 31, 2011	F-2
2.	Supplemental Note regarding the Reconciliation of the Interim Consolidated Financial Statements for the Three and Six Month Periods Ended March 31, 2011 and 2010 with U.S. GAAP	F-13
3.	Auditors' Report	F-20
4.	Audited consolidated financial statements for the years ended September 30, 2010 and 2009	F-21
5.	Auditors' Report	F-35
6.	Supplemental Note Regarding the Reconciliation of the Consolidated Financial Statements for the Years Ended September 30, 2010 and 2009 with U.S. GAAP	F-36

F-1

SQI Diagnostics Inc.

INTERIM CONSOLIDATED BALANCE SHEETS

(Unaudited)
(Amounts are in thousands of dollars)

	As at March 31, 2011			As at September 30, 2010

	(Unaudited)			(audited)
ASSETS
Current
Cash and cash equivalents	$	4,669		$	9,408
Amounts receivable		3			3
Investment tax credit recoverable		300			—
Inventory (Note 4)		513			260
Prepaids and deposits		303			165
Due from related party (Note 5)		67			66

		5,855			9,902
Due from related party (Note 5)		32			32
Property and equipment (Note 6)		2,794			2,731
Patents and trademarks		509			469

	$	9,190		$	13,134

LIABILITIES
Current
Accounts payable and accrued liabilities	$	734		$	972

Shareholders' Equity
Capital stock (Note 8)		35,329			35,026
Warrants (Note 9)		1,614			1,799
Employee share purchase loan (Note 8)		(10	)		(10	)
Contributed surplus (Note 11)		9,137			8,832
Deficit		(37,614	)		(33,485	)

		8,456			12,162

	$	9,190		$	13,134


Approved by the Board
	(Signed)PETER WINKLEY Director	(Signed)CLAUDE RICKS Director

See accompanying notes 2

F-2

SQI Diagnostics Inc.

INTERIM CONSOLIDATED STATEMENT OF OPERATIONS AND DEFICIT

(Unaudited)
(Amounts are in thousands of dollars except per share amounts)

		Three Month Period Ended March 31 2011			Three Month Period Ended March 31 2010			Six Month Period Ended March 31 2011			Six Month Period Ended March 31 2010

Revenue
Product sales		$	4		$	—		$	13		$	—
Consulting fees	7		—			10			9			15

			4			10			22			15

Expenses
Salaries and wages			172			142			332			265
General and administrative	7		154			116			324			202
Professional and consulting fees			94			176			200			297
Sales and marketing			109			129			215			193
Stock-based compensation	13		113			66			228			115
Research and development costs			1,114			1,273			2,612			2,327
Amortization — patents & trademarks			29			28			57			56
Amortization — property & equipment			111			107			225			209

			1,896			2,037			4,193			3,664

Operating loss before interest			(1,892	)		(2,027	)		(4,171	)		(3,649	)
Interest Income			18			9			42			12
Interest Expense			—			(2	)		—			(3	)

Net loss		$	(1,874	)		(2,020	)		(4,129	)		(3,640	)
Deficit at beginning of period			(35,740	)		(27,032	)		(33,485	)		(25,412	)

Deficit at end of period		$	(37,614	)		(29,052	)		(37,614	)		(29,052	)

Weighted average number of shares			33,852			29,917			33,806			28,924

Basic and diluted loss per share		$	(0.06	)		(0.07	)		(0.12	)		(0.13	)

F-3

SQI Diagnostics Inc.

INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)
(Amounts are in thousands of dollars)

	Three Month Period Ended March 31 2011			Three Month Period Ended March 31 2010			Six Month Period Ended March 31 2011			Six Month Period Ended March 31 2010

CASH FLOWS FROM OPERATING ACTIVITIES
Loss for the period	$	(1,874	)	$	(2,020	)	$	(4,129	)	$	(3,640	)
Add items not affecting cash
Amortization — patents & trademarks		29			28			57			56
— property and equipment		111			107			225			209
Stock-based compensation		113			66			228			115
Loss on sale of property and equipment Interest accrual		— —			— —			43 (1	)		— —

		(1,621	)		(1,819	)		(3,577	)		(3,260	)
Changes in non-cash working capital items
Amounts Receivable		13			(39	)		—			(49	)
Investment tax Credit Recoverable		(300	)		—			(300	)		—
Due from related party		—			7			—			7
Inventory		2			(11	)		(253	)		(305	)
Prepaids and deposits		(99	)		55			(139	)		(20	)
Accounts payable and accrued liabilities		166			(56	)		(239	)		205

		(1,839	)		(1,863	)		(4,508	)		(3,422	)

Cash flows used in investing activities
Purchase of property and equipment		(84	)		(80	)		(333	)		(103	)
Additions to patents and trademarks		(62	)		(15	)		(96	)		(78	)
Sale of property and equipment		—			—			2			—

		(146	)		(95	)		(427	)		(181	)

Cash flows from financing activities
Repayment of loans payable		—			(1	)		—			(2	)
Proceeds from private placement and exercise of warrants and options, net of share issuance costs		183			307			196			6,469

		183			306			196			6,467

Increase (decrease) in cash during the period		(1,802	)		(1,652	)		(4,739	)		2,864
Cash at beginning of period		6,471			7,696			9,408			3,180

Cash at end of period	$	4,669		$	6,044		$	4,669		$	6,044

Supplemental disclosure
Cash paid for interest	$	—		$	2		$	—		$	3

F-4

SQI Diagnostics Inc.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. NATURE OF OPERATIONS

SQI Diagnostics Inc., (the "Company"), has its head office and development centre in Toronto, Ontario. The Company is a medical systems company that develops proprietary technology in multiplexing, miniaturization and automation. The Company provides laboratories the ability to simultaneously analyse multiple biomarkers, deliver accurate and quantitative patient results in less time, significantly reduce labour cost, and increase profits when compared with current diagnostic instrumentation.

During fiscal 2009 the Company obtained Health Canada licenses and self authorization to sell in the EU and during fiscal 2010 received United States Food & Drug Administration ("FDA") clearance of its SQiDworks and IgXPLEX Rheumatoid Arthritis (RA) system. During fiscal 2010 the Company obtained a Health Canada license for its IgXPLEX Celiac™ microarray test kits that run on the Company's automated SQiDworks™ platform. The Company has earned limited revenues from its IgXPLEX RA™ and IgXPLEX Celiac™ test kits run on installed SQiDworks™ platforms to date and as such is considered to be a development stage company. The Company has a pipeline of additional autoimmune diagnostic products in various stages of development and commercialization. The Company expects to generate revenues from its IgXPLEX RA and IgXPLEX Celiac products as it grows its installed base of customers as well as from products to be launched as they complete commercialization. The continuation of the Company's research, development and commercialization activities is dependent upon the Company's ability to successfully generate product revenues, or to finance its cash requirements through further equity financings.

2. SIGNIFICANT ACCOUNTING POLICIES

These consolidated financial statements have been prepared by management in accordance with Canadian generally accepted accounting principles and follow the same accounting policies and methods of their application as the most recent audited consolidated financial statements for the years ended September 30, 2010 and 2009. These statements should be read in conjunction with the Company's above noted annual consolidated financial statements. The significant accounting policies are discussed below.

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions are eliminated upon consolidation.

Cash and Cash Equivalents

Cash and cash equivalents include bank deposits and highly liquid money market investments such as bankers acceptance notes, treasury bills, cashable money market funds, and cashable guaranteed investment certificates.

Inventory

Inventory is valued at the lower of cost and replacement cost, with cost determined on a first-in, first-out basis.

Property and Equipment

Property and equipment are recorded at cost and are amortized on the straight-line basis over their estimated useful lives as follows:


Computer hardware	—	3 years
Computer software	—	3 years
Laboratory fixtures and equipment	—	10 years
Office equipment	—	10 years
Leasehold improvements	—	10 years

Patents and Trademarks

Research and Development Costs

Research costs are charged to operations in the period in which they are incurred. Development costs are expensed as incurred or deferred if they meet the criteria for deferral under Canadian generally accepted accounting principles and are expected to provide future benefits with reasonable certainty.

F-5

SQI Diagnostics Inc.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

2. SIGNIFICANT ACCOUNTING POLICIES (Continued)

At March 31, 2011, the Company was developing IgXPLEX diagnostics assays for celiac, vasculitis, lupus (SLE), Crohn's (IBD), antiphospholipid syndrome and our second generation, fully quantitative IgXPLEX RA assay. The Company continued its work to complete scientific discovery and assay design work for a diagnostic assay to detect and measure infliximab (also referred to as anti-TNF) in the blood of autoimmune patients. Deferral criteria have not been met, and accordingly, all development costs have been expensed in the period.

Impairment of Long-Lived Assets

Long-lived assets comprise property and equipment and intangible assets with finite lives (patents and trademarks). The Company recognizes an impairment loss for a long-lived asset when events or changes in circumstances cause its carrying value to exceed the total undiscounted cash flows expected from its use and eventual disposition. An impairment loss is measured as the excess of the carrying value of the asset over its fair value.

Revenue Recognition

Product sales are recognized upon the shipment of products to customers, if a signed contract exists, the sales price is fixed and determinable, collection of the resulting receivables is reasonably assured and any uncertainties with regard to customer acceptance are insignificant. Sales are recorded net of discounts and sales returns.

The Company also provides consulting services from time to time. Consulting fee revenue is recognized when services are completed, amounts are invoiced to customers and collectability is reasonably assured.

Stock-Based Compensation and Other Stock-Based Payments

The Company applies a fair value based method of accounting for all stock-based payments. Accordingly, stock-based payments are measured at the fair value of the consideration received or the fair value of the equity instruments issued or liabilities incurred, whichever is more reliably measurable. Stock-based compensation is charged to operations over the vesting period and the offset is credited to contributed surplus. Consideration received upon the exercise of stock options is credited to share capital at which time the related contributed surplus is transferred to share capital.

Foreign Currency Translation

Monetary assets and liabilities denominated in foreign currencies are translated to Canadian dollars at exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are translated at rates of exchange in effect at each transaction date. Revenue and expenses are translated at the rate of exchange at each transaction date. Gains or losses on translation are included in operations.

Income Taxes

Investment Tax Credits

Investment tax credits are accrued when qualifying expenditures are incurred and there is reasonable assurance that the credits will be realized. Investment tax credits earned with respect to current expenditures for qualified research and development activities are included in the statements of operations as a reduction of research and development costs. Investment tax credits associated with capital expenditures are reflected as reductions in the carrying amounts of capital assets. During the three and six months ended March 31, 2011 the company recorded an amount of $300,000 (three and six months ended March 31, 2010 — nil) as a reduction of research and development costs.

Financial Instruments

Financial instruments are measured initially at fair value and thereafter based on their classification.

F-6

SQI Diagnostics Inc.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

2. SIGNIFICANT ACCOUNTING POLICIES (Continued)

The Company has classified and measured its financial instruments as follows:

Financial Instrument	Classification	Measurement Basis

Cash and cash equivalents	Held-for-trading	Fair value
Amounts receivable	Loans and receivable	Amortized cost
Investment Tax credits receivable	Loans and receivable	Amortized cost
Due from related party	Loans and receivable	Amortized cost
Accounts payable and accruals	Other financial liabilities	Amortized cost

Comprehensive Income

The Company has not presented a statement of comprehensive income as it has no other comprehensive income.

Loss Per Share

Basic loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted loss per share is computed using the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants determined using the treasury stock method.

Use of Estimates

Significant areas requiring the use of management estimates relate to the determination of the useful lives of property and equipment and patents and trademarks for amortization purposes, valuation of ITC's receivable, valuation of stock options and warrants and valuation allowance on future tax assets.

3. RECENT ACCOUNTING PRONOUNCEMENTS ISSUED AND NOT YET APPLIED

Business Combinations

International Financial Reporting Standards

The CICA plans to converge Canadian Generally Accepted Accounting Principles with International Financial Reporting Standards ("IFRS") over a transition period expected to end in 2011, when IFRS will be fully adopted. The transition date of October 1, 2010 for the Company will require restatement for comparative purposes of amounts reported by the Company for the year ended September 30, 2011. The Company continues to monitor, assess and quantify the impact of the convergence of Canadian GAAP and IFRS on its financial statements.

4. INVENTORY

Inventory consists of component parts that are to be used in the future production of SQiDworks™ Platform and IgXPLEX consumable assays.

F-7

SQI Diagnostics Inc.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

5. DUE FROM RELATED PARTY

	March 31, 2011			September 30, 2010

	(unaudited) ($000s)			(audited) ($000s)
Amount due from an officer and director, secured, bearing interest as described in note⁽ⁱ⁾, principal amount of $98,000 repayable in three equal payments on September 1, 2010, 2011 and 2012. Accrued interest of $1,000 is due on September 1, 2011	$	99		$	98
Less: Current portion		(67	)		(66	)

	$	32		$	32

(i): Terms of the promissory note were amended on April 16, 2010 as follows: interest bearing at Canada Revenue Agency prescribed rate for taxable benefits to employees and shareholders on interest-free and low-interest loans, which was 1% per annum at March 31, 2011. Prior to amendment, the loan was bearing interest at 4.25% per annum during the year ended December 31, 2009 and non-interest bearing from October 1, 2009 to April 15, 2010.
(ii): As at March 31, 2011, the first payment of $33,000 is in arrears.

6. PROPERTY AND EQUIPMENT

As at March 31, 2011 (unaudited):	Cost		Accumulated Amortization		Net

	($000s)		($000s)		($000s)
Computer hardware	$	266	$	163	$	103
Computer software		179		138		41
Laboratory fixtures and equipment		4,309		1,797		2,512
Office equipment		176		134		42
Leasehold improvements		265		169		96

	$	5,195	$	2,401	$	2,794

As at September 30, 2010 (audited):	Cost		Accumulated Amortization		Net

	($000s)		($000s)		($000s)
Computer hardware	$	193	$	141	$	52
Computer software		153		130		23
Laboratory fixtures and equipment		4,172		1,670		2,502
Office equipment		176		128		48
Leasehold improvements		263		157		106

	$	4,957	$	2,226	$	2,731

7. RELATED PARTY TRANSACTIONS

Transactions with related parties occur in the normal course of business and are measured at the exchange amount. Related party transactions have been listed below, unless they have been disclosed elsewhere in the financial statements.

F-8

SQI Diagnostics Inc.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

8. CAPITAL STOCK

(a): Authorized

unlimited common shares

Issued — common shares

	Number		Value

	(000s)		($000s)
Balance, September 30, 2010 (audited)		33,758	$	35,026

Options exercised		8		22
Balance, December 31, 2010		33,766	$	35,048

Options exercised		40		104
Warrants exercised (Note 9(i))		107		193
Share issuance costs		—		(16	)
Balance, March 31, 2011		33,913	$	35,329

(b): During the period ended September 30, 2007, the Company made a non-interest bearing loan to an officer, which was used to acquire 100,000 common shares. The loan has been accounted for as a share purchase loan and, accordingly, the $10,000 loan balance has been deducted from share capital.

9. WARRANT CAPITAL

The following summarizes the change in warrants:

				(audited)

	Six Months Ended March 31, 2011			Year Ended September 30, 2010
	($000s)			($000s)
Balance, beginning of period	$	1,799		$	461
Issued on private placement					1,424
Finder warrants					187
Exercise of warrants⁽ⁱ⁾		(60	)		(213	)
Expiry of warrants⁽ⁱⁱ⁾		(125	)		(60	)

Balance, end of period	$	1,614		$	1,799

(i): During the quarter ended March 31, 2011 106,520 warrants with an expiry of January 22, 2011 were exercised for proceeds of $133,000. Upon exercise $60,000 was transferred to share capital.
(ii): During the quarter ended December 31, 2010 143,886 warrants with an expiry of December 4, 2010 expired unexercised, and $125,000 was transferred to contributed surplus upon expiry.

10. WARRANTS

The Company had the following warrants outstanding at March 31, 2011:

Number of Warrants		Purchase Price

(000s)
	1,199	$	4.00	December 4, 2011
	237	$	1.90	December 23, 2011
	1,140	$	5.00	August 12, 2012
	57	$	2.50	August 12, 2012

	2,633

F-9

SQI Diagnostics Inc.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

11. CONTRIBUTED SURPLUS

The following summarizes the change in contributed surplus:

				(audited)

	Six Months Ended March 31, 2011			Year Ended September 30, 2010
	($000s)			($000s)
Balance, beginning of period	$	8,832		$	8,431
Stock-based compensation (Note 13)		228			402
Options exercised (Note 12 (i))		(48	)		(61	)
Warrants expired (Note 9(ii))		125			60

Balance, end of period	$	9,137		$	8,832

12. STOCK OPTIONS

The Company maintains a Stock Option Plan (the "Plan") for the benefit of directors, officers, employees and consultants. The aggregate number of common shares reserved for issuance under the Plan, together with any other employee stock option plans, options for services and employee share purchase plans, will not exceed 3,200,000. Options granted pursuant to the Plan will have terms not to exceed five years, and are granted at an option price which will not be less than the fair market price at the time the options are granted. All options granted to individual optionees, other than consultants, generally vest in three equal installments over a period of 36 months.

The following summarizes the stock option activities under the Plan:

	Six Month Period Ended March 31, 2011					Six Month Period Ended March 31, 2010

	Number of Options			Weighted Average Exercise Price		Number of Options			Weighted Average Exercise Price
	(000s)					(000s)
Beginning balance		1,764		$	1.75		2,368		$	1.31
Granted		175		$	2.88		149		$	2.42
Exercised⁽ⁱ⁾		(48	)	$	1.62		(500	)	$	0.60
Forfeited		(24	)	$	1.96		—		$	—

Ending balance		1,867		$	1.86		2,017		$	1.54

Exercisable		1,088		$	1.69		1,021		$	1.37

(i): On exercise of stock options, $48,000 (six months ended March 31, 2010 — $0) was transferred from contributed surplus to share capital.

There are no other options outstanding that are not part of the Plan.

F-10

SQI Diagnostics Inc.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

12. STOCK OPTIONS (Continued)

The Company had the following stock options outstanding under the Plan at March 31, 2011:

Number of Options		Exercise Price

(000s)
	33	$	1.20	June 29, 2011
	58	$	1.20	August 29, 2011
	143	$	1.74	August 7, 2012
	50	$	1.50	October 23, 2012
	758	$	1.60	February 26, 2013
	255	$	1.75	August 26, 2013
	78	$	1.30	May 22, 2014
	25	$	3.26	November 3, 2014
	57	$	2.25	February 22, 2015
	60	$	2.10	May 27, 2015
	175	$	2.50	August 16, 2015
	100	$	2.90	October 4, 2015
	75	$	2.85	January 31, 2016

	1,867

13. STOCK-BASED COMPENSATION

The fair value of the options granted during the six month period ended March 31, 2011 was $327,000 (six month period ended March 31, 2010 — $233,000), which will be recognized over the vesting period of 36 months. The total compensation expense for six month period ended March 31, 2011 was $228,000 (six month period ended March 31, 2010 — $115,000). The total amount credited to contributed surplus for the six month period ended March 31, 2011 was $228,000 (six month period ended March 31, 2010 — $115,000).

The fair value of each option granted has been estimated at the date of grant or the date when it became measurable using the Black-Scholes option pricing model with the following weighted average assumptions at the measurement date:

	Six Months Ended March 31, 2011			Six Months Ended March 31, 2010

Dividend yield		0	%		0	%
Expected volatility		80	%		80	%
Risk-free interest rate		2.31	%		1.98	%
Expected life (years)		5.00			5.00

Weighted average grant date fair value	$	1.87		$	1.57

The Company has assumed no forfeiture rate as adjustments for actual forfeitures are made in the year they occur.

14. CONTINGENCIES

In the ordinary course of business, the Company may be contingently liable for litigation and claims with customers, suppliers, former employees or competitors. Management believes that adequate provisions have been recorded in accounts where required.

15. CAPITAL RISK MANAGEMENT

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern so that it can complete its lead assay commercialization efforts and receive the required regulatory approvals to sell and market its products and provide returns for shareholders and benefits for other stakeholders.

The capital structure of the Company consists of shareholders' equity. The Company is not subject to externally imposed capital requirements.

F-11

SQI Diagnostics Inc.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

16. FINANCIAL RISK MANAGEMENT

a): Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company's cash and cash equivalents are exposed to credit risk. The credit risk on cash and cash equivalents is small because the counterparties are highly rated Canadian banks.

b): Interest Rate Risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's cash and cash equivalents are exposed to cash flow interest rate risk as the Company invests cash and cash equivalents at floating rates of interest in highly liquid instruments. Fluctuations in interest rates would not significantly impact interest income.

c): Currency Risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is exposed to currency risk due to its purchases in US dollars. A 1% change in the foreign exchange rate would result in a change of approximately $9,000 in the reported profit and loss.

d): Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company's accounts payable and accrued liabilities are all current. The Company ensures that it has sufficient capital to meet short term financial obligations after taking into account its cash on hand.

F-12

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE RECONCILIATION OF THE INTERIM
CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIODS
ENDED MARCH 31, 2011 AND 2010 WITH U.S. GAAP

(unaudited)
Dated July 4, 2011

The Company follows Canadian generally accepted accounting principles ("Canadian GAAP") which is different in some respects from the accounting principles applicable in the United States ("U.S. GAAP") and from practices prescribed by the United States Securities and Exchange Commission. These differences in Canadian GAAP and U.S. GAAP that would require restatement of any of the Company's reported financial statements and certain additional disclosures required under U.S. GAAP are detailed below:

(i): Leasehold Improvements

The company amortizes leasehold improvements over their expected useful life. U.S. GAAP requires that leasehold improvements be amortized over the lesser of their useful life or the term of the lease. As the Company does not have a term lease in place for its premises, expenditures relating to leasehold improvements are booked to general and administrative expense in the statement of operations. Accordingly, the following adjustments would be required under U.S. GAAP:

(amounts in thousands of dollars)

	March 31, 2011			September 30, 2010

Property and equipment — Canadian GAAP	$	2,794		$	2,731
Remove net book value of Leasehold Improvements		(96	)		(106	)

Property and equipment — U.S. GAAP	$	2,698		$	2,625

	March 31, 2011			September 30, 2010

Deficit — Canadian GAAP	$	(37,614	)	$	(33,485	)
Net Adjustment		(96	)		(106	)

Deficit — U.S. GAAP	$	(37,710	)	$	(33,591	)



Net loss — Canadian GAAP	(1,874	)	(2,020	)	(4,129	)	(3,640	)
Net adjustment to expense Leasehold Improvements and remove amortization of Leasehold Improvements	4		(1	)	10		6

Net loss — U.S. GAAP	(1,870	)	(2,021	)	(4,119	)	(3,634	)



Cash provided by (used in) operations — Canadian GAAP	(1,839	)	(1,863	)	(4,508	)	(3,422	)
Expense Leasehold Improvements	(2	)	(7	)	(2	)	(7	)

Cash used in operations — U.S. GAAP	(1,841	)	(1,870	)	(4,510	)	(3,429	)

Cash provided by (used in) investing — Canadian GAAP	(146	)	(95	)	(427	)	(181	)
Remove additions to Leasehold Improvements	2		7		2		7

Cash provided by (used in) investing — U.S. GAAP	(144	)	(88	)	(425	)	(174	)

F-13

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE RECONCILIATION OF THE INTERIM
CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIODS
ENDED MARCH 31, 2011 AND 2010 WITH U.S. GAAP (Continued)

(unaudited)
Dated July 4, 2011

(ii): The Company is a development stage company. Accordingly, the following tables detailing the Company's Statements of Operations, Shareholders' Equity and Cash Flows from inception (December 1, 1999) to March 31, 2011 are required to be presented:

Statement of Operations
(amounts in thousands of dollars)

		From Inception to March 31, 2011

Revenue
	Product Sales	$	23
	Consulting Fees		1,269

			1,292

Expenses
	Salaries and wages		4,187
	General and administrative		3,546
	Professional and consulting fees		3,211
	Sales and marketing		1,098
	Stock-based compensation		1,828
	Research and development costs		21,787
	Amortization — patents and trademarks		786
	Amortization — property and equipment		2,508

			38,951

Loss before the undernoted items		$	(37,659	)
Interest income			423
Interest expense			(87	)
Settlement of litigation			(205	)
Loss on disposal of property and equipment			(182	)

			(51	)

Net loss and deficit accumulated during the development stage, end of period		$	(37,710	)

F-14

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE RECONCILIATION OF THE INTERIM
CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIODS
ENDED MARCH 31, 2011 AND 2010 WITH U.S. GAAP (Continued)

(unaudited)
Dated July 4, 2011

Statement of Shareholders' Equity
(amounts in thousands of dollars, shares in thousands)

		Share Capital

		Share Capital											Deficit Accumulated in Development Stage
		Number of shares			Amount			Contributed Surplus			Warrant Capital		Deficit Accumulated in Development Stage
Balance At Inception			2		$	850								—
Net loss													$	(4,631	)

Balance December 14, 2002, 2001 and 2000			2		$	850			—				$	(4,631	)

Net loss	��													(3,112	)

Balance December 14, 2003			2		$	850			—				$	(7,743	)

Issued in connection with a private placement			10			1,516
Stock split			5,977			—
Issued in connection with a private placement			669			2,788
Forgiveness of indebtedness to parent on reorganization								$	7,120
Share issuance costs						(342	)
Stock based compensation									9
Net loss														(1,559	)

Balance December 14, 2004			6,658		$	4,812		$	7,129			—	$	(9,302	)

Issued on exercise of warrants			100			10
Stock based compensation									341
Net loss														(1,804	)

Balance December 14, 2005			6,758		$	4,822		$	7,470			—	$	(11,106	)

Conversion of convertible debentures			2,073			4,147
Convertible debenture issuance costs						(454	)
Stock based compensation									268
Net loss														(1,653	)

Balance December 14, 2006			8,831		$	8,515		$	7,738			—	$	(12,759	)

Shares of Emblem Capital			8,000		$	867
Share consolidation of Emblem Shares at 6 for 1			(6,667	)
Elimination of share capital due to reverse take over						(867	)
Common shares of Umedik exchanged for shares SQI			(8,831	)
Net asset value of SQI ascribed to issued shares						595
Issued on exercise of warrants			78			8
Share issued to former shareholders of Umedik			14,719
Proceeds from private placement units			3,568			5,212
Amount of private placement allocated to warrants						(89	)					89
Share issuance costs						(128	)
Stock based compensation									53
Net loss														(3,098	)

Balance, September 30, 2007			19,698		$	14,113		$	7,791		$	89	$	(15,857	)

Issued on exercise of warrants			52			5
Issued in connection with private placement			2,439			3,660
Issued on exercise of options			28			39			(6	)
Share issuance costs, including broker warrants						(494	)					185
Stock based compensation									283
Net loss														(3,765	)

Balance, September 30, 2008			22,217		$	17,323		$	8,068		$	274	$	(19,622	)

F-15

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE RECONCILIATION OF THE INTERIM
CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIODS
ENDED MARCH 31, 2011 AND 2010 WITH U.S. GAAP (Continued)

(unaudited)
Dated July 4, 2011

	Share Capital

	Share Capital											Deficit Accumulated in Development Stage
	Number of shares		Amount			Contributed Surplus			Warrant Capital			Deficit Accumulated in Development Stage
Issued on exercise of warrants		1,111		689
Issued in connection with private placement		3,732		4,664
Issued on exercise of options		133		35			(17	)
Share issuance costs, including broker warrants				(345	)					187
Stock based compensation							380
Net loss													(5,899	)

Balance, September 30, 2009		27,193	$	22,366		$	8,431		$	461		$	(25,521	)

Issued on exercise of warrants		970		2,008			60			(213	)
Proceeds from private placement units		4,678		12,295
Amount of private placement allocated to warrants				(1,424	)					1,424
Issued on exercise of options		917		755			(61	)
Expiry of warrants										(60	)
Share issuance				(974	)					187
Stock based compensation							402
Net loss													(8,070	)

Balance, September 30, 2010		33,758	$	35,026		$	8,832		$	1,799		$	(33,591	)

Issued on exercise of warrants		107		193						(60	)
Issued on exercise of options		48		126			(48	)		(125	)
Expiry of warrants							125
Share issuance				(16	)
Stock based compensation							228
Net loss													(4,119	)

Balance, March 31, 2011		33,913	$	35,329		$	9,137		$	1,614		$	(37,710	)

F-16

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE RECONCILIATION OF THE INTERIM
CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIODS
ENDED MARCH 31, 2011 AND 2010 WITH U.S. GAAP (Continued)

(unaudited)
Dated July 4, 2011

Cash Flow Statement
(amounts in thousands of dollars)

		From Inception to March 31, 2011

Cash provided by (used in)
Operations
Net loss		$	(37,710	)
Items not affecting cash
	Amortization — patents and trademarks		786
	— property and equipment		2,508
	Patents written off		97
	Stock-based compensation		1,964
	Loss on sale of property and equipment		225
	Interest accrual		(11	)
Changes in non-cash working capital items
	Amounts receivable		(615	)
	Investment tax credit recoverable		310
	Due from related party		7
	Inventory		(1,143	)
	Prepaids and deposits		(402	)
	Accounts payable and accrued liabilities		975

			(33,009	)

Investing
	Purchase of property and equipment		(4,797	)
	Additions to patents and trademarks		(1,556	)
	Sale of property and equipment		2
	Due from related party		(97	)

			(6,448	)

Financing
	Loans from related parties		7,120
	Advances (repayment) of loan/notes payable		3
	Proceeds from private placement and exercise of warrants and options, net of share issuance costs		35,749
	Employee share purchase loan		(10	)
	Cash acquired on reverse takeover		607
	Share subscription proceeds received		657

			44,126

Net change in cash and cash equivalents during the period and cash at end of period			4,669

Supplemental disclosure
Equipment reallocated from inventory and segregated for use by the Company		$	631
Cash paid for interest		$	109

(iii): Statements of Cash Flows

Canadian GAAP permits the disclosure of a subtotal of the amount of funds provided by operations before changes in non-cash operating working capital items in the consolidated statements of cash flows. United States GAAP does not permit this subtotal to be included.

F-17

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE RECONCILIATION OF THE INTERIM
CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIODS
ENDED MARCH 31, 2011 AND 2010 WITH U.S. GAAP (Continued)

(unaudited)
Dated July 4, 2011

(iv)

The Company grants stock options to directors, officers, employees and consultants as described in Note 12. The company has used the fair value method of accounting for stock options since the inception of the plan in accordance with Canadian GAAP and U.S GAAP. Other disclosures related to share-based compensation are as follows:

a.: The total intrinsic value of options exercised during the three and six months ended March 31, 2011 was $59,000 and $67,000, respectively (three and six months ended March 31, 2010 $825,000 and $912,000, respectively)
b.: The total number of options outstanding at March 31, 2011 had a weighted average remaining term of 2.5 years (March 31, 2010 — 2.5 years), and a total intrinsic value of $2,259,000 (March 31, 2010 — $1,472,000)
c.: The total number of options vested and exercisable at March 31, 2011 had a weighted average remaining term of 1.9 years (March 31, 2010 — 2.1 years), and a total intrinsic value of $1,502,000 (March 31, 2010 — $919,00)
d.: As at March 31, 2011 compensation costs not yet recognized relating to stock option awards outstanding was $1,058,000 (March 31, 2010 — $925,000). Compensation costs will be recognized over the remaining weighted average period of approximately 1.9 years (March 31, 2010 — 1.8 years)
e.: Estimated forfeiture rate did not result in a material impact on the stock based compensation expense.

(v)

Breakdown of accounts payable and accrued liabilities are as follows (amounts in thousands of dollars):

	March 31, 2011		September 30. 2010

Trade payables	$	565	$	763
Accruals		160		200
Payroll Liabilities		9		9

	$	734	$	972

(vi): Patents and trademarks

The aggregate amortization expense related to patents and trademarks for the next five years as at March 31, 2011 is as follows (amounts in thousands of dollars):


	2012			95
	2013			67
	2014			59
	2015			59
	2016			59

(vii): Recently adopted accounting pronouncements

In June 2009, the FASB launched the FASB Accounting Standards Codification, or the Codification, as the single source of authoritative U.S. GAAP recognized by the FASB. The Codification reorganizes various U.S. GAAP pronouncements into accounting topics and displays them using a consistent structure. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative U.S. GAAP for SEC registrants. The Codification is effective for interim and annual periods ending after September 15, 2009. The adoption of this standard had no impact on the Company's financial statements.

In February 2010, the FASB issued ASU No. 2010-09, "Subsequent Events (ASC Topic 855), Amendments to Certain Recognition and Disclosure Requirements." This Standard update requires a SEC Filer to (1) evaluate subsequent events through the date that the financial statements are issued or available to be issued, (2) defines "SEC Filer" as an entity that is required to file or furnish its financial statements with either the SEC or, with respect to an entity subject to Section 12(i) of the Securities Exchange Act of 1934, as amended, the appropriate agency under that Section, (3) not be bound to disclosing the date through which subsequent events have been evaluated, (4) note the definition ofpublic entity is not longer defined nor necessary for Topic 855, (5) note the scope of the reissuance disclosure requirements is refined to include revised financial statements only. These Updates are effective for interim or annual periods ending after June 15, 2010. ASU No. 2010-09 has no effect on the Company's financial position, statements of operations, or cash flows at this time.

F-18

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE RECONCILIATION OF THE INTERIM
CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIODS
ENDED MARCH 31, 2011 AND 2010 WITH U.S. GAAP (Continued)

(unaudited)
Dated July 4, 2011

In May 2009, the FASB issued new guidance for accounting for subsequent events. The new guidance, which is now part of ASC 855-10, Subsequent Events (formerly, SFAS No. 165, Subsequent Events) is consistent with existing auditing standards in defining subsequent events as events or transactions that occur after the balance sheet date but before the financial statements are issued or are available to be issued, but it also requires the disclosure of the date through which an entity has evaluated subsequent events and the basis for that date. The new guidance defines two types of subsequent events: "recognized subsequent events" and "non-recognized subsequent events." Recognized subsequent events provide additional evidence about conditions that existed at the balance sheet date and must be reflected in the Company's financial statements. Non-recognized subsequent events provide evidence about conditions that arose after the balance sheet date and are not reflected in the financial statements of a company. Certain non-recognized subsequent events may require disclosure to prevent the financial statements from being misleading. The new guidance was effective on a prospective basis for interim or annual periods ending after June 15, 2009. The Company adopted the provisions of ASC 855-10 as required.

F-19

AUDITORS' REPORT

To the Shareholders of
SQI Diagnostics Inc.

We have audited the consolidated balance sheets of SQI Diagnostics Inc. as at September 30, 2010 and 2009 and the consolidated statements of operations and deficit and cash flows for the years then ended. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the company as at September 30, 2010 and 2009 and the results of its operations and its cash flows for the years then ended, in accordance with Canadian generally accepted accounting principles.


		(Signed)COLLINS BARROW TORONTO LLP
Toronto, Ontario		Licensed Public Accountants
November 19, 2010		Chartered Accountants

F-20

SQI DIAGNOSTICS INC.

CONSOLIDATED BALANCE SHEETS

As at September 30, 2010 and 2009
(Amounts are in thousands of dollars)

	2010			2009

ASSETS
Current
Cash and cash equivalents	$	9,408		$	3,180
Amounts receivable		3			40
Inventory (Note 4)		260			322
Prepaids and deposits		165			67
Due from related party (Note 5)		66			40

		9,902			3,649
Due from related party (Note 5)		32			65
Property and equipment (Note 6)		2,731			2,097
Patents and trademarks		469			394

	$	13,134		$	6,205

LIABILITIES
Current
Accounts payable and accrued liabilities	$	972		$	369

Shareholders' Equity
Capital stock (Note 8)		35,026			22,366
Warrants (Note 9)		1,799			461
Employee share purchase loan (Note 8)		(10	)		(10	)
Contributed surplus (Note 11)		8,832			8,431
Deficit		(33,485	)		(25,412	)

		12,162			5,836

	$	13,134		$	6,205


Approved by the Board
	(Signed)PETER WINKLEY Director	(Signed)ERIC SCHNEIDER Director

See accompanying notes

F-21

SQI DIAGNOSTICS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND DEFICIT

Years Ended September 30, 2010 and 2009
(Amounts are in thousands of dollars, except per share amounts)

	2010			2009

Revenue
Product sales	$	5		$	5
Consulting fees (Note 7)		30			27

		35			32

Expenses
Salaries and wages		556			469
General and administrative (Note 7)		471			447
Professional and consulting fees		659			436
Sales and marketing		474			409
Stock based compensation (Note 13)		402			380
Research and development costs (Note 15)		5,059			3,362
Amortization — property and equipment		415			417
Amortization — patents and trademarks		100			98

		8,136			6,018

Loss before the undernoted items		(8,101	)		(5,986	)

Interest income		32			121
Interest expense		(4	)		(45	)

		28			76

Net loss		(8,073	)		(5,910	)
Deficit, beginning of year		(25,412	)		(19,502	)

Deficit, end of year	$	(33,485	)	$	(25,412	)

Loss per share
Basic and diluted	$	(0.27	)	$	(0.23	)

Weighted average number of common shares outstanding
Weighted average number of shares		30,349			25,158

See accompanying notes

F-22

SQI DIAGNOSTICS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Years Ended September 30, 2010 and 2009
(Amounts are in thousands of dollars)

			2010			2009

Cash provided by (used in)
Operations
Net loss			$	(8,073	)	$	(5,910	)
Items not affecting cash
	Amortization — patents and trademarks			100			98
		— property and equipment		415			417
	Patents written off			—			97
	Stock-based compensation			402			380
	Interest accrual			(2	)		(1	)

Net changes in non-cash working capital				(7,158	)		(4,919	)
	Amounts receivable			37			(15	)
	Inventory			(568	)		(211	)
	Prepaids and deposits			(98	)		(7	)
	Accounts payable and accrued liabilities			604			(16	)
	Investment tax credits recoverable			—			1,075
	Due from related party			7			—

				(7,176	)		(4,093	)

Investing
Purchase of property and equipment				(418	)		(113	)
Additions to patents and trademarks				(175	)		(186	)

				(593	)		(299	)

Financing
Repayment of loans payable				—			(732	)
Proceeds from private placement and exercise of warrants and stock options, net of share issuance costs				13,997			5,213

				13,997			4,481

Net change in cash and cash equivalents				6,228			89
Cash and cash equivalents, beginning of year				3,180			3,091

Cash and cash equivalents, end of year			$	9,408		$	3,180

Non-cash Investing Activity
Equipment reallocated from inventory and segregated for use by the Company			$	631		$	—

Supplemental Disclosure
Cash paid for interest			$	4		$	44

See accompanying notes

F-23

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2010 and 2009

1. NATURE OF OPERATIONS

During fiscal 2009 the Company obtained Health Canada licenses and self authorization to sell in the EU and during fiscal 2010 received United States Food & Drug Administration ("FDA") clearance of its SQiDworks and IgXPLEX Rheumatoid Arthritis (RA) system. During fiscal 2010 the Company obtained a Health Canada license for its IgXPLEX Celiac™ microarray test kits that run on the Company's automated SQiDworks™ platform. The Company has earned limited revenues from its IgXPLEX RA™ and IgXPLEX Celiac™ test kits run on installed SQiDworks™ platforms to date and as such is considered to be a development stage company. The Company has a pipeline of additional autoimmune diagnostic products in various stages of development and commercialization. The Company expects to generate revenues from its IgXPLEX RA and IgXPLEX Celiac products as it grows its installed base of customers as well as from products to be launched as they complete commercialization. The continuation of the Company's research, development and commercialization activities is dependent upon the Company's ability to successfully generate product revenues, or, to finance its cash requirements through further equity financings.

2. SIGNIFICANT ACCOUNTING POLICIES

These consolidated financial statements have been prepared by management in accordance with Canadian generally accepted accounting principles, within the framework of the significant accounting policies summarized below:

Basis of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions are eliminated upon consolidation.

Cash and Cash Equivalents

Inventory

Inventory is valued at the lower of cost and replacement cost, with cost determined on a first-in, first-out basis.

Property and Equipment

Property and equipment are recorded at cost and are amortized on the straight-line basis over their estimated useful lives as follows:


Computer hardware	—	3 years
Computer software	—	3 years
Laboratory fixtures and equipment	—	10 years
Office equipment	—	10 years
Leasehold improvements	—	10 years

Patents and Trademarks

The costs relating to initial patent and trademark fees are deferred and amortized over 10 years on a straight-line basis. Patents and trademarks are recorded net of accumulated amortization of $627,000 (2009 — $527,000). At year end all patents and trademarks were reviewed and were related to the Company's current systems under development. Net capitalized costs of $97,000 related to three abandoned patents were written off in fiscal 2009, with the write off included in general and administrative expense.

Research and Development Costs

F-24

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

2. SIGNIFICANT ACCOUNTING POLICIES (Continued)

At September 30, 2010, the Company was developing IgXPLEX diagnostics assays for celiac, vasculitis, lupus (SLE), Crohn's (IBD), antiphospholipid syndrome and our second generation, fully quantitative IgXPLEX RA assay. The Company continued its work to complete scientific discovery and assay design work for a diagnostic assay to detect and measure infliximab (also referred to as anti-TNF) in the blood of autoimmune patients. Deferral criteria have not been met, and accordingly, all development costs have been expensed in the period.

Impairment of Long-Lived Assets

Revenue Recognition

Stock-Based Compensation and Other Stock-Based Payments

The Company applies a fair value based method of accounting for all stock-based payments. Accordingly, stock-based payments are measured at the fair value of the consideration received or the fair value of the equity instruments issued or liabilities incurred, whichever is more reliably measurable. Stock-based compensation is charged to operations over the vesting period and the offset is credited to contributed surplus. Consideration received upon the exercise of stock options is credited to share capital at which time the related contributed surplus is transferred to share capital.

Foreign Currency Translation

Income Taxes

Investment Tax Credits

During the year ended September 30, 2010, the Company recorded an amount of $295,000 (2009 — $87,000) as a reduction in research and development costs.

Financial Instruments

Financial instruments are measured initially at fair value and thereafter based on their classification.

F-25

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

2. SIGNIFICANT ACCOUNTING POLICIES (Continued)

The Company has classified and measured its financial instruments as follows:

Financial Instrument	Classification	Measurement Basis

Cash and cash equivalents	Held-for-trading	Fair value
Amounts receivable	Loans and receivable	Amortized cost
Due from related party	Loans and receivable	Amortized cost
Accounts payable and accruals	Other financial liabilities	Amortized cost

Comprehensive Income

The Company has not presented a statement of comprehensive income as it has no other comprehensive income.

Loss Per Share

Basic loss per share is computed using the weighted average number of common shares outstanding during the year. Diluted loss per share is computed using the weighted average number of common and potential common shares outstanding during the year. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants determined using the treasury stock method.

Use of Estimates

3. RECENT ACCOUNTING PRONOUNCEMENTS ISSUED AND NOT YET APPLIED

Business Combinations

International Financial Reporting Standards

The CICA plans to converge Canadian Generally Accepted Accounting Principles with International Financial Reporting Standards ("IFRS") over a transition period expected to end in 2011, when IFRS will be fully adopted. The transition date of October 1, 2010 for the Company will require restatement for comparative purposes of amounts reported by the Company for the year ended September 30, 2011. The Company continues to monitor and assess the impact of the convergence of Canadian GAAP and IFRS on its financial statements.

4. INVENTORY

Inventory consists of component parts that are to be used in the future production of SQiDworks™ Platform and IgXPLEX consumable assays.

F-26

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

5. DUE FROM RELATED PARTY

	2010			2009

	($000s)			($000s)
Amount due from an officer and director, secured, bearing interest as described in note⁽ⁱ⁾, principal amount of $98,000 repayable in three equal payments on September 1, 2010, 2011 and 2012. Accrued interest is due on September 1, 2011	$	98		$	105
Less: Current portion		(66	)		(40	)

	$	32		$	65

(i): Terms of the promissory note were amended on April 16, 2010 as follows: interest bearing at Canada Revenue Agency prescribed rate for taxable benefits to employees and shareholders on interest-free and low-interest loans, which was 1% per annum at September 30, 2010. Prior to amendment, the loan was bearing interest at 4.25% per annum during the year ended December 31, 2009 and non-interest bearing from October 1, 2009 to April 15, 2010.
(ii): As at September 30, 2010, the first payment of $33,000 is in arrears.

6. PROPERTY AND EQUIPMENT

As at September 30, 2010:	Cost		Accumulated Amortization		Net

	($000s)		($000s)		($000s)
Computer hardware	$	193	$	141	$	52
Computer software		153		130		23
Laboratory fixtures and equipment		4,172		1,670		2,502
Office equipment		176		128		48
Leasehold improvements		263		157		106

	$	4,957	$	2,226	$	2,731

As at September 30, 2009:	Cost		Accumulated Amortization		Net

	($000s)		($000s)		($000s)
Computer hardware	$	141	$	114	$	27
Computer software		125		106		19
Laboratory fixtures and equipment		3,255		1,349		1,907
Office equipment		147		112		35
Leasehold improvements		240		131		109

	$	3,908	$	1,812	$	2,097

7. RELATED PARTY TRANSACTIONS

Included in general and administrative expense for the year ended September 30, 2010 is $49,000 (2009 — $50,000), related to recovery of occupancy costs, from a corporation in which an officer of the Company is also an officer. Consulting fee revenue of $30,000 for the year ended September 30, 2010 (2009 — $27,000) was earned from this corporation. At year end, $1,000 (2009 — $6,000) due from this corporation is included in amounts receivable.

F-27

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

8. CAPITAL STOCK

(a): Authorized

unlimited common shares

Issued — common shares

	Number		Value

	(000s)		($000s)
Balance, September 30, 2008		22,217	$	17,323
Warrants exercised		1,111		689
Issued in connection with a private placement⁽ⁱ⁾		3,732		4,664
Option exercised		133		35
Share issuance cost⁽ⁱ⁾		—		(345	)

Balance, September 30, 2009		27,193	$	22,366
Warrants exercised (Note 9(i))		970		2,008
Issued in connection with a private placement⁽ⁱⁱ⁾		4,678		12,295
Allocated to warrants		—		(1,424	)
Options exercised		917		755
Share issuance costs⁽ⁱⁱ⁾		—		(974	)

Balance, September 30, 2010		33,758	$	35,026

(i): On December 23, 2008, pursuant to a private placement, the Company issued 2,400,000 shares at a price of $1.25 per share, resulting in gross proceeds of $3,000,000. The Company paid a finder's fee in relation to the private placement satisfied through the issuance of 236,800 warrants with an exercise price of $1.90 and expiring on December 23, 2011, valued at $127,000. Total share issuance costs were $127,000.

On January 21, 2009, pursuant to a private placement the Company issued 1,331,500 shares at a price of $1.25 per share, resulting in gross proceeds of $1,664,000. The Company paid a finder's fee in relation to the private placement satisfied through the issuance of 106,520 warrants with an exercise price of $1.25 and expiring on December 23, 2011, valued at $60,000 and a cash payment of $133,000. Total share issuance costs were $193,000.

Additional share issue costs amounted to $25,000.

(ii): On December 4, 2009, pursuant to a private placement, the Company issued 2,398,104 units at a price of $2.75 per unit, each unit comprised one common share of the Company and one-half common share purchase warrant, resulting in gross proceeds of $6,595,000. Each whole warrant has an exercise price of $4.00 per share and expires on December 4, 2011. The value of capital stock includes value attributable to the warrants in the amount of $846,000, which has been included in warrant capital (see Note 9).

The Company paid a finder's fee in relation to the private placement satisfied through a cash payment of $453,000 and the issuance of 143,886 compensation unit warrants with an exercise price of $2.75 per unit and expiring on December 4, 2010, valued at $125,000. Each unit entitles the purchaser to purchase one common share and one-half common share purchase warrant with an exercise price of $4.00 per share, expiring on December 4, 2010. Total share issuance costs were $611,000.

On August 12, 2010, pursuant to a private placement the Company issued 2,280,000 units at a price of $2.50 per unit, each unit comprised one common share of the Company and one-half common share purchase warrant, resulting in gross proceeds of $5,700,000. Each whole warrant has an exercise price of $5.00 and expires on August 12, 2012. The value of capital stock includes value attributable to the warrants in the amount of $578,000, which has been included in warrant capital (see Note 9).

The Company paid a finder's fee in relation to the private placement satisfied through a cash payment of $260,000 and the issuance of 57,000 compensation unit warrants with an exercise price of $2.50 per unit and expiring on August 12, 2012, valued at $62,000. Each unit entitles the purchaser to purchase one common share at and one-half common share purchase warrant with an exercise price of $5.00 per share, expiring on August 12, 2012. The total share issuance costs were $363,000.

(b): During the period ended September 30, 2007, the Company made a non-interest bearing loan to its officer, which was used to acquire 100,000 common shares. The loan has been accounted for as a share purchase loan and, accordingly, the $10,000 loan balance has been deducted from share capital.

F-28

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

9. WARRANT CAPITAL

The following summarizes the change in warrants:

	2010			2009

	($000s)			($000s)
Balance, beginning of period	$	461		$	274
Issued on private placement (Note 8(ii))		1,424			—
Finder warrants (Note 8)		187			187
Exercise of warrants (Note 10 (i))		(213	)		—
Expiry of warrants (Note 10 (i))		(60	)		—

Balance, end of period	$	1,799		$	461

10. WARRANTS

The Company had the following warrants outstanding at September 30, 2010:

Number of Warrants		Purchase Price

(000s)
	144	$	2.750	December 4, 2010	⁽ⁱⁱ⁾
	107	$	1.250	January 22, 2011
	1,199	$	4.000	December 4, 2011
	237	$	1.900	December 23, 2011
	1,140	$	5.000	August 12, 2012
	57	$	2.500	August 12, 2012

	2,884

(i): During the year ended September 30, 2010, 194,200 warrants with an expiry of June 3, 2010 were exercised resulting in the issuance of 194,200 shares and net proceeds of $291,000, 576,563 warrants with an expiry of June 29, 2010 were exercised resulting in the issuance of 576,563 shares and net proceeds of $1,384,000 and 199,493 warrants with an expiry of April 26, 2010 were exercised resulting in the issuance of 199,493 shares and net proceeds of $120,000. On exercise, $213,000 (2009 — $Nil) was transferred from warrant capital to share capital. The remaining 1,207,213 warrants with an expiry date of June 29, 2010 expired unexercised. On expiry, $60,000 (2009 — $Nil) was transferred from warrant capital to contributed surplus.
(ii): Subsequent to the year ended September 30, 2010, these warrants expired unexercised.

11. CONTRIBUTED SURPLUS

The following summarizes the change in contributed surplus:

	2010			2009

	($000s)			($000s)
Balance, beginning of period	$	8,431		$	8,068
Stock-based compensation (Note 13)		402			380
Options exercised (Note 12 (i))		(61	)		(17	)
Warrants expired (Note 9(i))		60			—

Balance, end of period	$	8,832		$	8,431

12. STOCK OPTIONS

F-29

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

12. STOCK OPTIONS (Continued)

exceed five years, and are granted at an option price which will not be less than the fair market price at the time the options are granted. All options granted to individual optionees, other than consultants, generally vest in six equal installments over a period of 18 months.

The following summarizes the stock option activities under the Plan:

	September 30, 2010					September 30, 2009

	Number of Options			Weighted Average Exercise Price		Number of Options			Weighted Average Exercise Price
	(000s)					(000s)
Beginning balance		2,368		$	1.20		2,624		$	1.18
Granted		384		$	2.41		80		$	1.08
Exercised⁽ⁱ⁾		(850	)	$	0.75		(133	)	$	0.13
Expired		—		$	—		(36	)	$	0.60
Forfeited		(138	)	$	1.73		(167	)	$	0.60

Ending balance		1,764		$	1.75		2,368		$	1.20

Exercisable		985		$	1.60		1,792		$	1.09

(i): On exercise of stock options, $61,000 (2009 — $17,000) was transferred from contributed surplus to share capital.

In addition to the options exercised included in the table, there were 66,667 options that were not granted under the Plan that were exercised at a price of $0.90 per share during the year ended September 30, 2010.

There are no other options outstanding that are not part of the Plan.

The Company had the following stock options outstanding under the Plan at September 30, 2010:

Number of Options		Exercise Price

(000s)
	33	$	1.200	June 29, 2011
	67	$	1.200	August 29, 2011
	180	$	1.740	August 7, 2012
	50	$	1.500	October 23, 2012
	758	$	1.600	February 26, 2013
	269	$	1.750	August 26, 2013
	80	$	1.300	May 22, 2014
	25	$	3.260	November 3, 2014
	68	$	2.250	February 22, 2015
	60	$	2.100	May 27, 2015
	175	$	2.500	August 16, 2015

	1,764

13. STOCK-BASED COMPENSATION

The fair value of the options granted during the year ended September 30, 2010 was $591,000 (2009 — $67,000), which will be recognized over the vesting period of 18 to 36 months. The total compensation expense for the year ended September 30, 2010 was $402,000 (2009 — $380,000). The total amount credited to contributed surplus for the year ended September 30, 2010 was $402,000 (2009 — $380,000).

F-30

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

13. STOCK-BASED COMPENSATION (Continued)

	2010			2009

Dividend yield		0	%		0	%
Expected volatility		80	%		80	%
Risk-free interest rate		2.00	%		1.98	%
Expected life (years)		5.00			5.00

Weighted average grant date fair value	$	1.540		$	0.842

The Company has assumed no forfeiture rate as adjustments for actual forfeitures are made in the year they occur.

14. INCOME TAXES

(a): Income Tax Expense

The following table reconciles income taxes calculated at combined Canadian federal/ provincial tax rates with the income tax expense in the financial statements:

	2010			2009

	($000s)			($000s)
Loss before income taxes	$	(8,073	)	$	(5,910	)
Statutory rate		31.75	%		33.00	%

Expected income tax recovery	$	(2,563	)	$	(1,950	)
Effect on income taxes of unrecognized future income tax assets relating to deductible temporary differences on:
Change in valuation allowance related to operations		1,971			1,325
Change in future tax rates		1,150			121
Impact of SR&ED filings		(689	)		302
Non-deductible expenses and other items		131			202

Income tax expense	$	—		$	—

(b): Future Income Taxes

The temporary differences that give rise to future income tax assets and future income tax liabilities are presented below:

	2010			2009

	($000s)			($000s)
Amounts related to tax loss and other credits carry forwards	$	8,646		$	6,448
Property and equipment and intangibles		(279	)		(276	)
Share issue costs		280			231

Net future tax asset		8,647			6,403
Less: Valuation allowance		(8,647	)		(6,403	)

	$	—		$	—

F-31

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

14. INCOME TAXES (Continued)

(c): Loss and Tax Credit Carryforwards

As at September 30, 2010, the Company has non-capital losses of approximately $18,128,000 expiring as follows:


2013	$	879,000
2014		766,000
2025		1,146,000
2026		516,000
2027		1,154,000
2028		2,537,000
2029		3,287,000
2030		7,843,000

	$	18,128,000

The Company has undeducted scientific research and experimental development costs of approximately $9,726,000 and investment tax credits relating to scientific research and development costs of approximately $2,046,000 available to apply against future taxable income.

The potential tax benefit relating to the non-capital losses and tax credit carryforwards has not been reflected in these financial statements.

15. RESEARCH AND DEVELOPMENT COSTS

The Company's autoimmune diagnostic research and development programs focus primarily on the following technology platforms:

(a): Platform: The Company develops various platforms to enable its customers to run and analyze the Company's immunoassay IgXPLEX™ and QuantiSpot test kits. The Company's SQiDworks™ is a fully automated, multi plate system used to process up to three IgXPLEX™ or QuantiSpot test kits. SQiDworks™ is a fully load-and-go device that completes all sample handling, biochemistry, plate scanning and data analysis. SQiDman is a semi automated system used to process single IgXPLEX™ or QuantiSpot test kits. The Company's Platform research and development activities focus on continuous improvement to the Platforms, novel applications, required modifications for the Company's pipeline IgXPLEX™ and QuantiSpot content as well as the evolution of the Platform to meet customer needs and market demands. SQiDworksLITE™, in the concept stage in 2010, is designed to address customers' requirements for smaller, less costly, fully automated systems and is intended to address the IVD markets as well as the research and drug development markets.
(b): IgXPLEX™: The Company develops multiplex microarrays used to aid in the diagnosis of a variety of autoimmune diseases and with a goal of expanding the use of this technology into infectious diseases and allergens. The IgXPLEX™ research and development program includes basic and advanced research and development in materials science, surface chemistry, biochemistry, ELISA chemistry, multiplexing, antibody kinetics, autofluorescing anti body marker biochemistry and detection, multiplexed calibration and normalization, qualitative and quantitative measurement and automation of the assay biochemistry. The development of the core IgXPLEX™ technology was completed in parallel with the development of the Company's first QuantiSpot RA and IgXPLEX™ test kits licensed in Canada, cleared in the US and authorized in the EU to aid in the diagnosis of rheumatoid arthritis.
(c): Gastrointestinal ("GI"): The Company is developing a pipeline of IgXPLEX™ test kits targeted at autoimmune disorders of the digestive system. The first such test kit for Celiac disease has been licensed in Canada and is awaiting FDA approval in the United States. The IgXPLEX™ products currently in development include multiplex microarrays detecting and measuring serum antibodies to aid in the diagnosis of celiac disease and Crohn's/ulcerative colitis.
(d): Vascular: The Company is developing a pipeline of IgXPLEX™ test kits targeted at autoimmune disorders of the vasculature. The IgXPLEX™ products currently in development include multiplex microarrays detecting and measuring serum antibodies to aid in the diagnosis of vasculitis and Antiphospholipid Syndrome (APS).
(e): General Discovery Markers: The Company conducts discovery research as the first step in the development process. Discovery includes basic research to determine the suitability of candidate biomarkers that could be combined in marketable multiplex microarrays. The current research includes biomarkers used to aid in the diagnosis of autoimmune diseases and includes: lupus, thyroid disease, autoimmune hepatitis, autoimmune renal disease and food intolerance.

F-32

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

15. RESEARCH AND DEVELOPMENT COSTS (Continued)

(f): Therapeutic Monitoring: The Company has initiated a program to develop monitoring tests used to aid in the therapeutic treatment of autoimmune diseases. These tests are used to measure biologic therapies in patient's blood to assist clinicians in their use of various clinical approaches. Therapeutic Monitoring may be used alone, or in combination with the Company's IgXPLEX™ products.

The following table summarizes the Company's research and development costs for the years ending September 30, 2010 and 2009:

	2010			2009

	($000s)			($000s)
Platform	$	907		$	460
IgXPLEX Technology		1,431			2,050
Gastrointestinal		1,861			494
Vascular		345			217
General Discovery Markets		304			180
Therapeutic Monitoring		506			48

		5,354			3,449
ITC Refund		(295	)		(87	)

	$	5,059		$	3,362

16. CONTINGENCIES

17. CAPITAL RISK MANAGEMENT

The capital structure of the Company consists of shareholders' equity. The Company is not subject to externally imposed capital requirements.

18. FINANCIAL RISK MANAGEMENT

a): Credit Risk

b): Interest Rate Risk

c): Currency Risk

F-33

SQI Diagnostics Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2010 and 2009

18. FINANCIAL RISK MANAGEMENT (Continued)

d): Liquidity Risk

19. COMPARATIVE FIGURES

Certain comparative figures have been reclassified to conform with the current year's financial statement presentation.

F-34

AUDITORS' REPORT ON THE SUPPLEMENTAL NOTE REGARDING THE
RECONCILIATION OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 2010 AND 2009 WITH U.S. GAAP

To the Shareholders of
SQI Diagnostics Inc.

We have audited the consolidated balance sheets of SQI Diagnostics Inc. as at September 30, 2010 and 2009 and the consolidated statements of operations and deficit and cash flows for the years then ended and have issued our report thereon dated November 19, 2010. We have also audited the reconciliation from Canadian Generally Accepted Accounting Principles ("GAAP") to United States GAAP of the Company contained herein. This reconciliation from Canadian GAAP to United States GAAP is the responsibility of the Company's management. Our responsibility is to express an opinion based on our audits. In our opinion, such reconciliation from Canadian GAAP to United States GAAP, when considered in relation to the consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth herein.


Toronto, Ontario July 4, 2011		(Signed)COLLINS BARROW TORONTO LLP Licensed Public Accountants Chartered Accountants

F-35

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE
RECONCILIATION OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 2010 AND 2009 WITH U.S. GAAP

Dated July 4, 2011

(i): Leasehold Improvements

(amounts in thousands of dollars)	September 30, 2010			September 30, 2009

Property and equipment — Canadian GAAP	$	2,731		$	2,097
Remove net book value of Leasehold Improvements		(106	)		(109	)

Property and equipment — U.S. GAAP	$	2,625		$	1,988

	September 30, 2010			September 30, 2009

Net loss — Canadian GAAP	$	(8,073	)	$	(5,910	)
Net adjustment to expense Leasehold Improvements and remove amortization of Leasehold Improvements		3			11

Net loss — U.S. GAAP	$	(8,070	)	$	(5,899	)

	September 30, 2010			September 30, 2009

Deficit — Canadian GAAP	$	(33,485	)	$	(25,412	)
Net Adjustment		(106	)		(109	)

Deficit — U.S. GAAP	$	(33,591	)	$	(25,521	)

	September 30, 2010			September 30, 2009

Cash provided by (used in) operations — Canadian GAAP	$	(7,176	)	$	(4,093	)
Expense Leasehold Improvements		(23	)		(13	)

Cash used in operations — U.S. GAAP	$	(7,199	)	$	(4,106	)

Cash provided by (used in) investing — Canadian GAAP	$	(593	)	$	(299	)
Remove additions to Leasehold Improvements		23			13

Cash provided by (used in) investing — U.S. GAAP	$	(570	)	$	(286	)

F-36

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE
RECONCILIATION OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 2010 AND 2009 WITH U.S. GAAP (Continued)

Dated July 4, 2011

(ii): The Company is a development stage company. Accordingly, the following tables detailing the Company's Statements of Operations, Shareholders' Equity and Cash Flows from inception (December 1, 1999) to September 30, 2010 and 2009 are required to be presented:

Statement of Operations
(amounts in thousands of dollars)

		From Inception to September 30, 2010			From Inception to September 30, 2009

Revenue
	Product Sales	$	10		$	5
	Consulting Fees		1,260			1,230

			1,270			1,235

Expenses
	Salaries and wages		3,855			3,299
	General and administrative		3,220			2,727
	Professional and consulting fees		3,011			2,352
	Sales and marketing		883			409
	Stock-based compensation		1,600			1,198
	Research and development costs		19,175			14,116
	Amortization — patents and trademarks		729			629
	Amortization — property and equipment		2,295			1,905

		$	34,768		$	26,635

	Loss before the undernoted items		(33,498	)		(25,400	)
	Interest income		381			349
	Interest expense		(87	)		(83	)
	Settlement of litigation		(205	)		(205	)
	Loss on disposal of property and equipment		(182	)		(182	)

			(93	)		(121	)

	Net loss and deficit accumulated during the development stage, end of period	$	(33,591	)	$	(25,521	)

F-37

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE
RECONCILIATION OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 2010 AND 2009 WITH U.S. GAAP (Continued)

Dated July 4, 2011

Statement of Shareholders' Equity
(amounts in thousands of dollars, shares in thousands)

	Share Capital

	Share Capital											Deficit Accumulated in Development Stage
	Number of shares			Amount			Contributed Surplus			Warrant Capital		Deficit Accumulated in Development Stage
Balance At Inception		2		$	850								—
Net loss												$	(4,631	)

Balance December 14, 2002, 2001 and 2000		2		$	850			—				$	(4,631	)

Net loss													(3,112	)

Balance December 14, 2003		2		$	850			—				$	(7,743	)

Issued in connection with a private placement		10			1,516
Stock split		5,977			—
Issued in connection with a private placement		669			2,788
Forgiveness of indebtedness to parent on reorganization							$	7,120
Share issuance costs					(342	)
Stock based compensation								9
Net loss													(1,559	)

Balance December 14, 2004		6,658		$	4,812		$	7,129			—	$	(9,302	)

Issued on exercise of warrants		100			10
Stock based compensation								341
Net loss													(1,804	)

Balance December 14, 2005		6,758		$	4,822		$	7,470			—	$	(11,106	)

Conversion of convertible debentures		2,073			4,147
Convertible debenture issuance costs					(454	)
Stock based compensation								268
Net loss													(1,653	)

Balance December 14, 2006		8,831		$	8,515		$	7,738			—	$	(12,759	)

Shares of Emblem Capital		8,000		$	867
Share consolidation of Emblem Shares at 6 for 1		(6,667	)
Elimination of share capital due to reverse take over					(867	)
Common shares of Umedik exchanged for shares SQI		(8,831	)
Net asset value of SQI ascribed to issued shares					595
Issued on exercise of warrants		78			8
Share issued to former shareholders of Umedik		14,719
Proceeds from private placement units		3,568			5,212
Amount of private placement allocated to warrants					(89	)					89
Share issuance costs					(128	)
Stock based compensation								53
Net loss													(3,098	)

Balance, September 30, 2007		19,698		$	14,113		$	7,791		$	89	$	(15,857	)

Issued on exercise of warrants		52			5
Issued in connection with private placement		2,439			3,660
Issued on exercise of options		28			39			(6	)
Share issuance costs, including broker warrants					(494	)					185
Stock based compensation								283
Net loss													(3,765	)

Balance, September 30, 2008		22,217		$	17,323		$	8,068		$	274	$	(19,622	)

F-38

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE
RECONCILIATION OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 2010 AND 2009 WITH U.S. GAAP (Continued)

Dated July 4, 2011

	Share Capital

	Share Capital											Deficit Accumulated in Development Stage
	Number of shares		Amount			Contributed Surplus			Warrant Capital			Deficit Accumulated in Development Stage
Issued on exercise of warrants		1,111		689
Issued in connection with private placement		3,732		4,664
Issued on exercise of options		133		35			(17	)
Share issuance costs, including broker warrants				(345	)					187
Stock based compensation							380
Net loss													(5,899	)

Balance, September 30, 2009		27,193	$	22,366		$	8,431		$	461		$	(25,521	)

Issued on exercise of warrants		970		2,008			60			(213	)
Proceeds from private placement units		4,678		12,295
Amount of private placement allocated to warrants				(1,424	)					1,424
Issued on exercise of options		917		755			(61	)
Expiry of warrants										(60	)
Share issuance				(974	)					187
Stock based compensation							402
Net loss													(8,070	)

Balance, September 30, 2010		33,758	$	35,026		$	8,832		$	1,799		$	(33,591	)

F-39

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE
RECONCILIATION OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 2010 AND 2009 WITH U.S. GAAP (Continued)

Dated July 4, 2011

Statement of Cash Flows
(amounts in thousands of dollars)

		From Inception to September 30, 2010			From Inception to September 30, 2009

Cash provided by (used in) Operations
Net loss		$	(33,591	)	$	(25,521	)
Items not affecting cash
	Amortization
	— patents and trademarks		729			629
	— property and equipment		2,295			1,905
	Patents written off		97			97
	Stock-based compensation		1,736			1,334
	Loss on sale of property and equipment		182			182
	Interest accrual		(10	)		(8	)
Changes in non-cash working capital items
	Amounts receivable		(615	)		(652	)
	Investment tax credit recoverable		610			610
	Due from related party		7
	Inventory		(890	)		(322	)
	Prepaids and deposits		(163	)		(65	)
	Accounts payable and accrued liabilities		1,114			510

			(28,499	)		(21,301	)

Investing
Purchase of property and equipment			(4,466	)		(4,070	)
Additions to patents and trademarks			(1,460	)		(1,285	)
Due from related party			(97	)		(97	)

			(6,023	)		(5,452	)

Financing
	Loans from related parties		7,120			7,120
	Advances (repayment) of loan/notes payable		3			3
	Proceeds from private placement and exercise of warrants and options, net of share issuance costs		35,553			21,556
	Employee share purchase loan		(10	)		(10	)
	Cash acquired on reverse takeover		607			607
	Share subscription proceeds received		657			657

			43,930			29,933

Net change in cash and cash equivalents during the period, and cash and cash equivalents at end of period		$	9,408		$	3,180
Supplemental disclosure
	Equipment reallocated from inventory and segregated for use by the Company	$	631		$	—
	Cash paid for interest	$	109		$	105

(iii): Statements of Cash Flows

F-40

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE
RECONCILIATION OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 2010 AND 2009 WITH U.S. GAAP (Continued)

Dated July 4, 2011

(iv)

The Company grants stock options to directors, officers, employees and consultants as described in Note 12. The company has used the fair value method of accounting for stock options since the inception of the plan in accordance with Canadian GAAP and U.S. GAAP. Other disclosures related to share-based compensation are as follows:

a.: The total intrinsic value of options exercised during the year ended September 30, 2010 was $1,418,000 (September 30, 2009 — $149,000)
b.: The total number of options outstanding at September 30, 2010 had a weighted average remaining term of 2.8 years (September 30, 2009 — 2.4 years), and a total intrinsic value of $2,064,000 (September 30, 2009 — $2,179,000)
c.: The total number of options vested and exercisable at September 30, 2010 had a weighted average remaining term of 2.3 years (September 30, 2009 — 1.7 years), and a total intrinsic value of $1,300,000 (September 30, 2009 — $1,846,000)
d.: As at September 30, 2010, compensation costs not yet recognized relating to stock option awards outstanding was $989,000 (September 30, 2009 — $804,000). Compensation costs will be recognized over the remaining weighted average period of approximately 2 years (September 30, 2009 — 2.9 years)
e.: Estimated forfeiture rate did not result in a material impact on the stock based compensation expense.

(v)

Breakdown of accounts payable and accrued liabilities is as follows (amounts in thousands of dollars):

	September 30, 2010		September 30, 2009

Trade payables	$	763	$	187
Accruals		200		174
Payroll liabilities		9		5
Note payable to supplier, non-interest bearing		—		3

	$	972	$	369

(vi): Patents and trademarks

The aggregate amortization expense related to patents and trademarks for the next five years as at September 30, 2010 is as follows (amounts in thousands of dollars):


2011	$	116
2012		74
2013		59
2014		59
2015		59

(vii): Recently adopted accounting pronouncements

In February 2010, the FASB issued ASU No. 2010-09, "Subsequent Events (ASC Topic 855), Amendments to Certain Recognition and Disclosure Requirements." This Standard update requires a SEC Filer to (1) evaluate subsequent events through the date that the financial statements are issued or available to be issued, (2) defines "SEC Filer" as an entity that is required to file or furnish its financial statements with either the SEC or, with respect to an entity subject to Section 12(i) of the Securities Exchange Act of 1934, as amended, the appropriate agency under that Section, (3) not be bound to disclosing the date through which subsequent events have been evaluated, (4) note the definition of public entity is no longer defined nor necessary for Topic 855, (5) note the scope of the reissuance disclosure requirements is refined to include revised financial statements only. These Updates are effective for interim or annual periods ending after June 15, 2010. ASU No. 2010-09 has no effect on the Company's financial position, statements of operations, or cash flows at this time.

F-41

SQI Diagnostics Inc.

SUPPLEMENTAL NOTE REGARDING THE
RECONCILIATION OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 2010 AND 2009 WITH U.S. GAAP (Continued)

Dated July 4, 2011

F-42

• common shares

SQI DIAGNOSTICS INC.

Common Shares

Leerink Swann
Rodman & Renshaw, LLC
Kingsdale Capital Markets Inc.

Until • , 2011 (25 days after the commencement of this offering), all dealers that buy, sell or trade our common shares, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

PART II

INFORMATION NOT REQUIRED TO BE DELIVERED TO
OFFEREES OR PURCHASERS

Indemnification of Directors and Officers

Under theCanada Business Corporations Act (the "CBCA"), the Registrant may indemnify its current or former directors or officers or another individual who acts or acted at the Registrant's request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of his or her association with the Registrant or another entity, and the individual seeking indemnity shall have a right to such indemnity if such individual was not judged by the court or other competent authority to have committed any fault or omitted to do anything that such individual ought to have done. The CBCA also provides that the Registrant may advance moneys to such an individual for the costs, charges and expenses of such a proceeding.

The CBCA also provides that the Registrant may with the approval of a court, indemnify such an individual or advance moneys against all costs, charges and expenses reasonably incurred by the individual in connection with an action by or on behalf of the Registrant or other entity to procure a judgment in its favour, to which the individual is made a party because of the individual's association with the Registrant or other entity at the Registrant's request.

However, indemnification under any of the foregoing circumstances is prohibited under the CBCA unless the individual:

•: acted honestly and in good faith with a view to the Registrant's best interests, or the best interests of the other entity for which the individual acted as director or officer or in a similar capacity at the Registrant's request; and
•: in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the individual had reasonable grounds for believing that his or her conduct was lawful.

The Registrant's by-laws provide that the Registrant will indemnify a director or officer, a former director or officer or another individual who acts or acted at the Registrant's request as a director or officer (or an individual acting in a similar capacity) of another entity, against all costs, charges and expenses, including, without limitation, an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the Registrant or other entity.

The Registrant's by-laws provide that the Registrant may advance monies to a director, officer or other individual for the costs, charges and expenses of a proceeding referred to above. That person must repay the monies if the person does not fulfill the conditions in the following paragraph.

The Registrant's by-laws provide that the Registrant will not indemnify a person referred to above unless the person: (a) acted honestly and in good faith with a view to the best interests of the Registrant or, as the case may be, to the best interests of the other entity for which the person acted as a director or officer or in a similar capacity at the Registrant's request; and (b) in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the person had reasonable grounds for believing that the person's conduct was lawful.

The Registrant's by-laws provide that the Registrant also has the right to indemnify a person referred to above in such other circumstances as the CBCA or law permits or requires. The Registrant's by-laws do not limit the right of any person entitled to indemnity to claim indemnity apart from the provisions of the Registrant's by-laws.

Subject to the CBCA, the Registrant may purchase and maintain insurance for the benefit of any individual referred to above as the board of directors of the Registrant may from time to time determine. The Registrant has purchased and maintains such an insurance policy.

II-1

* * *

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

II-2

EXHIBITS

See the Exhibit Index hereto.

II-3

PART III

UNDERTAKING AND CONSENT TO SERVICE OF PROCESS

Item 1. Undertaking.

The Registrant undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Securities and Exchange Commission staff, and to furnish promptly, when requested to do so by the Securities and Exchange Commission staff, information relating to the securities registered pursuant to this Form F-10 or to transactions in said securities.

Item 2. Consent to Service of Process.

Concurrently with the filing of this Registration Statement, the Registrant is filing with the Securities and Exchange Commission a written Appointment of Agent for Service of Process and Undertaking on Form F-X.

Any change to the name or address of the agent for service of the Registrant shall be communicated promptly to the Securities and Exchange Commission by an amendment to Form F-X referencing the file number of this registration statement.

III-1

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-10 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Toronto, Ontario, Canada on this 6^th day of July, 2011.


		SQI DIAGNOSTICS INC.
		By:		/s/ ANDREW MORRIS Name: Andrew Morris Title: Chief Financial Officer

POWERS OF ATTORNEY

Each person whose signature appears below constitutes and appoints Claude Ricks and Andrew Morris and each of them, either of whom may act without the joinder of the other, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on July 6, 2011.

Signature		Title


/s/ CLAUDE RICKS Claude Ricks		President, Chief Executive Officer and Director (Principal Executive Officer)
/s/ ANDREW MORRIS Andrew Morris		Chief Financial Officer (Principal Financial and Accounting Officer)
/s/ ERIC SCHNEIDER Eric Schneider		Chairman of the Board of Directors
/s/ DAVID A. WILLIAMS David A. Williams		Director
/s/ PAUL MOUNTAIN Paul Mountain		Director

III-2

Signature		Title


/s/ PETER WINKLEY Peter Winkley		Director
/s/ SAIED NADJAFI Saied Nadjafi		Director
/s/ PETER LEA Peter Lea		Director

III-3

AUTHORIZED REPRESENTATIVE

Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, the undersigned has signed this Registration Statement, solely in its capacity as the duly authorized representative of SQI Diagnostics Inc. in the United States, on July 6, 2011.


		PUGLISI & ASSOCIATES
		/s/ DONALD J. PUGLISI
		Name:		Donald J. Puglisi
		Title:		Managing Director

III-4

EXHIBIT INDEX

		Description

3.1	*	Form of Underwriting Agreement.
4.1		Annual Information Form, dated June 15, 2011.
4.2		Management Proxy Circular, dated June 8, 2011, prepared in connection with the annual and special meeting of shareholders held on July 7, 2011.
4.3		Audited consolidated financial statements for the years ended September 30, 2010 and 2009, together with the auditor's report thereon (included in the prospectus forming a part of this Registration Statement).
4.4		Supplemental Note Regarding the Reconciliation of the Consolidated Financial Statements for the Years Ended September 30, 2010 and 2009 with U.S. GAAP (included in the prospectus forming a part of this Registration Statement).
4.5		Management's discussion and analysis of consolidated results of operations and financial condition for the fiscal year ended September 30, 2010.
4.6		Unaudited interim consolidated financial statements for the three and six months ended March 31, 2011 (included in the prospectus forming a part of this Registration Statement).
4.7		Supplemental Note Regarding the Reconciliation of the Interim Consolidated Financial Statements for the Three and Six Month Periods Ended March 31, 2011 and 2010 with U.S. GAAP (included in the prospectus forming a part of this Registration Statement).
4.8		Management's discussion and analysis of consolidated results of operations and financial condition for the three and six months ended March 31, 2011.
4.9		Material Change Report, dated July 5, 2011.
5.1		Consent of Collins Barrow Toronto LLP.
5.2	*	Consent of McCarthy Tetrault LLP.
6.1		Powers of Attorney (included on the signature page of this Registration Statement).

*: To be filed by amendment.

QuickLinks

PART I INFORMATION REQUIRED TO BE DELIVERED TO OFFEREES OR PURCHASERS
GENERAL MATTERS
FORWARD-LOOKING STATEMENTS
CURRENCY PRESENTATION AND EXCHANGE RATE INFORMATION
PROSPECTUS SUMMARY
RISK FACTORS
CAPITALIZATION
USE OF PROCEEDS
BUSINESS OF THE COMPANY
LEGAL PROCEEDINGS AND REGULATORY ACTIONS
ACQUISITION OF SCIENION AG
SELECTED CONSOLIDATED FINANCIAL INFORMATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
DIRECTORS AND OFFICERS
DESCRIPTION OF CAPITAL STRUCTURE
DIVIDEND POLICY
MARKET FOR SECURITIES
PRINCIPAL SHAREHOLDERS
PLAN OF DISTRIBUTION
DOCUMENTS INCORPORATED BY REFERENCE
WHERE YOU CAN FIND MORE INFORMATION
AUDITORS, TRANSFER AGENTS AND REGISTRARS
CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS
CERTAIN MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS
DOCUMENTS FILED AS PART OF THE U.S. REGISTRATION STATEMENT
ENFORCEABILITY OF CIVIL LIABILITIES
EXPERTS
LEGAL MATTERS
MATERIAL CONTRACTS
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
INTERIM CONSOLIDATED BALANCE SHEETS
INTERIM CONSOLIDATED STATEMENT OF OPERATIONS AND DEFICIT
INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
SUPPLEMENTAL NOTE
AUDITORS' REPORT
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED STATEMENTS OF OPERATIONS AND DEFICIT
CONSOLIDATED STATEMENTS OF CASH FLOWS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
AUDITORS' REPORT ON THE SUPPLEMENTAL NOTE
SUPPLEMENTAL NOTE
PART II INFORMATION NOT REQUIRED TO BE DELIVERED TO OFFEREES OR PURCHASERS
EXHIBITS
PART III UNDERTAKING AND CONSENT TO SERVICE OF PROCESS

Item 1. Undertaking.

Item 2. Consent to Service of Process.

SIGNATURES
POWERS OF ATTORNEY
AUTHORIZED REPRESENTATIVE
EXHIBIT INDEX

SQI Diagnostics (SQD.H) Inactive F-10Registration of securities (Canada)